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Abstract
Approximately one-third of all cellular proteins traverse the secretory pathway. After
translation and folding in the endoplasmic reticulum (ER), proteins are transported through the
Golgi to their final locations inside or outside of cells. At each step, proteins are helped by
chaperones, which both shepherd proteins towards their native structures and serve as
gatekeepers for export. Many proteins in the secretory pathway are also modified by installation
of polysaccharides on specific asparagine residues. These N-glycans are installed in the ER as
uniform precursors, but are trimmed and built up by Golgi glycan maturation enzymes into a
striking array of epitopes. N-glycans act as a second mechanism to stabilize protein structure
and prevent the release of misfolded proteins. Outside the cell, N-glycans on cell surfaces and
secreted, soluble proteins allow cells to interact with each other, with their environment, and
with distal tissues.
During development, cells encounter physiological ER stress incurred by high levels of
sustained protein production. Unresolved protein misfolding, on the other hand, results in
pathological ER stress and tissue dysfunction. Prior work has used small model substrates to
show that cells utilize secretory pathway chaperones and tune N-glycosylation to respond to ER
stress. This thesis examines how cells use similar strategies to accommodate challenging
cargoes such as collagen-1. In the human body, collagen-I constitutes the primary protein
component of bone, skin, and other organs; collagen-I misfolding results in pathological ER
stress and connective tissue diseases. We therefore set out 1) to identify cellular components
required for collagen-I secretion that could be targeted to address disease and 2) to assess the
effects of ER stress on both cellular N-glycan structures and individual glycoproteins.
Here, we employ a high-throughput assay for collagen-I secretion and find that the
cytosolic isoform of Hsp90 is required for collagen-I export. We also show that intracellular
stress signaling alters the structures of cell surface and secreted N-glycans. Finally, we
demonstrate that the collagen-I N-glycan buffers collagen-I folding against destabilizing
mutations and ER stress. Our results identify potential therapeutic leads for collagen misfolding
diseases and point to new mechanisms for maintaining secretory pathway proteostasis.
Thesis Supervisor: Matthew D. Shoulders
Title: Whitehead CD Associate Professor
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CHAPTER I
A Proteostasis Approach to Treating the Collagenopathies
Summary
The collagen-misfolding diseases, or collagenopathies, encompass mutations in more
than 31 genes and show clinical phenotypes in most connective tissues. Single mutations that
affect the folding of collagen chains can prevent secretion of sufficient protein levels for tissue
function; in other cases, mutant chains accumulate in the endoplasmic reticulum (ER), resulting
in sustained ER stress that leads to cellular dysfunction or death. The most severe disease
phenotypes often stem from a third class of mutants, whose deposition in the extracellular
matrix (ECM) disrupts packing of wild-type collagen fibrils or other ECM components. In addition
to these disease mechanisms, loss-of-function variants of chaperones required for collagen
folding, or mutations in other ECM proteins that share the same secretion pathway, also
contribute to chondro- and skeletal dysplasias. Cells employ a transcriptional program called the
Unfolded Protein Response (UPR) that is responsible for restoring homeostasis in the ER upon
cellular or organismal insult, and targeting each of the three arms of the UPR has shown
promise for diverse protein misfolding diseases. Increasing evidence suggests that UPR-
focused therapeutic strategies may be able to mitigate the consequences of collagen misfolding
and greatly improve patient outlook. Beyond the UPR, targeting individual components of the
cellular proteostasis network also holds therapeutic potential. In this chapter, we discuss
application of these strategies to the unique proteostatic challenges of collagen misfolding
diseases, and review potential directions for building upon recent advances in this area.
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Dysregulated Proteostasis and the Collagenopathies
Collagen is a strange, surprising protein. It completely lacks enzymatic activity, and yet
regulates processes such as receptor signaling, cell migration, and tissue repair.' The structure
of mature type I collagen (collagen-) is a simple right-handed triple helix formed from strands of
repeating Gly-X-Y amino acid motifs, but relies on specific sequence properties and post-
translational modifications to pre-organize and stabilize the triple helix.2' 3 Among the twenty-
eight other types of collagen, the triple helix is subjected to an impressive array of permutations,
from the interrupted helices of the FACIT (Fibril Associated Collagens with Interrupted Triple
helices) family to the modular, organizing appendages on the termini of network-forming
collagens (reviewed in [1] and [4]). Outside the cell, the collagens assemble with themselves,
with each other, and with other ECM components to form and maintain diverse tissues.
Unsurprisingly, delays or difficulties in any of these processes-translation, modification,
triple helix assembly, secretion, or fibril formation-cause disease. The affected tissues and
phenotypes are as varied as the collagens themselves, but many involve factors such as
insufficient or excess protein deposition, cellular stress, inflammation, and apoptosis.5 Because
the molecular basis for disease is not always clear, with some collagen genotypes giving rise to
6multiple distinct phenotypes, one approach to treating the collagenopathies would be to target
the network of cellular proteins responsible for collagen biosynthesis and turnover. Focusing on
regulators of collagen protein homeostasis (proteostasis) is not unprecedented: over twenty-five
years ago, small molecule inhibitors of the collagen prolyl-4-hydroxylase (P4H) enzyme were
presented as potential therapeutic compounds for cases of excess collagen deposition, and
compounds that selectively inhibit or activate P4H in the absence of general toxicity are now
available.f~9 Moreover, collagen does not contain clear binding sites or chemical handles; thus,
targeting the chaperones and modifying enzymes that regulate its production could expand
druggable space while simultaneously addressing multiple aspects of proteostatic imbalance
(see Section 3.3 of [10]).'
The Unfolded Protein Response
Collagen is synthesized and assembled in the ER, which safeguards organellar
proteostasis by means of the Unfolded Protein Response (UPR). Similar to the cytosolic heat
shock response, the UPR tunes protein folding and degradation machinery to restore ER
proteostasis upon accumulation of misfolded proteins. Activation of the three transmembrane
sensors IRE1, ATF6, and PERK produces transcription factors XBP1s, ATF6(1-373), and ATF4,
respectively, that together increase levels of chaperones, enhance protein degradation, and stall
new protein synthesis to allow the ER to recover. If ER stress continues, however, PERK-
induced ATF4 activity will increase levels of a protein termed CHOP in a signaling cascade that
leads to apoptosis.
The advent of chemical tools for selective, stress-independent activation of individual
arms of the UPR" has clarified the overlapping functions of each branch, as well as revealed
physiological roles for individual UPR transcription factors.12 XBP1s activity, for instance, has
been shown to regulate processes such as memory formation, innate immunity, and cell non-
autonomous signaling.-13 5 ATF6 has been less extensively studied, but has been linked to
regulation of ER size and mesodermal differentiation.16' 17 Importantly, selective activation of
individual arms of the UPR also mitigates protein misfolding in both gain-of-function and loss-of-
function disease models. In particular, ATF6 activation has been shown to reduce secretion and
aggregation of amyloid-forming mutants of transthyretin, 18 '9 as well as increase clearance of
(toxic) protein aggregates, either through ER-associated degradation by the proteasome or
autophagy.20 XBP1s activation is also able to reduce secretion of amyloidogenic proteins.19
Intriguingly, proteomics-based approaches to identify components of the collagen-I proteostasis
network found that a number of novel interactors are transcriptional targets of XBP1s and/or
ATF6."11 21 Such findings suggest that modulation of UPR signaling not only may play a role in
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collagen- biosynthesis, but also may have positive effects in the collagenopathies; we discuss
these possibilities in more detail below.
IREI-XBPls
IRE1 is the oldest stress sensor of the UPR, and fulfills dual roles in response to ER
stress. Accumulation of misfolded proteins titrates the ER chaperone BiP away from the luminal
portion of IRE1, causing oligomerization and auto-phosphorylation by the IRE1 kinase domain 2
The IRE1 RNase domain subsequently splices XBP1 mRNA to generate active XBP1s (spliced)
mRNA, which is translated to give the XBP1s transcription factor. In addition to generating
active XBP1s, IRE1 also degrades selective subsets of gene transcripts in a process known as
regulated IRE1-dependent decay. XBP1s was previously shown to enable antibody production
during B-cell differentiation by expanding the ER and increasing secretory pathway capacity.24
Given that many fibrillar collagens are too large to fit into standard COP-Il vesicles, and that
collagen-producing tissues are responsible for secreting large amounts of ECM proteins in
addition to collagen, it is plausible that XBP1s facilitates a similar change during cartilage or
bone development. Indeed, in addition to regulating the expression of genes involved in
collagen-I biosynthesis, the IRE1/XBP1s axis has numerous physiological roles in collagen-
producing tissues. IRE1 and XBP1s inhibit ER stress-induced apoptosis in differentiating
cartilage.26 XBP1s also controls the expression of the transcription factor Osterix, required for
osteoblast mineralization, in addition to chondrocyte proliferation and hypertrophic growth plate
shortening in cartilage maturation.2 7 28
The effects of IRE1-XBPls signaling, though, are multi-faceted, complicating efforts to
evaluate XBP1s as a therapeutic target for the collagenopathies. A transgenic mouse model in
which a 13-base pair deletion mutant of Coll0a(l) accumulates in hypertrophic chondrocytes
shows XBP1s splicing and increased BiP expression, suggestive of a protective UPR that
allows chondrocytes to survive ER stress. Chondrocyte differentiation in these mice, however, is
disrupted, leading to delayed endochondral bone formation and chondrodysplasia in a process
that may involve XBP1s-mediated increases in miRNA-214 . 29 31 Stress-induced IRE1 activity
has been proposed to exacerbate fibrosis through degradation of miR-150 and production of
XBP1s. 32 Moreover, expression of the Schmid metaphyseal chondrodysplasia (MCDS) mutant
Coll0a(l) N617K in XBP1s-depleted cartilage revealed that UPR activation suppresses
chondrocyte differentiation through CHOP, not XBP1s. 33 Thus, while XBP1s activity can protect
cells from apoptosis following collagen retention and ER stress, hyper-activation of XBP1s can
also disrupt normal development, or in other cases may not be related to pathology at all. 3
Still, targeted methods to control IRE1 and/or XBP1s activity independent of ER stress
may prove useful in addressing the collagenopathies. Clearance of misfolded collagen by
autophagy restored bone growth in osteoblasts expressing the osteogenesis imperfecta (01)
variant Cola2(1) G610C, and autophagy has been proposed as an innate protective mechanism
for dealing with collagen aggregates that accompany expression of many disease variants.3 3-
Small molecule autophagy activators such as carbamazepine (CBZ) have yielded promising
results in several instances, 39 -4 but may require high doses that could produce off-target effects.
A more selective approach might be XBP1s-mediated induction of autophagy, which could
reduce disease burden by removing aggregated collagen deposits and alleviating pathological
ER stress. Doxycycline-controlled expression of XBP1s has been used to profile UPR
transcriptional targets and achieve sustained, stress-independent XBP1s activity , small
molecule activators of IRE1 have also been developed that are well-suited for short (-8 h)
45periods of IRE1 activity. Application of similar strategies to collagen disease models may
identify a therapeutic window for IRE1 and/or XBP1s activation that can resolve collagen
misfolding in the absence of long-term effects on differentiation (Figure 1.1).
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Figure 1.1: Methods to regulate IRE1/XBPls activity for addressing the collagenopathies.
The small molecule IPA activates IRE1 RNase activity independent of its kinase domain,
leading to splicing of XBP1 mRNA and production of the active transcription factor XBP1s.
Among XBP1s transcriptional targets is Beclin-1, a positive regulator of autophagy that could
help clear misfolded collagen aggregates. Carbamazepine (CBZ) also activates autophagy,
but through IRE1 and XBPIs-independent signaling pathways. INS = inositol; IP3 = inositol
1,4,5-trisphosphate; PIP 2 = Phosphatidylinositol 4,5-bisphosphate. Phosphoinositol signaling
pathway adapted from Vidal et al.45
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A TF6 and A TF6-like transcription factors
Like XBP1s, ATF6 has physiological roles in the development of collagen-producing
tissues. Overexpression of active or dominant-negative ATF6 by adenoviral transduction linked
ATF6 expression to matrix mineralization downstream of bone morphogenic protein 2 (BMP2)
and Runx2 signaling.46 Activation of ATF6 also conferred protection against experimental
inflammatory arthritis by C/EBPP and mTOR-mediated inhibition of NF-KB signaling.47 ATF6
regulates a partially overlapping set of genes with IRE1, but is activated by a distinct
mechanism, in which the transcription factor is transported to the Golgi and processed by site 1
(S1) and site 2 (S2) proteases to give an active N-terminal fragment (ATF6f).
Engineered cell lines, in which ATF6 is fused to a metastable, small molecule-
responsive domain, have been used to examine effects of selective, stress-independent ATF6
activation.'' 18 An attractive alternate strategy is direct, small-molecule activation of ATF6 by
compounds identified in a recent high-throughput screen. 48 However, further studies have
revealed that the mechanism of action for one of these compounds involves covalent
modification of ER chaperones PDIA3, 4, and 5, as well as ERP29. 49 The extent of modification
was incomplete (-29%), but several of these chaperones have potential roles in collagen-I
biosynthesis,2' and so thorough characterization of ATF6-activating compounds will be needed
to avoid counterproductive effects.
Beyond ATF6, a family of ATF6-like transcription factors has been identified with strong
connections to collagen physiology. Despite low sequence homology, the osteoblast-specific
OASIS and chondrocyte-specific BBF2H7 share key features of ATF6 structure, including a
transcriptional activation domain, transmembrane domain, and motif for site 1 (S1) protease
processing. 50 BBF2H7 increases expression of Sec23a, a gene required for collagen secretion,
to promote chondrogenesis and protect chondrocytes from UPR-induced apoptosis; BBF2H7
knockout mice accordingly show chondrodysplasia along with a distended ER.27  In
osteoblasts, OASIS increases expression of Colal(I) to facilitate bone formation.52 OASIS and
BBF2H7 are regulated differently than ATF6, through stabilization of protein levels as opposed
to disulfide reduction-mediated monomerization, and may not respond to the identified ATF6
activators.53  Still, clarification of OASIS and UPRE binding motifs could allow for similar
reporter-based screening approaches to discover compound leads for modulating these ATF6-
like transcription factors in ways that could prove beneficial in the collagenopathies (Figure 1.2).
PERK
As the UPR branch responsible for initiating apoptotic signaling cascades, PERK is often
treated more as part of the problem than the solution in protein misfolding diseases. ER stress-
induced PERK signaling, however, is required for osteogenesiS54 and is activated in
chondrocytes to facilitate collagen secretion.55 But while PERK/ATF4 signaling protects
chondrocytes from apoptosis, it also promotes chondrodysplasia by reverting chondrocyte
differentiation.56 Notably, the small molecule ISRIB,57 which blocks PERK signaling by rendering
cells insensitive to elF2a phosphorylation, restored differentiation and lessened skeletal
deformities in a mouse model of MCDS.56 A similar approach using salubrinal showed positive
effects in an osteoarthritis model.58 However, the related compound guanbenz had no
therapeutic effect, and the classification of these two compounds as elF2a phosphorylation
inhibitors has been challenged.59 ~1 Obtaining a clearer understanding of the mode of action of
PERK signaling inhibitors will thus be critical for understanding PERK pathophysiology in the
context of collagen misfolding (Figure 1.3).
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Figure 1.2: Methods to regulate A TF6 activity for addressing the collagenopathies. The small
molecule 147 activates ATF6 by inhibiting the prolyl disulfide isomerases (PDIs) that promote
ATF6 oligomerization (ATF6o); inhibition of PDIA3, PDIA4, and/or PDIA5 promotes formation
of monomeric ATF6 (ATF6m), which is free to traffic to the Golgi. Processing by site 1 (S1P)
and site 2 (S2P) proteases yields the active transcription factor ATF6f. Among ATF6
transcriptional targets is BGLAP (Osteocalcin), a positive regulator of osteoblast
differentiation. The a-site specific PDIA1 inhibitor KSC-34 does not target PDIA3 or PDIA4,
but could potentially prevent PDIA1-mediated hydroxylation of collagen-I in the absence of
UPR activation. BBF2H7 and OASIS are two members of a family of ATF6-like transcription
factors whose target genes are important for chondrogenesis and osteoblast differentiation,
respectively. Methods for regulating the activity of these transcription factors may therefore
prove useful for chondro- or skeletal dysplasias.
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Figure 1.3: Methods to regulate PERK activity for addressing the collagenopathies. The
small molecule ISRIB desensitizes cells to downstream signaling of phosphorylated elF2a.
Salubrinal and guanabenz have also been proposed to block effects of elF2a
phosphorylation, but their mechanism of action is not yet confirmed. PERK/ATF4 signaling
can increase levels of the protein CHOP, which initiates apoptotic signaling cascades, but
PERK/ATF4 signaling has also been implicated in chondrocyte differentiation. More work is
therefore needed to determine therapeutic opportunities for modulating PERK activity in the
context of the collagenopathies.
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Targeting downstream proteostasis components
The class of compounds that has been most widely used to date in addressing the
collagenopathies is chemical chaperones. 4-Phenylbutyric acid (PBA) reduced cell death in 01
patient fibroblasts by promoting autophagic clearance of mutant Colal (1) and Cola2(l) chains
and has been used to reduce ER stress in Col2a(IV) mutant lines. 2 63 PBA also reduced ER
stress and autophagy, but increased Col5a(IV) expression in fibroblasts from patients with
Alport Syndrome (AS).64 Another chemical chaperone, trimethylamine N-oxide (TMAO), had a
larger effect on collagen-I triple helix thermostability when incubated with purified wild type,
R789C Col2a(l), or R992C Col2a(l) molecules than when added to cell culture, 5 suggesting
that such compounds may act through direct binding to the target molecule rather than by
modulating the cellular proteostasis network. 6 This explanation is consistent with the ability of
PBA to increase Col5a(IV) transcripts in both AS patient lines, but improve secretion of only one
mutant. In a separate study, PBA had minimal effects on retention of aggregated cartilage
oligomeric matrix protein (COMP), underscoring the need to consider misfolding, disease-
related proteins in the context of the proteostasis network.67
More promising than chemical chaperones, though still untested, are therapeutic
strategies that target individual components of the collagen proteostasis network. The existence
of at least nine genes linked to recessive forms of 01 demonstrates that individual collagen
chaperones can (and do) influence collagen production.68 Key advantages of this approach-in
contrast to the chemical chaperones-include disease-specific protein targets, improved
mechanistic understanding, and access to existing medicinal chemistry knowledge. Extensive
work on prolyl disulfide isomerase (PDI) inhibitors, for instance, enabled the recent development
of a compound, KSC-34, that selectively binds the a-site catalytic domain. 9 Importantly,
compound treatment has minimal effects on the UPR, indicating that PDIA1 can be targeted
independent of induced ER stress. Similar improvements to the selectivity of inhibitors for BiP
and other collagen-I chaperones will thus provide new opportunities for testing a proteostasis-
targeted therapeutic approach in collagen disease models.
Conclusions
The UPR is integrally linked with development and disease in collagen-producing
tissues. Connections between IRE1, ATF6, PERK, and multiple collagenopathies provide
compelling evidence that regulating the different arms of the UPR could address diseases with
varied causes and phenotypes. Due to the dual roles of UPR activation in development and
disease, therapeutic approaches that target individual components of the proteostasis network
will likely improve selectivity. However, many collagen-misfolding diseases result from
inactivating mutations in collagen chaperones, and small molecule activators for these proteins
are rare. Still, we note that significant advances in pharmacologic methods to tune UPR activity
have come from the development of new screening platforms. Continued studies of disease-
relevant signaling pathways can thus inform the design of screens for new compound leads. In
the following chapters, we apply a similar approach to collagen-I proteostasis. We report the
design and application of a high-throughput assay to identify selective small molecule
modulators of collagen-I secretion (Chapter II). We then describe the results of mechanistic
studies on a validated screening hit, 17-allylaminogeldanamycin (17-AAG), and the insights we
obtain regarding its cellular target (Chapter 1I). Our results demonstrate that elements of the
proteostasis network not traditionally considered to be collagen biosynthetic enzymes may also
be important players in the collagenopathies. In addition, our findings emphasize the importance
of the continued study of collagen biosynthesis and the physiology of collagen-producing tissues
for discovery of new therapeutic targets.
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CHAPTER II
Development of a High-Throughput Assay for Collagen-I Secretion
Summary
Collagen overproduction is a feature of fibrosis and cancer, while insufficient deposition
of functional collagen molecules and/or the secretion of malformed collagen are common in
genetic disorders like osteogenesis imperfecta. Collagen secretion is an appealing therapeutic
target in these and other diseases, as secretion directly connects intracellular biosynthesis to
collagen deposition and biological function in the extracellular matrix. However, small molecule
and biological methods to tune collagen secretion are severely lacking. Their discovery could
prove useful not only in the treatment of disease, but also in providing tools for better elucidating
mechanisms of collagen biosynthesis. We developed a cell-based, high-throughput luminescent
assay of collagen type I secretion and used it to screen for small molecules that selectively
enhance or inhibit that process. Among several validated hits, the Hsp9O inhibitor 17-
allylaminogeldanamycin (17-AAG) robustly decreases the secretion of collagen- by our model
cell line and by human primary cells. In these systems, 17-AAG reduces collagen-I secretion
post-translationally and is not a global inhibitor of protein secretion. Beyond 17-AAG, we also
identify the broad-spectrum antiparasitic compound nitazoxanide (NTZ) as a post-translational
inhibitor of collagen-I secretion. Our results highlight the potential of a cell-based high-
throughput screen for selective modulators of collagen secretion.
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Introduction
By both function and sheer mass percentage, collagen constitutes the major component
of animal tissue.' Twenty-eight distinct types of collagen play important roles in architecturally
diverse extracellular matrices, ranging from skin and bone to cartilage and basement
membranes. In addition to providing the structural framework for these tissues, the collagens
have dynamic functions in numerous biological processes.3' , For example, collagens engage
integrins on cell surfaces, influence wound-healing responses and inflammation, and play
critical roles in cell differentiation, organ development, and tissue maintenance.
Collagen biosynthesis is a complex process, encompassing extensive post-translational
modifications, folding and assembly, propeptide cleavage, secretion, and extracellular fibril
formation.5 It is not surprising, then, that dysregulated collagen homeostasis is closely related to
numerous pathologies.6 Fibrosis is characterized by collagen overproduction and often leads to
organ damage or failure.7 Many cancers also feature high levels of collagen secretion and
matrix remodeling, which promote metastasis.8 -10 Conversely, insufficient deposition of properly
structured collagen and/or excessive accumulation of misfolded collagen molecules give rise to
an array of phenotypically diverse pathologies." These genetic disorders, ranging from
osteogenesis imperfecta to Ehlers-Danlos syndrome, are typically caused by mutations in
collagen genes or chaperones.12
Despite substantial work characterizing fibrosis13 and the collagenopathies," 14 many of
the underlying disease mechanisms remain poorly defined, especially with respect to why and
how collagen homeostasis fails. Biological and small molecule tools that selectively target the
processes involved in the biosynthesis of collagen type 1, the most abundant collagen type, 1
could yield new mechanistic insights, in addition to providing leads for therapeutic strategies.
However, relatively few small molecules that can selectively alter either collagen-I folding or
secretion have been identified to date.16-18 Furthermore, high-throughput methods to facilitate
the discovery and design of new compounds are limited, in large part because assaying the
folding and secretion of a protein that not only lacks enzymatic activity but also requires a
complex cellular folding environment5 is inherently challenging.
To address this need, we developed a high throughput cell-based, luminescent assay for
modulators of collagen-I secretion. We screened 1228 known bioactive and FDA-approved
compounds, validating a number of hit molecules that selectively affect collagen-I secretion but
not the secretion of a control protein. Of particular interest, we find that the Hsp90 inhibitor 17-
allylaminogeldanamycin (17-AAG) selectively reduces the secretion of our collagen-I reporter.
We confirmed the ability of 17-AAG to reduce the secretion of endogenous collagen-I from
human primary cells independent of effects on collagen-I transcripts or synthesis. Beyond 17-
AAG, we also identify the broad-spectrum antiparasitic compound nitazoxanide (NTZ) as
another potential inhibitor of collagen-I secretion. Follow-up studies using these and other
screening hits are thus expected to provide additional insights into mechanisms of collagen-I
biosynthesis and secretion, as well as new potential opportunities for therapeutic intervention.
Results
Luminescent Assay Design and Validation. Because collagen-I lacks enzymatic activity, current
methods for assaying collagen-I levels in moderate- to high-throughput fashion primarily rely on
the binding of hydrophobic dyes to deposited collagen fibers.9 , 20 Other assays are conducted in
vitro with purified collagen-I and recombinant collagen binding proteins' 21 or measure collagen
transcription,22 rather than the many post-transcriptional processes key to collagen biosynthesis.
We reasoned that appending a luciferase enzyme to collagen-I would allow for direct
monitoring of fusion protein secretion, with increased sensitivity from the enzymatic signal
amplification. With this approach, the screen would be suitable for discovering both activators
and inhibitors and would not require prior knowledge of collagen folding, quality control, and
secretion pathways. For our reporter molecule, we selected the engineered, or "enhanced",
30
variant of Gaussia luciferase (eGLuc2). eGLuc2 is natively secreted, small, bright, ATP-
independent, and highly stable, and has been used successfully for high-throughput
screening.2 -27 As native collagen-I is a 2:1 Colal(1):Cola2() heterotrimer,28 we attached
eGLuc2 to Cola2(l) to control the stoichiometry of fusion protein incorporation. We positioned
eGLuc2 at the extreme N-terminus to avoid interfering with triple-helix nucleation by collagen's
C-terminal propeptide (Figure 2.1A). We also included the eGLuc2 signal sequence to direct
eGLuc2.Colca2(l) to the secretory pathway. Finally, we engineered the fusion protein gene to be
under control of a tetracycline repressor-regulated, doxycycline (Dox)-inducible promoter both to
simplify the long-term propagation of stable cell lines and to provide temporal control of
eGLuc2.Cola2() expression.
We next engineered Saos-2 osteosarcoma cells, which are osteoblast-like and produce
endogenous collagen-I,30 31 to stably and inducibly express eGLuc2.Cola2(l). We had previously
shown that Saos-2 cells stably expressing the tetracycline repressor (termed Saos-2-TREx
cells) can be used to control the heterologous expression of antibody epitope-tagged collagen-I
variants.32 Building on that work, we transduced Saos-2-TREx cells with an eGLuc2.Coa2(l)-
encoding lentivirus, selected for stable gene incorporation, validated protein expression by
immunoblotting (Figure 2.2A), and isolated a genetically homogeneous single-colony line for
assay development. eGLuc2.Cola2() secretion can be assayed in the resulting Saos-2GLuc.Co1
cells by inducing transcription with Dox and then measuring the extent of secretion via a
luminescence assay on the conditioned media (Figure 2.1A). We verified that the intensity of the
extracellular luminescent signal is increased in response to sodium ascorbate (Figure 2.2B),
which induces collagen-I translation and also facilitates collagen-I secretion by recycling the
prolyl-4-hydroxylase metallocofactor.' " " The level of eGLuc2.Cola2() secretion is also
strongly reduced by treatment with the ER-to-Golgi transport inhibitor Brefeldin A (Figure
2.2C).35 Thus, the secretion of our eGLuc2.Cola2() fusion protein is dependent on mechanisms
known to be involved in collagen export. In tandem, we also prepared a Saos-2GLuC cell line,
which inducibly expresses unfused eGLuc2 under the tetracycline repressor, as a control for our
high-throughput screen.
Although we and others3 2' 36 have generated N-terminal fusions to collagen-I and shown
that such proteins are well-behaved, we sought to directly evaluate whether the presence of
eGLuc2 disrupts collagen-I folding or assembly. We first determined whether eGLuc2.Cola2()
associates with Colal (1) intracellularly. Immunoprecipitating eGLuc2.CoIca2() with an a-GLuc
antibody from Saos-2GLuc.Col cell lysate revealed that both eGLuc2.Cola2(l) and Colal() are
enriched in the eluted fraction (Figure 2.1B), indicating formation of a stable heteromeric
complex, as expected, and suggesting that eGLuc2.Colca2(l) can successfully assemble with
Cola (1).
We next sought to determine if secreted eGLuc2.Cola2(l) also formed stable heteromers
with Colal(1). As disulfide-bond formation in the C-terminal propeptide is needed to initiate
collagen-I triple-helix formation,5 we precipitated collagen-I from conditioned media of Saos-
2 GLuc.Col cells and assayed for disulfide-dependent assembly by SDS-PAGE (Figure 2.1C). We
observed that secreted eGLuc2.Cola2(l) associates with Colal(I), as detected by the co-
staining of a-GLuc and Colal(l) antibodies under nonreducing conditions. While we observe
monomeric (-190 kDa) and dimeric (-245 kDa) species for both Colal (I) and eGLuc2.Cola2()
under non-reducing conditions, likely owing to disulfide shuffling during SDS-PAGE separation,
the banding pattern is consistent with previous observations by us and others for native
collagen-I. 37 38 Importantly, in the presence of the reducing agent 1,4-dithiothreitol (DTT), both
eGLuc2.CoIa2(l) and Colal(l) collapse to the monomeric molecular weight, as expected for
dissociation of disulfide-linked trimers.
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Figure 2.1: High-throughput screening strategy and results. (A) Schematic of screen design.
Addition of 1 pig/mL doxycycline (Dox) to the stable single-colony Saos-2GLuc.Col cell line
induces expression of the eGLuc2.Cola2(l) fusion protein, which can be proteolytically
processed postsecretion. Luminescence generated by the fusion protein may be assayed
upon addition of the eGLuc2 substrate. (B) eGLuc2.Cola2(l) from Saos-2GLuc.Col lysate was
immunoprecipitated with an a-GLuc antibody and analyzed by immunoblotting, revealing that
eGLuc2.Cola2(l) associates intracellularly with Cola1(I). (C) Disulfide-dependent assembly
of eGLuc2.Cola2(l) with Cola1(I). Collagen-I precipitated from conditioned media of Saos-
2GLuc.Col cells was treated with iodoacetamide and heated in Laemmli buffer with or without
DTT. Samples were separated by SDS-PAGE and analyzed by immunoblotting. (D) Plot of
filtered screening results. (E) Validated small molecule modulators of collagen-I secretion.
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Figure 2.2: Validation of Saos-2GLuc.CO! cells to assay collagen-I secretion. (A) Western blot
showing Dox-inducible expression of the eGLuc2.Cola2(I) fusion protein in a Saos-2-TREx
heterostable cell line. Cells were treated for 48 h with 2 pig/mL Dox prior to harvesting and
analysis; conditioned media or 50 ~g lysate from cells was boiled with Laemmli buffer + 167
mM dithiothreitol. Samples were then separated by SDS-PAGE on homemade 4/8/12% Tris-
Gly gels, transferred to nitrocellulose membranes, and developed with a rabbit anti-GLuc
antibody. The band at ~-200 kDa corresponds to intact fusion protein; post-secretion,
collagen-I produced by Saos-2-TREx cells can be proteolytically processed by proteinases
that cleave the N-propeptide from the triple-helical domain, leaving a GLuc-reactive band at
~40 kDa. (B) eGLuc2.Colcz2(l) luminescent activity was measured in conditioned media from
intact cells (treated briefly with trypsin and washed with media), or from cells lysed by
repeated freeze-thaw cycles. Significant luminescence is detected only from media and cell
lysates. Cells were treated with 1 ~g/mL Dox for 24 h and/or 50 pM sodium ascorbate, as
indicated, prior to a GLuc assay. * = p < 0.05; *** = p < 0.001 (n = 3). (C) GLuc assay
performed on cells induced for 24 h with 1 ptg/mL Dox and treated with DMSO or increasing
concentrations of Brefeldin A (L to R: 0, 3.56, 17.8, or 35.6 pM). * = p < 0.05 (n = 3).
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We also performed pepsin digests of precipitated collagen-I from Saos-2GLuc.Col cells.
Properly folded collagen-I triple helices are known to be pepsin-resistant39 and, indeed, we find
that upon Dox treatment, a second pepsin-resistant band corresponding to propeptide-cleaved
eGLuc2.Cola2(l) appears in addition to propeptide-cleaved Cola1(l) (Figure 2.3). Together,
these results suggest that the eGLuc2.Cola2() fusion protein is incorporated into stable triple
helices with Colal (1) and that eGLuc2 tagging does not significantly disrupt collagen-I assembly
or folding.
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Figure 2.3: eGLuc2.Cola2(I) incorporates into pepsin-resistant structures. Collagen-I was
selectively precipitated from conditioned media of Saos-2GLuc.Col cells with ammonium sulfate.
Precipitated collagen-I pellets were then resuspended in 0.5 M acetic acid and incubated
with or without 0.2 mg/mL pepsin for 48 h at 4 *C. While pepsin-resistant Colal (1) is clearly
visible for both digested lanes, treatment with Dox gives rise to a second band in the pepsin-
digested lane corresponding to pepsin-stable eGLuc2.Cola2(l).
High-Throughput Screening for Collagen-I Secretion Modulators. We next miniaturized our
collagen secretion assay for high-throughput screening in 384-well plates, tested for linearity,
and optimized a timeline for induction of collagen expression and compound addition (detailed
assay parameters are presented in Materials and Methods; full, normalized screening data are
presented in Table S1 of ref. [75]). For our initial screen of eGLuc2.Cola2(I) secretion, we
employed the Harvard Medical School Institute of Chemistry and Cell Biology (ICCB) Bioactives
and the FDA-Approved small molecule libraries, commercially available from Enzo Life
Sciences. Together, the libraries contained 1228 unique compounds spanning at least 22 drug
target classes. Our results from analyzing conditioned media after eGLuc2.Cola2(l) secretion for
24 h were quite reproducible, as indicated by a low coefficient of variation (% CV, vehicle-
treated wells) and a Pearson's correlation coefficient of 0.9611 between eGLuc2.Cola2(l)
replicates for compound treatments across both libraries (Figure 2.4A, C).
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A. Assay Reproducibility
% Cv Pearson's Coefficient
Cell Line Avg (%) Std Dev (%) r, Confidence Interval
Saos-2GLuc 8.79 1.84 0.9214 (0.9126-0.9294)
Saos-2Guc.Col 5.84 0.89 0.9611 (0.9567-0.9651)
B.
HTS Filtering Schematic
GLuc2.Cola2(l) 1228 1' screen
Luminescence mpD
Keep if 21.25 or
:50.80 fold-change
Celliter-GlW7302 2* screen
Luminescence hits
KI e if <3SDf
p.C. correlation of eGLuc2.Cola2() , from DMSO Average
107 Screening Replicates eGLuc2 199 counter
Luminescence hits screen
1.Keep if <1SD
E 105 + from DMSO Average
104 .Follow-up Testing 17
._ 1 in aos-2G cells hit
E same result
Z 10 4, as screen?
Normalized Luminescence 6 Validated, Selective Collagen(Replicate 1) Secretion Modulators
Figure 2.4: Assay reproducibility. (A) Average coefficient of variation and Pearson's
correlation coefficient. (B) Overview of counterscreening and filtering strategies and results.
Conditions for cell plating and compound addition in all screens are described in the
Materials and Methods. (C) Correlation between screening replicates of unfiltered,
normalized eGLuc2.Cola2(l) data for all compounds.
A number of factors, including compound toxicity or effects on fusion protein
transcription/translation, general protein secretion, or luciferase enzyme activity, might produce
a response in this high-throughput assay, despite being unrelated to our desired phenotype of
selective effects on collagen-1 secretion. We performed two counterscreens to filter out such
false positives: (1) we used a CellTiter-Glo assay to remove cytotoxic compounds, and (2) we
employed an eGLuc2 secretion assay to remove compounds that shift the eGLuc2-derived
signal in the same direction as the eGLuc2.Cola2(l)-derived signal (Figure 2.4B). The results
are presented in Figure 2.1D. Notably, many of the compounds that strongly decreased
eGLuc2.Cola2(l) luminescence were also flagged in our CellTiter-Glo secondary screen as
cytotoxic (signal more than three standard deviations below the average DMSO signal) at the
concentrations used and were therefore triaged. Meanwhile, many of the compounds that
yielded the largest changes in normalized luminescence in our eGLuc2.Cola2(l) secretion
assay, some on the order of -5-fold increases, were triaged because they had similar effects on
the luminescence signal obtained in media from our control Saos-2GLuc cell line. The striking
effects on protein secretion yielded by some of these compounds (see Table S1 of ref. [75])
suggest that they may prove useful as broad-spectrum modulators of secretory pathway
function, although the effects may also be due merely to modification of eGLuc2 luminescence.
Regardless, the aim of our screening protocol was to identify compounds that selectively target
collagen-I secretion. Those with obviously non-specific effects on protein secretion were not
pursued further in this study.
After filtering the primary screening results as described above, we obtained 17 putative
hit compounds that selectively modulate secretion of eGLuc2.Cola2(l) from Saos-2 cells. A list
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of these compounds, their effects on eGLuc2.Cola2(l) secretion, and their annotated functions
is provided in Table 2.1, and structures of the six validated hits are presented in Figure 2.5.
Table 2.1. Candidate Hit Compounds.
Effect on Effect on eGLuc2
Compound eGLuc2. Cola2( ) (% Change vs DMSO- Annotated(% Change vs DMSO- treated cells) Function/Mechanism
treated cells)
17-AAG -30.7 0.2 25.9 14.7 Hsp90 inhibitor
Ac-Leu-Leu- 30.5 1.3 7.6 3.4 Calpain inhibitorNie-CHO
AG1478 -24.4 2.3 -1.0 0.6 Tyrosine kinase inhibitor
Benazepril HCI 25.0 6.7 3.2 2.5 ACE inhibitor
Bromocriptine -29.0 9.7 -0.9 12.3 Dopaminergic receptor
Mesylate agonist
Ceftazidime 27.1 15.4 0.6 0.6 Antibiotic
Chlorphenirami 25.7 4.3 6.9 2.5 Antihistamine
ne Maleate
15-deoxy-
prostaglandin -32.3 7.7 -5.0 7.4 Bioactive prostaglandin
J2
Gefitinib -34.0 0.4 -1.6 0.7 EGFR inhibitor
L-744, 832 33.3 0.5 -4.7 19.5 Ras farnesyltransferaseinhibitor
Losartan 27.4 3.3 7.2 0.6 Type-1 angiotensin I
Potassium receptor (AT1) antagonist
Mitomycin C -26.8 3.8 -0.3 3.0 DNA crosslinker
MY-5445 -25.3 0.1 8.5 22.7 Phosphodiesterase (PDE5)inhibitor
Oxaprozin 26.5 5.9 -17.1 44.1 NSAID
RG-14620 -31.2 3.6 -8.2 4.4 EGFR inhibitor
SDZ-201106 -22.6 1.5 -5.7 12.3 Sodium channel ligand
Tolcapone 28.5 4.5 5.6 1.7 Catechothyltransferase(COMT) inhibitor
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Figure 2.5: Structures of validated compounds that selectively modulate collagen-I secretion.
Associated screening results and annotated functions are given in Table 2.1.
The Hsp9O Inhibitor 17-AAG Reduces the Secretion of Endogenous Collagen-. We
repurchased and retested 15 of the 17 compounds that passed our screening filters, yielding six
validated small molecules that selectively alter eGLuc2.Cola2(), but not eGLuc2, secretion and
are not cytotoxic in Saos-2 cells at the tested concentrations (Figure 2.1E and 2.5). 17-
Allylaminogeldanamycin (17-AAG), a particularly well-characterized inhibitor of Hsp90-type
chaperones,40' 4 stood out to us from these validated compound hits because it has opposite
effects on eGLuc2.Cola2(l) and eGLuc2 secretion (Figure 2.1E). Furthermore, 17-AAG and its
analogue 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) have been
reported to display beneficial effects in fibrosis models, by a mechanism involving reduction of
inflammatory signaling but not by direct inhibition of collagen biosynthesis, folding, or
secretion.42 -45 We, however, hypothesized that Hsp90 inhibition might directly impede collagen-I
secretion. To explore this possibility further, we chose to follow up on the 17-AAG results from
our high-throughput screen and investigate the mechanism of action.
To begin, we treated Saos-2GLuc.Col cells with a range of 17-AAG concentrations and
observed a dose-dependent reduction in the intensity of the luminescent signal (Figure 2.6A).
Next, we focused on testing whether these results would be recapitulated in primary cells
expressing endogenous collagen-1, instead of an eGLuc2.Cola2(I) fusion protein with a non-
native promoter and signal sequence. In this regard, we chose to employ primary human
fibroblasts, which can be readily cultured in vitro and are one of the major producers of
collagen-I in humans. After a 24 h treatment with Hsp90 inhibitor, immunoblotting revealed
significant decreases in the level of endogenous collagen-I secretion relative to that of vehicle-
treated cells (Figure 2.6B and D). We observed no changes in intracellular levels of collagen-I
(Figure 2.6C). We also confirmed functional inhibition of cytosolic Hsp90 at the concentrations
used, indicated both by the expected increase in Hsp70 levels due to induction of a
compensatory heat shock response (HSR) and by the loss of signal from the cytosolic Hsp90
client Akt (Figure 2.6C).
To test whether the effects of Hsp90 inhibitor treatment on secretion of endogenous
collagen-I by primary fibroblasts were cell line-specific, we obtained a second primary fibroblast
line. As expected, 17-AAG treatment caused similar reductions in the level of secretion of
collagen-I from these cells (Figure 2.6E), indicating that our results are not dependent on a
particular primary fibroblast genotype.
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17-AAG Reduces Collagen-I Secretion via a Post-Translational Effect. We next investigated the
mechanism by which inhibition of Hsp90-type chaperones reduces the level of collagen-I
secretion. Possible trivial explanations we considered were (1) that a reduced level of collagen-I
secretion in primary fibroblasts is caused by compound cytotoxicity, (2) that Hsp90 inhibitors
reduce the levels of collagen-I transcripts, and/or (3) that Hsp90 inhibitors lower the level of
collagen-I translation. Our Saos-2 data (Figure 2.1) suggested that these explanations were not
applicable, as we had already counterscreened for cytotoxicity and we employed a non-native
promoter, but it was nonetheless important to test all three possibilities in primary cells.
We treated primary fibroblasts with 17-AAG for 24 h and then tested for cytotoxicity by
staining cells with Annexin-V/Alexa Fluor 488 and propidium iodide followed by FACS analysis.
Treatment with 17-AAG was not toxic by this assay, confirming that Hsp90 inhibitors do not
decrease the level of secretion of collagen-I from primary fibroblasts simply by promoting cell
death (Figure 2.7A). Next, we performed qPCR analysis of collagen-I transcripts from Hsp90
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Figure 2.6: 17-AAG reduces endogenous collagen-I secretion. (A) Dose-response curve for
the screening hit 17-AAG in Saos-2 GLuc.Col cells. Cells were plated in 384-well plates and co-
treated 5-6 h after being plated with 1 Vg/mL Dox and 17-AAG. After 23 h, plates were
cooled at room temperature for 1-1.5 h, substrate was added, and luciferase activity was
assayed. Western blot of conditioned media (B) and lysate (C) from primary dermal
fibroblasts. Cells were plated and allowed to adhere overnight before receiving fresh media
with 200 tM ascorbate and 250 nM 17-AAG. After being treated for 24 h, conditioned media
and cells were harvested for immunoblotting. (D) Quantification of Western blot results. *p <
0.05 (n = 3). (E) Western blot of conditioned media from a second healthy fibroblast line. *p <
0.05; **p < 0.01 (n = 3).
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Figure 2.7: Effects of Hsp90 inhibition on collagen-I secretion are post-translational. (A)
FACS analysis of Annexin-V/Alexa Fluor 488 and propidium iodide staining to detect
cell death. Cells were plated in triplicate for each condition and allowed to adhere
overnight before being treated as in Figure 2.6B. After 24 h, cells were trypsinized and
labeled for FACS analysis. (B) qPCR analysis of collagen-I transcript levels from cells
treated as in Figure 2.6B. Average values are shown with the standard deviation for
each condition (n = 3). (C) Measurement of collagen-I synthesis by [2,3-3H]proline
Fulse. Cells treated for 6 h with ascorbate and 17-AAG (250 nM) were pulsed with [2,3-
H]proline for 30 min prior to being harvested and analyzed. Quantitation of newly
synthesized collagen-I (mean standard deviation) is shown along with a
representative gel image (n = 3).
inhibitor-treated primary fibroblasts. We found that COLIA1 and COL1A2 transcript levels are
not significantly altered, indicating that the mechanism of action is post-transcriptional (Figure
2.7B). Finally, we used a tritium pulse assay to test whether collagen-I translation is altered by
17-AAG treatment. Briefly, we pulsed treated fibroblasts with [2,3-3H]proline for 30 min to label
the proline-rich collagen-I protein, followed by collection of cell lysate and auto-radiography
analysis of the collagen-I bands (identified by bacterial collagenase treatment). We observed no
significant alterations in levels of newly synthesized, radiolabeled collagen-I upon 17-AAG
treatment (Figure 2.7C). Cumulatively, these data indicate that 17-AAG reduces collagen-I
secretion via a post-translational mechanism.
17-AAG Selectively Reduces Collagen-I, but Not General Protein, Secretion. Another potential
explanation for our results is that Hsp9O inhibitors non-selectively reduce the level of protein
secretion. We had established that 17-AAG treatment does not inhibit eGLuc2 secretion in
Saos-2 cells (Figure 2.1), but it remained unclear whether effects on endogenous collagen-I
secretion in primary fibroblasts would be selective. Indeed, prior work suggests that Hsp90
inhibitors can disrupt protein secretion in yeast 0 or inhibit ER-to-Golgi transport by perturbing
Rab1 GTPase recycling in mammalian cells,47 so we wondered if the effects of Hsp90 inhibitor
treatment on collagen-I secretion might extend generally to other proteins.
To examine this question, we transduced primary fibroblasts with adenoviruses
expressing FLAG-tagged transthyretin (TTR) or fibulin-3 (two well-characterized and soluble
secreted proteins), treated the cells with 17-AAG at a concentration that reduces the level of
collagen-I secretion, and assayed for altered secretion of these additional ER client proteins
(Figure 2.8A). Treatment with 17-AAG did not alter TTR secretion, while fibulin-3 secretion was
actually enhanced -3-fold by 17-AAG treatment (Figure 2.81). We next tested the secretion of
fibronectin, an endogenous secreted protein that interacts with collagen-I but is secreted in
globular form.48, 4 Again, 17-AAG robustly decreased the level of collagen-I secretion but did
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Figure 2.8: 17-AAG does not affect general protein secretion. (A) Experimental workflow.
Cells were plated and allowed to adhere overnight before being transduced with either GFP,
transthyretin (TTR), or fibulin-3-expressing adenoviruses. The next day, transductions were
split 1:2 and allowed to adhere overnight; cells were then treated with ascorbate and DMSO
or 17-AAG (250 nM) for 24 h prior to being harvested. (B) Western blot of conditioned media
from primary dermal fibroblasts transduced with FLAG-tagged transthyretin (TTR) or fibulin-
3. (C) Immunoblot analysis of the secretion of endogenous fibronectin after treatment with
17-AAG. Cells were plated and treated as described in Figure 2.6B. (D) Quantification of
Western blot results. *p < 0.05 (n = 3). (E) Phosphorimage of 35S-labeled secreted proteins.
Cells were plated in triplicate for each condition and allowed to adhere overnight before
being pretreated with ascorbate and DMSO or 17-AAG (250 nM) for 2 h. Cells were then
washed and cultured in radiolabeled media containing ascorbate, [35S]-Met/Cys, and
DMSO/1 7-AAG for 6 h. A representative radiograph is shown.
not alter fibronectin export (Figure 2.8C, D). Although these proteins are not representative of all
possible secretory pathway cargo, their response to 17-AAG treatment, in contrast to what we
observe for collagen-I from the same cells, strongly suggests that 17-AAG at the concentrations
employed reduces the level of collagen-I secretion with considerable selectivity. However,
because high concentrations of Hsp90 inhibitors had been reported to induce Golgi
fragmentation, 7 we sought to more rigorously test whether global protein secretion was
inhibited under our experimental conditions.
We first evaluated Golgi integrity using imaging techniques. We treated primary
fibroblasts with ascorbate and DMSO or 17-AAG for 20 h and then stained cells with an
antibody raised against the cis-Golgi marker GM-1 30. Confocal microscopy showed that
treatment with Brefeldin A resulted in a punctate a-GM-130 distribution, as expected (Figure
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Figure 2.9: Confocal microscopy analysis of Golgi structure with 17-AAG treatment.
GM05659 fibroblasts were plated and treated with ascorbate and DMSO or the indicated
compounds for 20 h. Cells were then fixed and stained with a-GM130, a cis-Golgi marker,
before imaging on a Zeiss spinning disk confocal microscope.
2.9). By contrast, 17-AAG did not significantly alter Golgi structure relative to that seen upon
DMSO treatment, either at the concentration used in our collagen-I secretion experiments (250
nM) or at a 10-fold larger dose. We also performed electron microscopy on fibroblasts treated
with ascorbate and 17-AAG for 6 or 18 h. In addition to the characteristic Golgi stacks, some
regions of vesicular tubular networks were visible in all samples; however, neither 6 nor 18 h of
17-AAG treatment resulted in Golgi collapse or a loss of morphology relative to that seen upon
DMSO treatment (Figure 2.10). Next, we employed radiolabeling to globally assess protein
secretion. We pretreated fibroblasts with ascorbate and 17-AAG for 2 h and then incubated the
cells with [3 5S]Met and Cys-labeled medium, ascorbate, and 17-AAG for 6 h. The resulting
phosphorimages, shown in Figure 2.8E, reveal that treatment with 17-AAG does not broadly
affect the secretion of radiolabeled proteins in our system. On the basis of these results, we
conclude that inhibiting Hsp90-type chaperones can reduce the level of secretion of collagen-I
from primary fibroblasts without globally inhibiting protein trafficking.
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17-AAG Treatment Does Not Result in Intracellular Collagen-I Deposits. Because we had
observed significant reductions in collagen-I secretion in the absence of an apparent increase in
intracellular collagen-I levels (Figure 2.6), we wondered what could account for the decreased
collagen-I levels. To address this question, we treated primary fibroblasts with ascorbate and
DMSO or 17-AAG for 6 h and performed confocal microscopy to visualize collagen-I (using the
polyclonal antibody LF-68) and its co-localization with ER (PDI; Figure 2.11A), Golgi (GM-130;
Figure 2.11B), and lysosomal (Lamp1; Figure 2.11C) markers. As expected given that we see a
partial but not complete ablation of collagen-I secretion, collagen-I distribution as detected using
LF-68 is broadly similar by this technique. One possibility not tested here is that collagen-I
accumulates in plasma membrane-bound deposits, as has been observed for collagen IV in
Drosophila;50 alternatively, repeating the imaging analysis at multiple time points may reveal
DMSO, 18 h
~im
1AAG, 6h
- 17-AAG, 18 h
Figure 2.10: Electron microscopy analysis of Golgi structure. GM05659 fibroblasts were
plated and treated with ascorbate and DMSO or 17-AAG (250 nM) for 18 h. A third plate was
treated with ascorbate and 17-AAG for 6 h. Cells were then fixed, embedded, stained, and
imaged on an FEI Tecnai Spirit equipped with an AMT CCD camera. Representative images
are shown, and portions of rough ER are labeled with text; arrowheads indicate Golgi stacks.
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effects of 17-AAG treatment on collagen-I localization. Yet while the mechanistic details of 17-
AAG mediated decreases in collagen-I levels remain unknown, our data collectively confirm the
ability of Hsp9O-type chaperone inhibitors to selectively reduce collagen-I secretion independent
of effects on cell viability, collagen-I synthesis, or general protein trafficking.
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Figure 2.11: 17-AAG does not affect collagen-I localization. GM05659 fibroblasts were
plated on poly-D-lysine-coated coverslips and allowed to adhere overnight. The next day,
cells were treated for 6 h with 200 M sodium ascorbate and 250 nM 17-AAG, and
processed for confocal microscopy to visualize collagen-I (using the polyclonal antibody LF-
68) and its co-localization with ER (PDI; (A)), Golgi (GM-130; (B)), and lysosomal (Lamp1;
(C)) markers. As expected given that we see a partial but not complete ablation of collagen-I
secretion, collagen-I distribution as detected using LF-68 is broadly similar by this technique.
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The Broad-Spectrum Anti-Parasitic Nitazoxanide Also Reduces Collagen-I Secretion. Finally,
we repurchased the anti-parasitic compound nitazoxanide (NTZ) and tested it for effects on
endogenous collagen-I secretion by primary cells. While NTZ had not, in fact, met our fold-
change or cytotoxicity cut-offs in the high-throughput screen, we nonetheless selected NTZ for
retesting because it had shown opposite, if moderate, effects on eGLuc2.Cola2(l) and eGLuc2
secretion. We treated primary fibroblasts with 200 tM ascorbate and 10 1tM NTZ for 24 h, and
then harvested conditioned media for immunoblotting. Notably, NTZ showed a reduction in
collagen-I secretion by primary fibroblasts, of equal (or larger, for Cola2(1)) magnitude to that
observed in our screening cell line (Figure 2.12A and B).
We were concerned that these results might be primarily due to cytotoxicity, and so we
tested NTZ for effects on cell viability using the same FACS assay employed previously. We
found that NTZ did not reduce cellular viability under the conditions tested (Figure 2.12C),
consistent with reports of high pharmacological tolerability.5 1 We also used the tritium pulse
assay to test effects of NTZ treatment on collagen-I synthesis. As shown in Figure 2.12D, we
did not detect any significant change in the amount of newly synthesized collagen-I from cells
treated with NTZ. Together, our results suggest that NTZ can also reduce collagen-I secretion in
a post-translational manner, and motivate further studies to identify its mechanism of action.
Discussion
Although 17-AAG did not alter global protein secretion or the export of transthyretin or
fibronectin, the Hsp90 inhibitor had significant and opposite effects on collagen-I (-50%
decrease) and fibulin-3 (-3-fold increase) secretion. Intriguingly, 17-AAG had opposite effects
on eGLuc2 and eGLuc2.Cola2(l) secretion in our screening cell line, similar to what we observe
with fibulin-3 and collagen-I in primary fibroblasts. The diversity of 17-AAG effects on secreted
proteins examined here suggests more nuanced rules for secretion than size or shape. The
precise mechanism by which 17-AAG decreases collagen-I secretion may therefore prove
useful for understanding how Hsp90-type chaperones participate in protein export;46 47 our
efforts on this front are discussed in Chapter I1.
We note that -50% reductions in collagen-I levels, on the order of what we observe in
primary fibroblasts, are sufficient to reduce the fibrotic area in tissue sections from mouse
models, suggesting that the effect sizes we detect upon Hsp90 inhibition could be sufficient to
reduce disease burden. Moreover, the level of collagen-I secretion is reduced by 17-AAG in
some cases to levels similar to that of the ascorbate-untreated control and thus likely
approaches the realistic limit for collagen-I secretion inhibition in our model system. However,
recent reports that collagen stiffness, rather than concentration, determines disease severity
suggest that co-treatment with collagen secretion and collagen cross-linking inhibitors may
prove most effective as a therapeutic strategy.
In addition to the specific insights we obtained regarding the capacity of Hsp90 inhibitors
to reduce the level of collagen-I secretion, we note that as a large, multimeric protein that
simultaneously lacks enzymatic activity and requires highly specialized cellular folding
machinery, collagen is a challenging protein to assay. We believe the cell-based, high-
throughput screen for collagen-I secretion designed and validated here provides a viable
solution to this challenge that will prove useful on numerous accounts. Indeed, in addition to the
Hsp90 inhibitors we also identified six other functionally and structurally distinct small molecules
that selectively affect collagen-I secretion. These validated hits include two structurally related
EGFR tyrosine kinase inhibitors (AG1478 and gefitinib), a Ras farnesyl transferase inhibitor (L-
744,832), a dopamine D2 receptor agonist (bromocriptine mesylate), and mitomycin C. While
most of these compounds have not been tested in collagen-related disease models, mitomycin
C was previously used as a wound healing adjuvant, where it was found to slow the healing
process but also to reduce the level of fibrosis.53 55 Follow-up studies using these compounds
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Figure 2.12: Nitazoxanide also reduces collagen-I secretion without affecting cell viability or
collagen-I synthesis. GM05659 fibroblasts were plated and allowed to adhere overnight
before receiving fresh media with 200 1 !M ascorbate and 10 tM nitazoxanide (NTZ; Sigma).
After being treated for 24 h, conditioned media and cells were harvested for immunoblotting.
Representative gel images and quantification are shown in (A) and (B), respectively. (C)
FACS analysis of Annexin-V/Alexa Fluor 488 and propidium iodide staining to detect cell
death. Cells were plated in triplicate and allowed to adhere overnight before being treated as
in (A). After 24 h, cells were trypsinized and labeled for FACS analysis. (D) Measurement of
collagen-I synthesis by [2,3-3H]proline pulse. Cells treated for 6 h with ascorbate and NTZ
(10 tM) were pulsed with [2,3-3H]proline for 30 min prior to being harvested and analyzed.
Quantitation of newly synthesized collagen-I (mean standard deviation) is shown along
with a representative gel image (n = 3).
are expected to provide additional insights into mechanisms of collagen-I biosynthesis and
secretion, as well as new potential opportunities for therapeutic intervention.
The anti-parasitic compound NTZ has been linked to many diseases beyond its original
application, with proposed activity as an antiviral and anticancer drug.56 ' 57 The breadth of
reported uses might suggest that NTZ is a promiscuous small molecule with multiple off-target
effects, but NTZ nonetheless appears to be well tolerated in humans and has been used for
treating Giardia lamblia or Cryptosporidium parvum infection since receiving FDA approval in
2002.51, 58 Among its proposed mechanisms of action are parasite membrane depolarization,
pyruvate:ferredoxin oxidoreductase inhibition, depletion of ER- or Golgi-Ca 2 stores, induction of
PKR and elF2a phosphorylation, and stimulation of autophagy; inhibition of viral protein
maturation; and inhibition of P-catenin signaling. 1' 57-61 In addition to these processes, the thiol
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oxidoreductase ERp57 was recently identified as a possible target of NTZ.62 Using both
recombinant and endogenous ERp57, the authors showed that NTZ acts as a non-competitive
inhibitor of ERp57's non-catalytic domains, blocking paramyxovirus infection by causing
aggregation of a viral protein required for host cell entry. Notably, the proposed drug-binding site
mediates association of ERp57 with the chaperones calnexin and calreticulin, consistent with a
separate report of calreticulin as a putative NTZ binder.
While the other mechanisms cannot yet be ruled out, the prospect that NTZ functions as
an ERp57 inhibitor in human cells presents exciting opportunities for future studies. A proteomic
study with engineered cell lines previously identified ERp57 as a novel collagen- interactor.
Testing effects of NTZ treatment on secretion of the collagen-I C-terminal propeptide domain
alone, which like the paramyxoviral F-protein utilizes both inter- and intra-chain disulfide bonds
to stabilize a protein trimer, could thus help clarify whether the preliminary collagen- secretion
results obtained here are due to a direct effect of NTZ on ERp57.
In summary, we screened 1228 compounds against our cell-based, high-throughput
assay and identified six selective small molecule modulators of collagen-I secretion. Using the
compound 17-AAG identified in our screen, we further validate inhibition of Hsp9O-type
chaperones as a viable antifibrotic strategy42-45, 63-65 that points to a possible role for Hsp90 in
post-translationally regulating collagen-I secretion. Our screen design employs cells that
natively synthesize collagen-I and uses stably engineered cell lines for improved convenience
and consistency. Our high-throughput assay can also be readily adapted to study disease-
causing, misfolding variants of collagen-I by mutagenizing the wild-type Cola2(l) gene in our
eGLuc2.Cola2(l) fusion protein, and we expect this flexibility to provide a valuable addition to
the suite of current tools to study the collagenopathies.
Materials and Methods
Ce// Lines and Reagents. Saos-2TREx cellS32 were grown in complete DMEM (Corning)
supplemented with 15% heat-inactivated fetal bovine serum (FBS), 100 IU penicillin, 100 tg/mL
streptomycin, and 2 mM L-glutamine (Corning). Healthy dermal fibroblasts (GM05659, denoted
"Line 1", or GM05294, denoted "Line 2"; Coriell Cell Repositories) were cultured in complete
MEM supplemented with 15% FBS, 100 IU penicillin/100 tg/mL streptomycin, and 2 mM L-
glutamine (Corning). Expression of eGLuc2 and eGLuc2.Cola2(l) was induced in stable Saos-2
lines by treating cells with 1 tg/mL doxycycline (Dox; Alfa Aesar). Secretion of endogenous
collagen-I was induced in Saos-2 cells or primary fibroblasts using 50 or 200 VM sodium
ascorbate (Amresco), respectively. The ICCB Bioactives and FDA-approved compound decks
were purchased from Enzo as DMSO stock solutions in 96-well plate format and stored at -80
*C for <2 years prior to use. For screening, the compounds were rearrayed in V-bottom 96- and
384-well plates. Compound plates were thawed overnight at room temperature before being
pinned and heat-sealed before being refrozen at -20 'C. The Alexa Fluor 488 Annexin V/Dead
Cell Apoptosis Kit with Alexa Fluor 488 Annexin V and propidium iodide was obtained from Life
Technologies. Luciferase assays were performed either with homemade buffers66 containing an
assay stabilizer from the commercially available Biolux kit (New England Biolabs) and 10 tg/mL
coelenterazine (prepared from a 1 mg/mL stock in acidified methanol; Biotium) for high-
throughput screening or using the Biolux kit (with a commercial stabilizer) for dose-response
curves. Immunoblots were probed with the following primary antibodies, as indicated: GLuc
(New England 126 Biolabs E8023), Colal(l) (DSHB SP1.D8), Cola2(1) (Abcam ab96723),
Colal(l) (NIH LF-68), Hsp70/Hsp72 (Cell Signaling Technologies 4873), Akt (Cell Signaling
Technologies 9272), s-actin (Sigma A1978), fibronectin (Sigma F7387), FLAG (Agilent 131
200473).
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Vector and Stable Cell Line Construction. The gene encoding eGLuc2 was amplified via
polymerase chain reaction (PCR) from an eGLuc2.pENTR1A plasmid23 to remove the stop
codon and then reinserted into the pENTR1A plasmid. COL1A2 (UniProt entry P08123) was cut
from a previously developed PPT.FLAG.Cola2(1).pENTR1A plasmid32 and inserted after
eGLuc2 using the Notl and EcoRV sites to create the eGLuc2.Cola2().pENTR1A plasmid.
eGLuc2 and eGLuc2.Cola2(l) were then recombined into pLenti.CMV.TO.DEST Gateway
destination vectors67 using LR clonase (Life Technologies). Lentiviruses were generated as
described previously68 and used to transduce Saos-2-TREx cells. Stable cells were selected
with 250 tg/mL hygromycin B and propagated in the same, with the addition of 10 ptg/mL
blasticidin to maintain the tetracycline repressor. Single colonies inducibly expressing moderate
levels of eGLuc2.Cola2() (termed Saos-2GLuc.Col cells) were selected using immunoblotting.
High-Throughput Screening and Dose-Response Curves. Saos-2GLuc.Col cells were plated in flat-
bottom, white 384-well plates (Corning) at a density of 7000 cells/well with an EL406 Washer
Dispenser (BioTek) in a total volume of 50 tL of complete medium; 5-6 h postplating, 1 ptL of a
50 tg/mL Dox stock solution was added, and cells were treated with 50 nL of compound using a
Freedom Evo 150 Liquid Handler (Tecan) fitted with a floating, slotted pin tool (V&P Scientific).
Plates were incubated for 23 h at 37 *C, followed by equilibration for 1-1.5 h at room
temperature in a single layer before reading. Ten microliters of assay buffer was then dispensed
into the wells using a plate washer; plates were mixed by orbital shaking for 5 s, and the
luminescence signal was read using a Thermo Infinite M1000 Plate Reader (Tecan) with a 100
ms integration time, beginning 35 s after buffer addition. Saos-2GLuc cells were plated at a
density of 3000 cells/well prior to screening using an otherwise identical protocol. For
cytotoxicity counterscreening, intracellular ATP was quantified after the same time courses of
Dox and compound treatments using the CellTiter-Glo Assay (CTG; Promega). Briefly, 10 pAL of
CTG buffer was added to the cells; the plate was incubated for 10 min at room temperature, and
then the luminescence was read using an integration time of 100 ms. All screens were
performed in biological duplicate. Screening results were filtered for cytotoxicity using three
standard deviations below the average of DMSO-treated cells as a cutoff. A Z' factor of 0.72
was approximated for the assay by calculating the separation between the highest and lowest
compound-treated wells, according to Zhang et al. 69 The coefficient of variation (% CV) was
calculated by taking the ratio of the SD to the average DMSO signal for each cell line. Complete
raw screening results are presented in Table S1 of ref. [75].
Co-Immunoprecipitation Experiments. Saos-2GLuc.Col cells were plated in 10 cm dishes at a
density of 1.25 x 106 cells/plate and allowed to adhere overnight. The next day, the medium was
changed and cells were treated with ascorbate with or without 1 ptg/mL Dox. After 24 h, cells
received fresh medium and were retreated with fresh ascorbate and Dox. After an additional 24
h, the medium was removed, and cells were trypsinized, pelleted, washed with 1 x phosphate-
buffered saline (PBS), and then lysed in Triton-X lysis buffer [200 mM NaCl, 1% Triton X-100,
50 mM Tris (pH 7.5), 1 mM EDTA, and 1.5 mM MgC 2] with 1.5 mM phenylmethanesulfonyl
fluoride (PMSF; Sigma) and a protease inhibitor tablet (Thermo Fisher). Lysates were cleared
by centrifugation at 21.1 x 10 3 xg and 4 'C for 15 min; total protein was quantified using the
bicinchoninic acid assay, and 2 mg of lysate was incubated with 5 tL of a-GLuc antibody (NEB)
in a 500 piL volume end over end at 4 "C. After 4 h, 30 pL of a Protein A/G PLUS-Agarose bead
slurry (Santa Cruz) was added and samples were incubated end over end at 4 0C overnight.
The next day, samples were washed three times with Triton-X lysis buffer, dried with a 30.5
gauge needle, and eluted by being boiled in Laemmli buffer supplemented with 167 mM 1,4-
dithiothreitol (DTT; Sigma). Samples were separated on 4/8/12% Tris-Gly sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, with 2.5% of unprecipitated
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lysate as input and 50% of the elution, before being transferred to nitrocellulose membranes
(Bio-Rad). Blots were probed using an anti-GLuc antibody or SP1.D8, a mouse monoclonal
antibody against the N-terminal propeptide of Colal (1) (DSHB).
Precipitation of Collagen-I from Conditioned Media. Saos-2GLuc.Col cells were plated in 10 cm
dishes at a density of 1.25 x 106 cells/plate and allowed to adhere overnight. The next day, the
medium was changed and cells were treated with ascorbate either with or without 1 pXg/mL Dox.
After 24 h, cells were retreated with fresh ascorbate and Dox. After an additional 24 h, the
conditioned medium was transferred to falcon tubes and spun at 228 xg for 5 min to pellet cell
debris. The supernatants were then transferred to new tubes, and collagen-I was precipitated
according to the procedure described by Makareeva and co-workers.70
Disulfide-Dependent Assembly Assays. Precipitated collagen-I pellets were thawed on ice,
resuspended in 80 tL of 0.1 M NaHCO 3 (pH 8.3), and split into Eppendorf tubes (35 RL each);
3.5 ptL of 200 mM DTT in 0.1 M NaHCO 3 (pH 8.3) was then added (to give a final concentration
of 20 mM), and samples were heated at 60 *C for 15 min. Nonreduced samples were treated
with an equal volume of 0.1 M NaHCO 3 (pH 8.3) before being heated. After reduction, samples
were cooled at room temperature for 15 min, and then 4.3 ptL of 600 mM iodoacetamide (IAA;
VWR) in NaHCO 3 buffer was added to yield a final concentration of 60 mM. Samples were
incubated in the dark with IAA at room temperature for 1 h, mixed with 8.6 pL of Laemmli buffer,
heated, and separated on 4/7% Tris-Gly SDS-PAGE gels. Proteins were then transferred to
nitrocellulose membranes, which were developed with anti-GLuc and SP1.D8.
Pepsin Digestion. Pepsin digestions were performed as described by Makareeva et al. 70
Precipitated collagen-I pellets were thawed on ice and resuspended in 1 mL of pre-chilled (4 0C)
0.5 M acetic acid. Samples were then split into Eppendorf tubes (450 tL each) and combined
with 50 [AL of 0.5 M acetic acid with or without 2 mg/mL pepsin (Amresco). Samples were
inverted gently to mix and incubated at 4 0C for 36 h. Pepsin-stable collagen-I was then
precipitated by adding 110 tL of pre-chilled (4 0C) 5 M NaCl, to give a final concentration of 0.9
M, and incubating end-over-end at 4 *C for 2 h. Tubes were then centrifuged at 21.1x103 xg at
4 'C for 10 min, inverted, and centrifuged again for 10 min. The supernatant was removed,
pellets were dissolved by vortexing in Laemmli buffer containing 1 M DTT, heated, and
separated on 4/7% Tris-Gly SDS-PAGE gels. Bands were visualized by Coomassie staining.
Western Blotting Analysis. GM05659 primary fibroblasts were plated in 6-well plates at a density
of 2 x 10' cells/well and allowed to adhere overnight. The next day, the medium was changed to
full MEM with 0.5x penicillin/streptomycin, collagen expression was induced with 200 piM
sodium ascorbate (Amresco), and cells were treated with DMSO or the indicated compound
concentrations for 24 h. Samples of medium were denatured by being boiled in Laemmli buffer
(supplemented with 167 mM DTT), separated on homemade 4/8% Tris-Gly SDS-PAGE gels,
and transferred to nitrocellulose membranes. Because of cross-reactivity between the collagen-I
antibodies, samples of medium for collagen-I blots were run on duplicate gels, transferred, and
then probed separately for either rabbit anti-Cola2(l) or rabbit anti-Cola1 (I).
For Western blots of cell lysates, cells were trypsinized, washed with PBS, and lysed in
Triton-X lysis buffer with 1.5 mM PMSF and a protease inhibitor tablet (Pierce). Total protein
was quantified using the bicinchoninic acid assay, and equal amounts of total protein were
analyzed for each sample. Each experiment was performed in biological triplicate. Blots were
imaged after incubation with appropriate primary and 800CW or 680LT secondary antibodies
(LI-COR) by scanning on an Odyssey infrared imager (LI-COR), followed by quantification using
ImageJ.
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Fluorescence-Assisted Cell Sorting. GM05659 primary fibroblasts were plated at a density of 1
x 106 cells/plate in 6-cm dishes and allowed to adhere overnight. The next day, cells were
treated as described for Western blotting. After being treated with the compound for 24 h, cells
were harvested and labeled with an Annexin V-Alexa Fluor 488 conjugate and propidium iodide
(Life Technologies) according to the manufacturer's instructions and analyzed on a FACSAria
sorter (BD Biosciences) using a flow rate of 2.7 mL/h with 2 x 10 4 events gated to exclude cell
debris.
Quantitative PCR (qPCR). GM05659 primary fibroblasts were plated and treated as described
above for Western blotting. After being treated with the compound for 24 h, cells were washed
with PBS, and RNA was extracted using the Omega E.Z.N.A. Total RNA extraction kit. cDNA
was prepared from 500 ng of RNA, normalized for all samples in each run, using an Applied
Biosystems Reverse Transcriptase cDNA Kit in a Bio-Rad Thermocycler. Samples were run on
a Light Cycler 480 I Real Time PCR Instrument in the MIT BioMicro Center using previously
described primers32 71 and analysis methods. 68
Pulse Labeling. Collagen translation was assessed by [2,3- 3H]proline labeling. GM05659
primary fibroblasts were plated at a density of 1.2 x 105 cells/well in 12-well plates and allowed
to adhere overnight. The next day, cells were treated as described for Western blotting. After a
6 h treatment, the medium was removed, and cells were washed three times with PBS and then
serum-starved in MEM with 15% dialyzed FBS and 2 mM L-glutamine. Medium was changed to
radiolabeled medium (100 kCi of [2,3-3H]proline/mL; PerkinElmer) for 30 min, after which cells
were washed three times with full, nonradiolabeled MEM and harvested. Both ascorbate and
17-AAG (250 nM) were included during the 30 min serum starvation and 30 min pulse.
Harvested samples were washed with PBS, lysed in standard RIPA buffer containing protease
inhibitor tablets and 1.5 mM PMSF, and run on 4/6% Tris-Gly SDS-PAGE gels. Gels were
dehydrated, incubated with a scintillant solution [20% (w/w) 2,5-diphenyloxazole in DMSO;
Sigma], washed, and then dried as previously described.72 Results were quantified in ImageJ.
Adenoviral Production. Adenoviral vectors encoding FLAG-tagged TTR or FLAG-tagged fibulin-
373 were used to produce adenovirus according to the manufacturer's instructions
(LifeTechnologies ViraPower Adenoviral Expression System). The FLAG-tagged TTR virus was
constructed using lambda red recombineering and ccdB74 counterselection to insert the TTR
gene from a pcDNA3.1 vector into the El region of adenovirus. Viruses were subsequently
amplified in 293A cells and titrated with GM05659 cells to select an appropriate volume to use
for experiments.
Transthyretin and Fibulin-3 Secretion. GM05659 primary fibroblasts were plated at a density of
2 x 105 cells/well in 6-well plates the day before transduction. After being allowed to adhere
overnight, cells received fresh media and were transduced with adenoviruses encoding GFP,
transthyretin (TTR), or fibulin-3. The next day, cells were split 1:2 into 12-well plates. Collagen-I
expression was induced the following day as described for Western blotting, and cells were
treated with either DMSO or 250 nM 17-AAG. After 24 h, the media was collected, separated on
4/8% (collagen-), 4/10% (fibulin-3), or 4/15% (TTR) Tris-Gly SDS-PAGE gels, and probed for
collagen-I or FLAG.
Metabolic Labeling of Secreted Proteins. GM05659 primary fibroblasts were plated at a density
of 2 x 105 cells/well in 6-well plates and allowed to adhere overnight. The next day, cells
received fresh medium containing ascorbate and DMSO or 17-AAG (250 nM) and were returned
to the incubator for 2 h. After pretreatment, the medium was then replaced with [3 5S]Met and
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Cys-containing medium: 100 ptCi of EXPRESS Protein Labeling Mix [35S] (Sigma) per mL of
Met- and Cys-free DMEM (Corning) supplemented with 15% dialyzed FBS and 2 mM L-
glutamine. Cells were retreated with ascorbate and DMSO/17-AAG and incubated for 6 h.
Plates were then removed to ice, and then samples of medium were transferred to Eppendorf
tubes, spun at 207g and 4 *C for 10 min to pellet cell debris, and transferred to new tubes.
Samples of medium were separated on 4/8% Tris-Gly SDS-PAGE gels and dried on a gel slab
dryer for 75 min at 80 *C. Dried gels were developed with a GE Healthcare PhosphoScreen and
imaged the next day on a Typhoon FLA 7000 instrument.
Confocal Microscopy. GM05659 primary fibroblasts were plated in 24-well plates on poly-D-
lysine-coated coverslips (Chemglass Life Sciences, NJ) at a density of 4 x 104 cells/well and
allowed to adhere overnight. The next day, cells were treated as described for Western blotting
and incubated with DMSO, 17-AAG (250 nM or 2.5 VM), or Brefeldin A (5 pM) for 20 h. Media
was then removed and cells were fixed in 4% paraformaldehyde / PBS for 30 min at rt. Cells
were washed 4x with PBS, blocked in 2% bovine serum albumin (BSA) / PBS for 30 min at rt,
and incubated with a-GM130 (BD Biosciences #610822) at a 1:100 dilution in 2% BSA/PBS
overnight at 4 *C; a subset of samples received only 2% BSA/PBS to control for non- specific
secondary staining. The next day, cells were washed again 4x with PBS and incubated with
Alexa Fluor 568 goat-anti mouse (Life Technologies) at a 1:1000 dilution in 2% BSA/PBS for 2 h
at rt in the dark. Cells were then washed 4x with PBS, incubated with DAPI at a 1:1000 dilution
in PBS for 10 min at rt, washed again 5x with PBS, and mounted on slides in ProLong Gold
Antifade Mountant (Life Technologies). Slides were cured overnight at rt before imaging with a
10OX 1.40NA oil objective mounted onto a Zeiss RPI spinning disk confocal microscope
equipped with MetaMorph acquisition software and a Hamamatsu ORCA-ER CCD camera.
Representative images were chosen from 10 images per slide in biological triplicate.
Electron Microscopy. GM05659 primary fibroblasts were plated in 10-cm dishes at a density of
1.6 x 106 cells per plate and allowed to adhere overnight. The next day (18 h before fixation),
two plates received fresh media containing ascorbate and either 0.1% DMSO or 250 nM 17-
AAG. The day after (6 h before fixation), the third plate received fresh media containing
ascorbate and 250 nM 17-AAG. Prior to fixation, an aliquot of media was taken from each plate
to confirm 17-AAG reductions in collagen-I secretion by immunoblot. Samples were then
removed from the incubator and immediately fixed in 2.5% glutaraldehyde, 3%
paraformaldehyde with 5% sucrose in 0.1M sodium cacodylate buffer (pH 7.4), pelleted, and
post-fixed in 1% Os0 4 in veronal-acetate buffer. The cells were stained en block overnight with
0.5% uranyl acetate in veronal-acetate buffer (pH 6.0), then dehydrated and embedded in
Embed-812 resin. Sections were cut on a Leika EM UC7 microtome with a Diatome diamond
knife at a thickness setting of 50 nm, stained with uranyl acetate, and lead citrate. The sections
were examined using an FEl Tecnai Spirit at 80KV and photographed with an AMT CCD
camera in the W. M. Keck Microscopy Facility at the Whitehead Institute at MIT.
Statistical Analyses. Data are presented as the mean and standard deviation from at least three
biological replicates, with the exception of screening data, which were generated in biological
duplicate. Statistical significance was assessed on normalized data from immunoblots using an
unpaired Student's t-test (unequal variances), with the following significance thresholds: *p <
0.05, and **p < 0.01.
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CHAPTER III
A Role for Cytosolic Hsp90s in Collagen-I Secretion
Summary
In previous work, we found that the Hsp90 inhibitor 17-AAG reduces collagen-I secretion
post-translationally and does not disrupt global protein secretion. This chapter describes our
efforts to determine the mechanism of action of pan-isoform Hsp90 inhibitors. We show that
Hsp90 inhibitors do not reduce collagen secretion by activating the heat shock response.
Surprisingly, we also show that the consequences of Hsp90 inhibition cannot be attributed to
inhibition of the endoplasmic reticulum's Hsp90 isoform, Grp94. Instead, collagen-I secretion
likely depends on the activity of cytosolic Hsp90 chaperones, even though these chaperones
cannot directly engage nascent collagen molecules. Results obtained with isoform-selective
inhibitors and genetic knockdown experiments suggest that the constitutively expressed,
cytosolic Hsp90P is specifically required for collagen-I secretion. Finally, we present preliminary
evidence consistent with a role for the cytosolic protein NudCL and propose a possible model
for our observations.
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Figure 3.5 and for constructive feedback. We also thank Louis J. Papa, l1l, for generating the
adenoviral shRNA constructs, and Professor John Hulleman at the University of Texas
Southwestern Medical Center in Dallas, TX and Dr. Andrew S. DiChiara for experimental advice
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Introduction
As one of the most abundant components of human cells, comprising 1-2% of total
protein, it is hardly surprising that Hsp90 participates in a large number of cellular processes.'
Though first discovered as part of the chromatin "puffs" induced by heat shock, the repertoire of
Hsp90 functions has since expanded to encompass organismal development, evolution, and
disease.-6 In addition to regulating cellular responses to hypoxia, nitric oxide, and viral
infection,' Hsp9O assists in protein secretion in both yeast and possibly mammalian cells.7
Specifically, the chaperone has been linked to function of vesicle-tethering proteins such as the
COG and TRAPP families, Rab GTPase recycling, and export of model secretory cargo.7' 8
The Hsp90 chaperone cycle has been studied extensively, and involves rounds of ATP
hydrolysis coupled to still unknown conformational changes in Hsp90 that promote client
maturation.' Improvements to early natural product-based Hsp90 inhibitors have enabled
identification of additional clients, as well as structural and biochemical studies of Hsp90-client
interactions.9' 10 However, the molecular details of how Hsp90 interacts with its co-chaperones
and clients, or how these interactions contribute to diseases like cancer, are still largely
unknown.
Due to the abundance of Hsp90 and the presence of multiple isoforms and transcript
variants," small-molecule inhibitors provide a key alternative to genetic approaches to
investigate chaperone function. One of the challenges to using such compounds, however, is
the lack of isoform selectivity. Hsp9O exists as not one, but two cytosolic isoforms (the stress-
inducible a and constitutively-expressed P), in addition to isoforms that reside in the
mitochondria (TRAP1) and endoplasmic reticulum (Grp94). While certain processes and clients
seem to prefer Hsp90a over Hsp90s,"' 12 others appear to require only sufficient levels of total
Hsp90.13 Many Hsp90 inhibitors, including those tested in this study, target the N-terminal
domain of Hsp90, functioning as competitive inhibitors of ATP binding. 14 5 However, the high
similarity of this region, with 95% sequence identity among the cytosolic isoforms, limits the
utility of such compounds for parsing isoform-specific functions.' 6
Among the proposed Hsp90 clients with isoform-specific requirements is collagen type I,
hereafter referred to as collagen-1. A key structural component of skin and bone, collagen-I is
synthesized and then exported from the ER as rigid, -300 nm triple helical molecules, which are
deposited in the extracellular space and then self-assemble into fibrils.17 Collagen-I molecules
are too large to fit into conventional COP-Il vesicles, which average 60-90 nm in diameter, for
export from the ER.1 ' Other collagen types have varying lengths and spatial constraints: type 11,
for instance, is similar to collagen-1, with 360 uninterrupted repeats of the [Gly-X-Y] amino acid
triplet; by contrast, type VIII is less than half the length of type 11, with multiple breaks that allow
it to fold in on itself. 19
Across collagen types, insufficient collagen deposition and/or intracellular accumulation
lead to cellular stress and tissue dysfunction.20 21 How collagen-I is exported from the ER to the
extracellular space, and whether other collagen types or proteins utilize the same secretion
pathway, thus constitute key questions for the field of collagen biosynthesis. Collagen-I has
been shown to associate with Grp94 in the ER, although the functional importance of the
interaction was not determined. However, it seemed likely that Grp94 association with
collagen-I reflected a role for this ER-resident Hsp90 isoform in collagen folding and/or
secretion.
We previously designed a high-throughput luminescent assay for collagen-I secretion
and used it to screen two libraries of FDA-approved or bioactive small-molecules. In that work,
we identified six validated, small molecule modulators that selectively inhibit collagen-I secretion
by primary dermal fibroblasts. Of those compounds, the Hsp90 inhibitor 17-AAG had shown
efficacy as an anti-fibrotic compound, through a mechanism proposed to involve altered
inflammatory signaling.26 -31 We, however, showed that 17-AAG also operates post-
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translationally to directly and selectively affect collagen-I secretion (Chapter Il). Based on that
work, we wanted to explore the mechanism of action of Hsp90 inhibition. Here, we present
results from a panel of pan-isoform Hsp90 inhibitors, as well as recently developed isoform-
selective small molecule inhibitors.16 We find that while Grp94 is dispensable for collagen-
secretion, selective inhibition or knockdown of cytosolic Hsp90s recapitulates our initial results
with 17-AAG. Genetic knockdown studies also suggest a potential role for the Hsp90s adapter
and co-chaperone NudCL in facilitating collagen- secretion, perhaps by regulating dynein motor
dynamics.
Results
Structurally Diverse Hsp90 Inhibitors Reduce the Secretion of Endogenous Collagen-I. We had
previously found that the Hsp90 inhibitor 17-AAG was capable of reducing collagen-I secretion
both in our screening cell line and in primary human fibroblasts. Furthermore, we had shown
that 17-AAG acted in a post-translational manner, and that the observed reduction in collagen-1
secretion was independent of adverse effects on cell viability or Golgi morphology. We next
wanted to confirm that the response to 17-AAG was a result of Hsp90 inhibition, and not an
unappreciated off-target effect. We therefore obtained four additional Hsp90 inhibitors spanning
diverse molecular scaffolds (Figure 3.1A) and tested the entire Hsp90 inhibitor set for effects on
collagen-I secretion in primary human fibroblasts.
After a 24 h treatment with pan-isoform Hsp90 inhibitors, immunoblotting revealed
significant decreases in endogenous collagen-I secretion relative to that of vehicle-treated cells
for 17-AAG, 17-DMAG, EC 144, and STA-9090 (Figure 3.1B, C). We observed no changes in
intracellular levels of collagen-. We also confirmed functional inhibition of cytosolic Hsp90 at the
concentrations used, indicated both by the expected increase in Hsp70 levels due to induction
of a compensatory heat shock response (HSR) and by the loss of signal from the cytosolic
Hsp90 client Akt (Figure 3.1C). One pan-isoform Hsp90 inhibitor, radicicol, caused a notable but
not significant decrease in collagen-1 secretion (Figure 3.1 B, C). However, radicicol was later
found to be mildly cytotoxic (see Figure 3.2A), and radicicol treatment induced Akt degradation
less effectively than the other pan-isoform Hsp90 inhibitors, perhaps explaining its less striking
effects on collagen-1 secretion. Cumulatively, the data in Figure 3.1 indicate that reductions in
collagen-I secretion mediated by diverse Hsp9O inhibitors do occur in primary cells and that the
reduced level of collagen-1 secretion is an on-target consequence of Hsp90 inhibitor treatment.
We then tested the pan-isoform Hsp90 inhibitors for effects on cell viability, collagen-1
transcripts, and collagen-I translation. We first treated primary fibroblasts with pan-isoform
Hsp90 inhibitors for 24 h and then tested for cytotoxicity by staining cells with Annexin-V/Alexa
Fluor 488 and propidium iodide followed by FACS analysis. With the exception of radicicol,
which we found to be mildly cytotoxic, none of the Hsp90 inhibitors tested were toxic at the
concentrations used, confirming that Hsp90 inhibitors do not decrease the secretion of collagen-
I from primary fibroblasts simply by promoting cell death (Figure 3.2A).
Next, we performed qPCR analysis of collagen-1 transcripts from Hsp90 inhibitor-treated
primary fibroblasts. We found that COLIAI and COLIA2 transcript levels were not significantly
altered, indicating that the mechanism of action is post-transcriptional (Figure 3.2B). Finally, we
used a tritium pulse assay to test whether collagen-1 translation is altered by Hsp90 inhibitor
treatment. Briefly, we pulsed treated fibroblasts with [5- 3H]proline for 30 min to label the proline-
rich collagen-1 protein, followed by collection of cell lysate and autoradiography analysis of the
collagen-1 bands (identified by bacterial collagenase treatment). We observed no significant
alterations in levels of newly synthesized, radiolabeled collagen-1 upon treatment with any of the
Hsp90 inhibitors tested (Figure 3.2C). Cumulatively, these data indicate that structurally diverse
Hsp90 inhibitors reduce collagen-1 secretion via a post-translational mechanism.
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Figure 3.1: Pan-isoform Hsp90 inhibitors reduce the level of endogenous collagen-I
secretion. (A) Structures, names, and compound classes of tested pan-isoform Hsp90
inhibitors. (B) Western blot of conditioned media (top) and lysate (bottom) from primary
dermal fibroblasts. Cells were plated and allowed to adhere overnight before receiving fresh
media with 200 pM ascorbate and the following concentrations of Hsp90 inhibitors, as
indicated: 17-AAG (250 nM), 17-DMAG (250 nM), EC 144 (100 nM), radicicol (250 nM), and
STA-9090 (300 nM). After being treated for 24 h, conditioned media and cells were
harvested for immunoblotting. (C) Quantification of Western blot results. *p-value < 0.05 (n =
3).
Reduced Collagen-I Secretion Does Not Require the Heat Shock Response. While our data
indicated that diverse Hsp9O inhibitors could reduce secretion of endogenous collagen-1, we
wondered if our results might be due to secondary, rather than direct, effects of Hsp90
inhibition. Hsp90 inhibition is known to activate a protective heat shock response (HSR), which
increases levels of small heat shock proteins in response to cellular stress.3 2 ' Among these
proteins is Hsp70, a chaperone whose function in clathrin uncoating might suggest a more
general role in vesicle-mediated transport.34 In addition to Hsp70, the heat shock protein
Hsp47 is a well-established collagen-specific chaperone whose level of expression increases
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Figure 3.2: Effects of Hsp90 inhibition on collagen-I secretion are post-translational. (A)
FACS analysis of Annexin-V/Alexa Fluor 488 and propidium iodide staining to detect cell
death. Cells were plated in triplicate for each condition and allowed to adhere overnight
before being treated as in Figure 3.1B. After 24 h, cells were trypsinized and labeled for
FACS analysis. (B) qPCR analysis of collagen-1 transcript levels from cells treated as in
Figure 3.1B. Average values are shown with the standard deviation for each condition (n =
3). (C) Measurement of collagen-1 synthesis by [5-3H]proline pulse. Cells treated for 6 h with
ascorbate and 17-AAG (250 nM) were pulsed with [5-3H]proline for 30 min prior to being
harvested and analyzed. Quantitation of newly synthesized collagen-1 (mean standard
deviation) is shown (n = 3).
upon HSR activation. We therefore examined the possibility that Hsp9O inhibitors reduced
collagen-1 secretion by increasing Hsp47 (or Hsp70) availability through the HSR.
To test this hypothesis, we transduced primary fibroblasts with lentivirus encoding a
previously published, dominant negative version of Heat Shock Factor 1 (dncHSF1), the key
transcriptional activator of the HSR.33 We then treated cells with DMSO or 17-AAG and
analyzed HSR induction by qPCR (Figure 3.3A). Our experimental time course was kept short
to allow for expression of dncHSF1 prior to treatment with DMSO or 17-AAG, while minimizing
repression of basal chaperone levels from prolonged dncHSF1 activity. Transcript levels of
Hsp70 (HSPAIA) were clearly induced by 17-AAG treatment in a background of GFP-
containing lentivirus. By contrast, co-treatment of cells with dncHSF1 lentivirus prevented
upregulation of Hsp70 transcripts by 17-AAG, indicating that we are able to inhibit Hsp9O in the
absence of a compensatory HSR. We found that HSR suppression did not rescue collagen-1
secretion after treatment with 17-AAG (Figure 3.3B, C). Thus, our results suggest that Hsp90
itself, and not the HSR, is required for collagen-1 secretion.
Grp94 Knockdown Does Not Inhibit Collagen-I Secretion. There are several Hsp9Q isoforms in
the cell: Hsp90a and Hsp90s in the cytosol, Grp94 in the ER, and TRAP1 in mitochondria
(Figure 3.4A). Although 17-AAG and the other Hsp90 inhibitors employed can bind to and inhibit
all Hsp9O isoforms, nascent collagen-1 molecules are found only in the ER and Golgi. We
therefore considered it likely that inhibition of Grp94, which is already known to engage
collagen-1 in the ER, was responsible for the observed effects of pan-isoform Hsp9Q inhibitors
on collagen-1 secretion, possibly by slowing or preventing the folding of collagen-1. To test this
hypothesis, we generated lentiviruses encoding a non-mammalian control shRNA or three
distinct shRNA constructs targeting Grp94 (Table 3.1). We examined the levels of cytosolic
Hsp9Oa and Hsp90s and the mitochondrial isoform TRAP1 and showed that they were
unaffected by Grp94 knockdown, confirming the specificity of our shRNA constructs (Figure
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Figure 3.3: HSFI is dispensable for 17-AAG mediated reductions in collagen-I secretion.
Primary dermal fibroblasts were plated and allowed to adhere overnight. Cells were then
transduced with lentivirus encoding GFP or a constitutive, dominant-negative HSF1
(dncHSF1) in the presence of polybrene. The next day, cells were split and allowed to
adhere for 24 h, after which cells were changed to fresh media with 200 pM ascorbate and
either DMSO or 250 nM 17-AAG, as indicated. Cells and conditioned media were harvested
after 24 h of treatment for qPCR analysis and immunoblotting. (A) qPCR analysis shows
effective suppression of Hsp70 (HSPAIA) induction by dncHSF1. Collagen transcripts (blue
columns) were not altered under any of the experimental conditions. (B) Western blot of
conditioned media and (C) quantification showing that 17-AAG reduces collagen-I secretion
even when the HSR is inhibited.
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Figure 3.4: Grp94 is dispensable for secretion of collagen-I from primary fibroblasts. (A)
Diagram of cellular Hsp90 isoforms along with the known collagen-I secretion pathway.
Grp94, in the ER, is the only Hsp90 isoform capable of directly interacting with nascent
collagen-I. (B) Western blot of lysate after lentiviral shRNA knockdown of Grp94. Cells were
plated in triplicate for each construct and allowed to adhere overnight before being
transduced with nontargeting control (nmc) or Grp94 shRNA lentiviruses. Media was
changed the next day, and cells were left until 72 h post- transduction, when they received
fresh media with ascorbate for 24 h prior to being harvested. (C) Immunoblots of
corresponding media for the experiment described in panel B. (D) Experimental workflow.
Cells were plated in triplicate for each construct and allowed to adhere overnight before
being transduced with a nontargeting control or a Grp94 shRNA lentivirus. After 48 h,
transductions were split 1:2 and allowed to adhere overnight. Cells subsequently received
fresh media and were treated with ascorbate and DMSO or 17-AAG for 24 h prior to being
harvested. (E) Immunoblots of conditioned media from cells co-treated with shRNA-
containing lentivirus and DMSO or 17-AAG (n = 3).
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3.5A). We then transduced primary fibroblasts with these lentiviruses, induced collagen-I
expression with ascorbate 72 h post-transduction, collected media for 24 h, and then assayed
levels of secreted collagen-I by immunoblotting (Figure 3.4C). Strikingly, we observed no
reduction in collagen-I levels in conditioned media, despite strong knockdown of Grp94 at the
protein level (Figure 3.4B).
We next evaluated whether Hsp90 inhibitors could reduce collagen-I secretion even in a
background of Grp94 knockdown. We repeated the Grp94 shRNA knockdown and then co-
treated cells with DMSO or 17-AAG (Figure 3.4D). qPCR of these cells confirmed that Grp94
transcript levels decreased upon shRNA knockdown; in addition, we observed that Hsp70
transcript levels increased upon 17-AAG treatment, indicating functional inhibition of Hsp90
(Figure 3.5B). We then collected and analyzed conditioned media by immunoblotting and found
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Figure 3.5: Grp94 knockdown does not affect the levels of other Hsp90 isoforms. (A) Levels
of other Hsp90 isoforms do not change upon Grp94 shRNA knockdown. GM05659
fibroblasts were plated and transduced as described in the Materials and Methods. Equal
amounts of lysate were separated on 4/8% Tris-Gly SDS-PAGE gels and probed for the
indicated proteins. (B) qPCR analysis of transcript levels for CHOP (indicative of unfolded
protein response activation), Grp94 (indicative of shRNA knockdown efficiency), and Hsp70
(indicative of heat shock response activation by 17-AAG treatment). GM05659 fibroblasts
were plated and treated as outlined in Figure 3.4D.
that treating fibroblasts with 17-AAG decreased collagen-I secretion for both a nontargeting
control and a Grp94-targeting shRNA (Figure 3.4E). These results demonstrate that Hsp90
inhibitors can reduce collagen-I secretion independent of Grp94 and suggest that Grp94 is in
fact dispensable for collagen-I secretion under the conditions studied here. Instead, inhibition of
another Hsp9O isoform, most likely cytosolic Hsp9O, is likely to be responsible for reductions in
collagen-I secretion.
Isoform-Selective Inhibitors Suggest that Cytosolic Hsp90g is Specifically Required for
Collagen-I Secretion. We next sought to determine which Hsp90 isoform(s) is(are) required for
collagen-I secretion. To do so, we employed a panel of isoform-selective small molecule Hsp9O
inhibitors developed by the Blagg group (University of Notre Dame). The panel included one
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inhibitor selective for each of the Hsp90 isoforms (Figure 3.6A; structures for the remaining
unpublished compounds are not known), 36 and primary fibroblasts were treated at
concentrations that did not significantly compromise cell viability, as assessed by Cell-TiterGlo
and resazurin assays. After 24 h of treatment, immunoblotting revealed significant decreases in
endogenous collagen-I secretion relative to that of vehicle-treated cells only for the Hsp90P-
selective inhibitor (Figure 3.6B-D).
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Figure 3.6: Isoform-selective Hsp90 inhibitors suggest a role for cytosolic Hsp906 in
collagen-I secretion. Cells were plated and allowed to adhere overnight before receiving
fresh media with 200 pM ascorbate and the following concentrations of Hsp9O inhibitors, as
indicated: A (TRAP-1 selective, 10 pM), B (Grp94 selective, 5 [AM), C (Hsp90a selective, 5
[iM), or D (Hsp90P selective, 5 pM). After being treated for 24 h, conditioned media and cells
were harvested for immunoblotting. (A) Structure of the Grp94-selective inhibitor, reported in
Crowley, et al.36 The remaining compounds are unpublished, and so structures are not
shown. Representative Western blot images (B) are shown along with quantification of
results in (C). Compound D was subsequently tested in dose at the indicated concentrations
shown in (D).
Genetic Knockdown of Hsp90a and Hsp906. Isoform selectivity remains a challenge for the
development of small molecule Hsp90 inhibitors, 6' 37, 38 and so we wanted to verify our
compound results by genetic knockdown. We had already shown that Grp94 shRNA had no
effect on collagen-I secretion or the inhibitory action of 17-AAG (Figure 3.4). As the
mitochondrial Hsp90 TRAP1 is separated from collagen-I biosynthesis and export by two
membranes, and TRAP1 inhibition did not affect collagen-I secretion, we focused our efforts on
the cytosolic isoforms. We obtained shRNA constructs for Hsp90a and Hsp90P (Table 3.1),
generated lentivirus, and transduced primary fibroblasts with Hsp90-targeting constructs or a
non-mammalian control. Collagen-I secretion was induced with ascorbate 72 h after
transduction, and secreted collagen-I was collected for 24 h prior to analysis by immunoblotting.
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Table 3.1: Sequences of shRNA constructs.
Target Construct Name Vector ID Sequence
Non-mammalian CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTG
GFP control SHCOO2 CTCTTCATCTTGTTGTTTTT
shRNA 1 TRCN CCGGCCTGTGGATGAATACTGTATTCTCGAGAATACAG0000029425 TATTCATCCACAGGTTTTT
TRCN CCGGCGTGGTCTGTTTGACGAATATCTCGAGATATTCG
Grp94 shRNA 2 0000029426 TCAAACAGACCACGTTTTT
shRNA 3 TRCN CCGGGCGAGACTCTTCAGCAACATACTCGAGTATGTT0000276248 GCTGAAGAGTCTCGCTTTTTG
shRNA 1 TRCN CCGGTACTTGGAGGAACGAAGAATACTCGAGTATTCTT
HspNA 1 0000315009 CGTTCCTCCAAGTATTTTTG
Hsp9a shRNA 2 TRCN CCGGGTTATCCTACACCTGAAAGAACTCGAGTTCTTTC
0000314936 AGGTGTAGGATAACTTTTTG
shRNA 1 TRCN CCGGCCAACTCATGTCCCTCATCATCTCGAGATGATGA0000008750 GGGACATGAGTTGGTTTTT
TRCN CCGGCGCATGGAAGAAGTCGATTAGCTCGAGCTAATC
Hsp9Os shRNA 2 0000315415 GACTTCTTCCATGCGTTTTTG
shRNA 3 TRCN CCGGCTTGTGTTGAAGGCAGTAAACCTCGAGGTTTACT0000315416 GCCTTCAACACAAGTTTTTG
shRNA 1 TRCN CCGGCCCTGCTTTAATAAACAGCAACTCGAGTTGCTGT0000134970 TTATTAAAGCAGGGTTTTTTG
NudCL shRNA 2 TRCN CCGGCCCTGCTTTAATAAACAGCAACTCGAGTTGCTGT0000338520 TTATTAAAGCAGGGTTTTTG
shRNA 3 TRCN CCGGCCCAGCAAATTGGGATCACATCTCGAGATGTGA0000138360 TCCCAATTTGCTGGGTTTTTTG
shRNA 1 TRCN CCGGCTCCACTGCGAGCGAAGTATTCTCGAGAATACTT
sh RNA1 0000376670 CGCTCGCAGTGGAGTTTTTGUSPshRNA 2 TRCN CCGGCCGGTACTCTGTGAGTGTATTCTCGAGAATACAC
0000371020 TCACAGAGTACCGGTTTTTG
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Figure 3.7: Hsp9O/3, but not Hsp9Oa, shRNA knockdown decreases collagen-I secretion.
GM05294 cells were plated at a density of 2 x 105 cells per well in 6-well plates the day
before transduction. Cells then received 500 pL of each virus in triplicate along with
polybrene. The next day, cells received fresh media, and were incubated until 72 h post-
transduction, when collagen-I secretion was induced with ascorbate. Conditioned media was
collected for 24 h before immunoblotting analysis. Representative Western blots for shRNA
knockdown of (A) Hsp90P and (B) Hsp90a are shown along with quantification.
Although we were only able to deplete Hsp90a to -75% of control levels, Hsp90a knockdown
had no effect on collagen-I secretion, as we observed with the small molecule inhibitors (Figure
3.7A).
Hsp90P knockdown proved much more challenging than knockdown of Hsp90a. We
first transduced primary fibroblasts and induced collagen-I secretion 72 h after transduction.
Immunoblots showed that both of our shRNA constructs resulted in 50% knockdown of the
protein, with an ~20% reduction in collagen-I levels (Figure 3.7B). An additional construct also
reduced Hsp90P levels, but surprisingly appeared to increase levels of secreted collagen-I
(Figure 3.7B). Subsequent attempts to knockdown Hsp90P gave mixed results, including visible
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cytotoxicity, no change in Hsp90p levels, and Hsp90s depletion in the absence of reduced
collagen-I secretion. The high variability between experiments has been previously observed by
us for other lentiviral shRNA targets, and may be at least partially attributed to an inconsistent
multiplicity of infection (based on different titers of lentiviral batches or variations in the number
of plated cells). However, it seems likely that an additional barrier to robust, reproducible
knockdown is the essential function of Hsp90. In support of this explanation, higher volumes of
Hsp90s shRNA lentivirus induces expression of Hsp90a, likely by activating the HSR, and
Hsp90s knockout cells and animals are not viable.3 , " Thus, future efforts to validate the Hsp90s
inhibitor results by shRNA depletion will require careful attention to handling of lentiviral stocks,
in addition to a thorough optimization of both viral volume and length of knockdown.
Genetic Knockdown of USP19 and the Co-Chaperone NudCL. Despite the substantial
challenges of shRNA knockdown, the results of the small molecule inhibitors and failure of
either Hsp90a or Grp94 knockdown to reduce collagen-I secretion suggested that Hsp90p was
indeed the relevant isoform. This finding was surprising to us, as Hsp90p exists in the cytosol,
and thus would not directly interact with collagen-. Recent work, however, had identified
cytosolic adapter and signaling proteins involved in protein ER export. Among these proteins
was an E3 ubiquitin ligase complex composed of Cullin3 (CUL3) and the adapter protein
KLHL12, which together installed a non-degradable mono-ubiquitin signal on the COP-Il coat
protein Sec3la;39 ubiquitylation of Sec3la was sufficient to trigger assembly of enlarged COP-Il
vesicles capable of accommodating the collagen-I triple helix. Overexpression of KLHL12 led to
installation of polyubiquitin chains on Sec3la and induced Sec3la degradation by the
proteasome, but the mechanism for selecting mono- over poly-ubiquitination remained
unknown.
One means of ensuring single modification by E3 ligases is by the action of a de-
ubiquitinase (DUB). The ER-associated DUB USP19 had previously been reported to recruit
misfolded substrates to endosomes for extracellular release; USP19 is also the only DUB
known to interact with Hsp90, which was found to promote USP19 DUB activity in vitro.40 We
therefore wondered if Hsp90p enabled collagen-I secretion by enhancing USP19 DUB activity
towards Sec3la in the cytosol. Selective inhibitors for USP19 do not exist, and initial
USP19 shRNA knockdown
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Figure 3.8: USP19 shRNA knockdown does not affect collagen-I secretion. GM05294 cells
were plated at a density of 2 x 105 cells per well in 6-well plates the day before transduction.
Cells then received 500 giL of each virus in triplicate along with polybrene. The next day,
cells received fresh media, and were incubated until 72 h post-transduction, when collagen-I
secretion was induced with ascorbate. Conditioned media was collected for 24 h before
immunoblotting analysis.
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experiments with the pan-DUB inhibitor PR-61941 proved toxic to cells. Thus, to test our
hypothesis, we obtained shRNA constructs against USP19 (Table 3.1) and transduced primary
fibroblasts with generated lentiviruses. Collagen-I was induced with ascorbate 72 h post-
transduction, and conditioned media was harvested for immunoblotting after 24 h; transcript
levels of USP19 were analyzed by qPCR. While we were not able to detect endogenous USP19
by immunoblotting, qPCR confirmed that we were able to deplete USP19 transcripts to -40% of
control levels. However, this modest level of USP19 depletion did not affect collagen-1 secretion
(Figure 3.8).
Because our USP19 knockdown results did not affect collagen-I secretion, we next
considered whether Hsp90 might participate in assembly or activation of the CUL3-KLHL12
complex. Hsp90 was previously found to influence assembly of the DBC2-CUL3-COP9 complex
and bind CUL3 in vitro.42 43 In addition, the co-chaperone NudCL (encoded by the gene
NUDCD3) could be co-purified from cellular lysates by KLHL12; a separate study used
recombinant Hsp9O in the luminescent LUMIER assay and found that NudCL also associated
with Hsp90s. * We thus hypothesized that NudCL might serve as an adapter protein, allowing
Hsp90P to bind to and promote the assembly of CUL3-KLHL12. We were able to deplete NudCL
transcripts to -50% of control levels using two lentiviral shRNA constructs (Figure 3.9A). In both
cases, NudCL depletion reduced collagen-I secretion (Figure 3.9B and C). Later efforts to
repeat NudCL shRNA knockdown, however, proved difficult, underscoring the problem of batch-
to-batch variability in lentiviral titers and highlighting the importance of careful optimization of
viral volume and length of knockdown.
Discussion
How does cytosolic Hsp90P, which should never interact with collagen-I directly inside
cells, influence collagen-I secretion? As the heat shock protein Hsp47 is a well-established
collagen-specific chaperone23 whose level of expression increases upon HSR activation,46 it is
possible that Hsp90 inhibitors reduce the level of collagen- secretion by increasing Hsp47
availability through the HSR. However, we found that suppression of the HSR via expression of
a constitutive, dominant-negative HSF1 was unable to rescue collagen-I secretion in the
presence of the Hsp9O inhibitor 17-AAG, suggesting that the HSR is not involved. Moreover, a
recent report revealed that a small molecule inhibitor of the Hsp47-collagen interaction instead
reduces the level of collagen secretion, indicating that a different mechanism is likely operating
here.
A more likely possibility is that cytosolic Hsp90 influences collagen-I secretion via
interactions with cytosolic components of the secretory pathway. Because of its size and rigidity,
collagen-I cannot be exported from cells in conventional COP-Il secretory vesicles. Recent work
has suggested that collagen is instead transported via a unique secretion pathway involving
expanded COP-Il vesicle coats.39 4" A combination of live-cell imaging, correlated light electron
microscopy, and super-resolution microscopy techniques showed that enlarged COP-Il vesicles
are competent to carry collagen-I and are physically separated from the ER. 48 Because the
inhibitors we tested selectively reduce the level of secretion of collagen-, but not the level of
secretion of the more compact proteins eGLuc2, TTR, fibulin-3, and fibronectin (see Chapter II),
we speculate that cytosolic Hsp90 may be required for the assembly or transport of these large,
collagen-specific vesicles.
Significant efforts by multiple groups have revealed how another large collagen, type VII,
is exported from cells. Specifically, Tangol concentrates collagen-VII at ER exit sites (ERES),
recruits ERGIC membranes to the growing collagen carrier, and cooperates with cytosolic
protein partners such as cTAGE5, Sedlin, and Slyl to regulate vesicle growth (and possibly
geometry) .4 9-55 A separate study found that transcription factor BBF2H7 upregulates the
expression of genes involved in COP-Il vesicle expansion to facilitate a switch from export of
short chain collagen type VIII to extended collagen type 11.19 These results suggest that the
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Figure 3.9: NudCL shRNA knockdown and model. GM05659 cells were plated at a
density of 2 x 105 cells per well in 6-well plates the day before transduction. Cells then
received 200 IL of each virus in triplicate along with polybrene. Media was changed the
next day, and changed again after 72 h. Collagen secretion was induced with ascorbate
24 h prior to harvesting, and samples were harvested 7 d post-transduction. (A) shRNA
knockdown was validated by qPCR analysis of transcript levels. (B) Immunoblots of
conditioned media from cells transduced with control or NudCL shRNA-containing
lentivirus (n = 3). (C) Quantification of Western blot data. (D) Potential model for NudCL
involvement in collagen-I secretion. (1) Hsp90P and NudCL stabilize Lis1 and protect the
protein from proteasomal degradation. (2) Lis1 is then able to bind the microtubule motor
dynein, delaying the power-stroke and prolonging association of dynein with the
microtubule. (3) Such interactions may promote collagen-1 secretion by facilitating
transport of collagen-containing vesicles to the plasma membrane.
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mode of collagen secretion may be tailored to specific types, based on developmental
signaling"9 or the directionality of collagen secretion. Indeed, the dependence of collagen-I
secretion on the Sec16 binding protein TFG implies the existence of analogous, but distinct,
mechanisms of endoplasmic reticulum exit site organization for collagen-I and collagen-VII
export. 6 Exactly how TFG, Tango1, and their partners facilitate the secretion of specific
collagen types (Table 3.2) awaits further clarification.49' 5'
Table 3.2: Consequences of secretory pathway component depletion.
Protein Method Collagen Type! Other Secretory Cargo! ReferenceSecretion Defect Secretion Defect
cTAGE5 siRNA Type VII / ER VSVG, general protein secretion / Saito et al.
export blocked none (Ref. [51])
Mutational Matrilin / blocked Sarmah et al.Sec24D Mcren Type Il / blocked B1 integrin receptor, cadherins / (Ref. [71])
none
Sedlin siRNA Type 1, 11 / ER tsVSVG, CD8a, albumin, a1AT, Venditti et al.export blocked general protein secretion / none (Ref. [52])
Type I / none General protein secretion / none
Slyl siRNA Type VII / 75% ssHRP / blocked Nogueira et al.
reduction BiP, ERGIC-53 / none (Ref. [53])
Syntaxin siRNA Type 1, VII /-_ Nogueira et al.
5 blocked (Ref. [53])
Syntaxin siRNA Type I / none __ Nogueira et al.
18 Type VII / blocked (Ref. [53])
siRNA Type VII / 90% ssHRP / 50% inhibition Nogueira et al.reduction (Ref. [53])Tango1
KO Type I-IV, VII, IX /COMP / blocked Wilson et al.blocked (Ref. [57])
TFG siRNA Type 1, IV, VI / Mannosidase 11, VSVG, E- McCaughey et al.blocked cadherin, GaIT / none (Ref. [56])
Beyond these proteins, recent work has
the Ca2+-binding protein ALG2 to ERES.58 ALG2
KLHL12 and Sec3l, and proposed to serve
shown that calcium flux triggers localization of
was previously identified as a joint interactor of
as a Ca2+-sensing triaaer for COP-Il vesicle
growth. ALG2, in turn, interacts with TFG, and has been hypothesized to promote TFG
retention at ERES as well as TFG polymerization in response to Ca2 .59 Such findings add
another potential layer of Ca2+-dependent regulation to collagen-I secretion, in which ALG2 not
only bridges the interaction between the CUL3/KLHL12 complex and its ubiquitylation target
Sec3la, but also facilitates organization of the transitional ER via TFG polymerization.44'56 A
separate study suggested that TFG does not function at ERES, but instead migrates with COP-
I vesicles to promote release of outer coat proteins in preparation for fusion with the ERGIC.60
NudCL had been identified in affinity purification and in vitro binding assays as an
interactor of both KLHL12 (but not Sec3l) and Hsp90p.44' 4 Because Hsp90 had been
implicated in the assembly of CUL3 E3 ligase complexes before,43 we wondered if NudCL might
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be acting as an adapter for Hsp90, allowing the chaperone to assist in the folding and/or
association of KLHL12 with CUL3. However, we have thus far been unable to isolate a ternary
complex between CUL3/KLHL12, NudCL, and Hsp90P. Moreover, difficulties in reproducing the
initial NudCL shRNA knockdown results have further hindered our efforts to conclusively test
this hypothesis.
The cytotoxicity we observed with NudCL depletion suggested that, like Hsp9O, the co-
chaperone might have critical, general roles in cells. Indeed, NudCL is required for stabilization
of the microtubule motor protein dynein, and depletion of NudCL leads to mitotic defects and
cell death.61 NudCL also acts in concert with Hsp90 to stabilize the protein Lis1, which regulates
dynein ATPase activity and has been implicated in mitotic defects as well.62 -4 But while the
importance of NudCL in stabilizing dynein complicates genetic approaches to test NudCL
involvement in collagen-I secretion, it also presents another, alternate mechanism by which
NudCL might facilitate protein export. In addition to binding Sec3l, the protein ALG2 was shown
to complex with MISSL and microtubule-associated protein 1 B (MAP1 B) in a Ca2+-dependent
manner. MAP1B binds Lis1, and shares a microtubule-binding motif with dynein, leading the
authors of the study to suggest that MAP1B may compete with dynein for access to
microtubules to regulate protein secretion.65 The reductions in collagen- secretion we observe
upon Hsp90P and NudCL inhibition or depletion are thus consistent with a role for NudCL in
promoting collagen-I export, not by promoting CUL3/KLHL12 complex formation, but instead by
generating sufficient levels of dynein and Lis1 to allow for microtubule-mediated (and possibly
Ca2+-dependent) transport of COP-Il vesicles (Figure 3.9D).
NudCL binds the N-terminal domain of Hsp90, and the pan-isoform inhibitor STA-9090
blocks this interaction in vitro;66 meanwhile, the pan-isoform, N-terminal inhibitors geldanamycin
and radicicol both reduced Lis1 protein levels in HeLa cells.6 2 It will thus be interesting to
determine if shorter treatment times (on the scale used here) are also sufficient to disrupt this
interaction, and whether altered Lis1 levels can affect the MISSL-ALG2-MAP1 B complex or the
secretion of cargo besides secreted alkaline phosphatase.
While the precise interactions described above remain to be validated and clarified, a
striking feature of our collagen-I secretion data is the importance of abundant, multi-functional
proteins like NudCL and Hsp90. Adding to the puzzle is the absence of TFG, cTAGE5, and
other Tangol isoforms in Drosophila, which can nonetheless secrete collagen IV and has been
used as a model for studying collagen secretion.21 ' 5" The single Drosophila Tangol isoform,
however, is not only sufficient for collagen export, but also required for general protein
secretion, pointing to a possible generic mechanism of ER export.6 7 It will therefore be of
interest to test the involvement of NudCL and Hsp90 in collagen secretion by Drosophila and
other organisms, and perhaps determine if the chaperones are also part of a minimal secretion
cohort that was later expanded in specialized mammalian cells.
Finally, the apparent involvement of NudCL and Hsp9OP in the non-canonical secretion
of collagen-I also highlights the advantages of post-translational regulation. Hsp90 is subject to
phosphorylation, acetylation, S-nitrosylation, ubiquitylation, and SUMOylation, all of which can
regulate chaperone activity.68 Linking collagen-I export to an abundant protein whose activity is
regulated by a post-translational modification would allow for tight temporal control, as has been
proposed for the monoubiquitylation of Sec3l in response to transient Ca 2 influx.4 4 The
discovery of other modifications, such as O-GlcNAcylation of Sec23A69 and Tango1 70 and the
ubiquitylation of PEF1,4 suggest that post-translational regulation may be a common theme of
collagen-I secretion, allowing a large pool of general chaperones, enzymes, and effectors to be
rapidly mobilized in response to changing developmental or physiological demands.
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Materials and Methods
Cell Lines and Reagents. Healthy dermal fibroblasts (GM05659, Coriell Cell Repositories) were
cultured in complete MEM supplemented with 15% FBS, 100 IU penicillin/100 pg/mL
streptomycin, and 2 mM L-glutamine (Corning). Immunoblots were probed with the following
primary antibodies, as indicated: Colal (I) (Sigma HPA008405), Cola2(1) (Sigma SAB4500363),
Cola2(1) (Abcam ab96723), Cola (1) (NIH LF-68), Hsp70/Hsp72 (Cell Signaling Technologies
4873), Akt (Cell Signaling Technologies 9272), P-actin (Sigma A1978), fibronectin (Sigma
F7387), KDEL (Enzo 10C3 ADI-SPA-827; recognizes Grp94 and Grp78), Hsp90a (Santa Cruz
sc515081), Hsp90P (Abcam ab53497), TRAP1 (Santa Cruz sc13557), or NudCL (Sigma
HPA019136). Duplicate blots from representative experiments were probed with both sets of
Cola1 (1) or Cola2(l) antibodies to compare antibody sensitivity (Figure 3.7).
Western Blotting Analysis. GM05659 primary fibroblasts were plated in 6-well plates at a density
of 2 x 105 cells/well and allowed to adhere overnight. The next day, the medium was changed to
full MEM with 0.5x penicillin/streptomycin, collagen expression was induced with 200 VM
sodium ascorbate (Amresco), and cells were treated with DMSO or the indicated compound
concentrations for 24 h. Samples of medium were denatured by being boiled in Laemmli buffer
(supplemented with 167 mM 1,4-dithiothreitol; DTT), separated on homemade 4/8% Tris-Gly
SDS-PAGE gels, and transferred to nitrocellulose membranes. Because of cross-reactivity
between the collagen-I antibodies, samples of medium for collagen-I blots were run on duplicate
gels, transferred, and then probed separately for either rabbit anti-Cola2(1) or rabbit anti-
Cola1 (I).
For Western blots of cell lysates, cells were trypsinized, washed with phosphate-buffered
saline (PBS), and lysed in Triton-X lysis buffer with 1.5 mM PMSF and a protease inhibitor tablet
(Pierce). Total protein was quantified using the bicinchoninic acid assay, and equal amounts of
total protein were analyzed for each sample. Each experiment was performed in biological
triplicate. Blots were imaged after incubation with appropriate primary and 800CW or 680LT
secondary antibodies (LI-COR) by scanning on an Odyssey infrared imager (LI-COR), followed
by quantification using ImageJ.
Lentivirus Production. Lentiviral vectors (Sigma) encoding shRNA constructs against Grp94,
Hsp90a, Hsp90P, USP19, NudCL, or GFP (referred to in the text as a non-mammalian control)
were amplified and prepped along with the lentiviral packaging vectors RRE, REV, and VSVG
(Addgene). 9 x 106 293FT cells were plated on poly-D-lysine (Sigma)-coated 10-cm dishes and
allowed to adhere overnight. The next day, 15 pg of each lentiviral vector was combined with 15
pg of RRE, 6 pg REV, 3 pg VSVG, and 60 pL Lipofectamine 2000 in OptiMEM (Life
Technologies). Transfection mixtures were incubated for 40 min at rt and 293FT cell media was
changed to OptiMEM. The transfection complexes were then added dropwise to the plate and
incubated 12-16 h at 37 *C, after which the OptiMEM was removed and replaced by full
medium. Lentivirus was harvested 48 h after the media change, spun at 207 xg for 5 min to
remove cell debris, and stored in single-use aliquots at -80 *C.
Quantitative PCR (qPCR). GM05659 primary fibroblasts were plated and treated as described
above. Cells were then washed with PBS, and RNA was extracted using the Omega E.Z.N.A.
Total RNA extraction kit. cDNA was prepared from 500 ng of RNA, normalized for all samples in
each run, using an Applied Biosystems Reverse Transcriptase cDNA Kit in a Bio-Rad
Thermocycler. Samples were run on a Light Cycler 480 11 Real Time PCR Instrument in the MIT
BioMicro Center using previously described primers and analysis methods. The following qPCR
primer sequences were used for detecting transcript levels of Grp94 (HSP90B1): 5'-
GGCCAGTTTGGTGTCGGT-3' and 5'-CGTTCCCCGTCCTAGAGTGTT-3'; Hsp90s
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(HSP90AB1): 5'-CGAAGTTGGACAGTGGTAAAGAG-3' and 5'-
TGCCCAATCATGGAGATGTCT-3'; USP19: 5'-TACCACCGCTGAACTCCCAA-3' and 5'-
ACAGTCATCTTTCCCAGGGTT-3'; or NudCL (NUDCD3): 5'-CACCACAGAATTGGATGGGCA-
3' and 5'-CACCATTGTAACTGTCGGGATTT-3'.
shRNA Knockdown. GM05659 primary fibroblasts were plated at a density of 2 x 105 cells/well
in 6-well plates the day before transduction. After being allowed to adhere overnight, cells were
given fresh medium (with 4 pg/mL Polybrene) and the indicated amounts of lentivirus. The next
day, cells were subjected to a medium change and incubated until 72 h post-transduction, when
the medium was changed and collagen-I expression was induced with ascorbate. Conditioned
medium was collected 24 h later for Western blotting, as described above. Sequences for
shRNA constructs are provided in Table 3.1. Transductions for co-treatment experiments with
Grp94 shRNAs and 17-AAG were performed as described above, but using 300 pL of the
indicated lentivirus. shRNA knockdown of Hsp90a and Hsp90P was performed as described
above but using GM05294 fibroblasts.
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CHAPTER IV
Adapting Secretory Proteostasis and Function through the Unfolded Protein Response
Summary
Cells address challenges to protein folding in the secretory pathway by engaging
endoplasmic reticulum (ER)-localized protective mechanisms that are collectively termed the
unfolded protein response (UPR). By the action of the transmembrane signal transducers IRE1,
PERK, and ATF6, the UPR induces networks of genes whose products alleviate the burden of
protein misfolding. The UPR also plays instructive roles in cell differentiation and development,
aids in the response to pathogens, and coordinates the output of professional secretory cells.
These functions add to and move beyond the UPR's classical role in addressing proteotoxic
stress. Thus, the UPR is not just a reaction to protein misfolding, but also a fundamental driving
force in physiology and pathology. Recent efforts have yielded a suite of chemical genetic
methods and small molecule modulators that now provide researchers with both stress-
dependent and -independent control of UPR activity. Such tools provide new opportunities to
perturb the UPR and thereby study mechanisms for maintaining proteostasis in the secretory
pathway. Numerous observations now hint at the therapeutic potential of UPR modulation for
diseases related to the misfolding and/or aggregation of ER client proteins. Growing evidence
also indicates the promise of targeting ER proteostasis nodes downstream of the UPR. Here,
we review selected advances in these areas, providing a resource to inform ongoing studies of
secretory proteostasis and function as they relate to the UPR.
Contributions
This chapter is adapted by permission from Springer: Springer International Publishing,
Coordinating Organismal Physiology Through the Unfolded Protein Response (Wiseman, R. L.,
and Haynes, C. M., Eds.), Wong, M.Y. et al (2018) Adapting Secretory Proteostasis and
Function Through the Unfolded Protein Response, pp 1-25. Copyright 2018.
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Introduction
The endoplasmic reticulum (ER) is responsible for secretory proteostasis, involving the
coordinated folding, processing, quality control, and trafficking of -1/3 of the proteome. Protein
folding is a highly complex and error-prone process, requiring a delicate balance between
function and risk of aggregation in crowded biological microenvironments where total protein
concentrations can range from 100-400 mg/mL.' 2 ER clients, which include secreted,
membrane, and lysosomal proteins, face additional challenges, including unique post-
translational modifications (e.g., N-glycosylation) that require specialized cellular machinery,3
oxidative folding processes associated with selective disulfide bond formation,4 and both spatial
and temporal restraints on the completion of folding, modification, assembly, and transport
steps. Cells account for this complexity via a diverse array of folding2 and quality control
mechanisms, 5 some of which are only recently coming to light. The resulting balance of protein
synthesis, folding, and recycling is essential for health. Dysregulated proteostasis in the
secretory pathway underpins a diverse array of diseases.
Maintaining secretory proteostasis requires the ability to dynamically respond to
challenges such as protein misfolding, often by large-scale remodeling of the ER and the ER
proteostasis environment.6 The unfolded protein response (UPR; Figure 4. 1) is the central
stress response pathway involved. The three arms of the metazoan UPR are controlled by the
signal transducers IRE1, PERK, and ATF6. 71 0 Activation of these ER transmembrane proteins
induces a transcriptional response mediated by three transcription factors, XBP1s,"' 12 ATF4,13 ,
14 and ATF6f (ATF6-fragment). 1 5 This coordinated transcriptional response alleviates the burden
of protein misfolding in the secretory pathway by upregulating ER chaperone, quality control,
and secretion mechanisms. 13, 15, 16 UPR activation also inhibits protein translation to lower the
net nascent protein load on the ER, a process mediated primarily by PERK activation and
subsequent phosphorylation of elF2a,8 but also influenced by the selective degradation of ER-
directed mRNA transcripts by IREl 17, 18 If proteostasis cannot be restored, pro-apoptotic
mechanisms within the UPR are engaged leading to programmed cell death primarily through
induction of the transcription factor CHOP downstream of PERK.
While extensive research has yielded a relatively well-defined picture of the UPR, the
discovery of new regulatory mechanisms continues to shape our understanding of how the UPR
relates to ER homeostasis. The ER not only functions as a protein-folding factory, but also
participates in calcium storage and lipid biosynthesis.19 Along these lines, a recent study
highlighted the capacity of IRE1's membrane spanning domain to activate the protein in
response to lipid perturbation even when the luminal protein misfolding stress-sensing domain is
deleted using CRISPR/Cas9 0 Moreover, the ER is involved in cellular responses to oxidative
stress, metabolic imbalance, and pathogen invasion. Each of these processes is modulated
by the UPR. Thus, despite its moniker, the UPR is not simply a reaction to protein misfolding,
but is instead a fundamental driving force for physiology and pathology. The central roles of the
UPR in health and disease have catalyzed the development of methods to modulate the UPR,
with the goal of better understanding key regulatory axes and identifying opportunities to
influence phenotypic outcomes. Below, we review our current picture of the metazoan UPR in
the context of secretory proteostasis, from its connections to health and disease, to methods for
selectively perturbing the UPR and their potential applications in disease therapy, to efforts to
target downstream nodes in ER proteostasis.
The UPR in Health and Disease
Key functional nodes within the ER proteostasis network include chaperones, quality
control mechanisms, post-translational modifiers, and trafficking pathways (Figure 4.2). Each of
these nodes is dynamically regulated by the UPR to match proteostatic capacity to demand,
thereby maintaining balanced levels of protein folding and quality control both during normal
cellular function and under stressful conditions.
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Figure 4.1: The unfolded protein response (UPR). Accumulation of
misfolding proteins in the endoplasmic reticulum (ER) activates the
transmembrane protein UPR signal transducers PERK, IRE1, and
ATF6. Dimerization and auto-phosphorylation of PERK and IRE1, or
trafficking to the Golgi and subsequent proteolytic processing of
ATF6, result in the production of the UPR transcription factors by
enhancing translation of ATF4, splicing XBPI mRNA to yield XBP1s,
and releasing ATF6f from the Golgi membrane. These transcription
factors proceed to the nucleus and remodel the ER proteostasis
environment by upregulating chaperones, quality control
components, and other UPR target genes to maintain or recover
secretory proteostasis. PERK can globally reduce the nascent
protein load on the ER via phosphorylation of elF2a, a pathway that
can be similarly induced by the integrated stress response. The
RNase domain of activated IRE1 degrades several ER-targeted
transcripts and may play a related role.
Development, Professional Secretory Cells, and Immunity. The UPR has critical roles during
development that have been demonstrated in several model systems. 2 In particular, UPR
activation appears to upregulate ER-resident chaperones and signaling pathways, which work
collectively to relieve stress and regulate development in differentiating cells. 26 -28 For example,
upon beta-cell differentiation into plasma cells, the ER undergoes extensive XBP1-driven
expansion 28, 29 in part to accommodate high levels of antibody synthesis. Beta-Cell
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Figure 4.2: Representative nodes in the secretory proteostasis network. Diverse
proteins and pathways collectively modulate folding, secretion, quality control,
and/or degradation of ER clients. ATP-dependent chaperones and PDlases assist
in the folding of client proteins, as do lectin-based chaperones such as calnexin and
calreticulin. Terminally misfolded proteins are typically cleared by ER-associated
degradation (ERAD) via the ubiquitin-proteasome system. ER-phagy can serve as
a counterpart to membrane expansion mechanisms, reducing organelle size to
regulate ER proteostasis. Meanwhile, calcium flux, vesicle trafficking, and UPR-
mediated changes in the chaperone:client balance, import, disulfide bond
formation, and N-glycosylation of nascent polypeptides help to maintain or create
favorable folding conditions and buffer ER protein-folding capacity. A handful of
chaperones, including ERdj3, can accompany proteins to the extracellular space.
differentiation in vitro also induces the UPR-regulated proteins XBP1s, BiP and Grp94. Notably,
the process occurs without expression of CHOP or inhibition of protein translation, suggesting
that a physiologic UPR need not involve all three UPR arms, in contrast to the case of
attenuating stress-induced protein misfolding. Moreover, induction of XBP1, BiP and Grp94
transcripts apparently occurs prior to any significant protein-folding load on the ER, suggesting
further differences between developmental and stress-associated signaling pathways. Other
professional secretory cells such as pancreatic beta-cells, hepatic cells, and osteoblasts also
must sustain high rates of ER client protein synthesis, folding, and secretion, and thus rely on
the UPR and its downstream signaling mechanisms for survival and function.
Other work highlights roles of the UPR in cellular responses to pathogen invasion.
Binding of unfolded cholera toxin A subunit induces IRE1a ribonuclease activity but not the
canonical UPR involving PERK and ATF6. 3 ' The fragments of endogenous mRNA produced by
IREla prompt RIG-I to activate NF-KB and interferon signaling. Other work indicates that Toll-
like receptors (TLRs) in macrophages promote splicing of XBP1 to optimize the production of
proinflammatory cytokines, although XBP1s can also be essential in protecting against the
effects of prolonged inflammation. 3 * Intriguingly, viral pathogens are capable of hijacking the
UPR to promote proliferation in host cells. For example, IRE1 activity is critical for the replication
of at least some strains of the influenza virus." In contrast, HSV1 suppresses both PERK and
IRE1 signaling: glycoprotein B interacts with the luminal domain of PERK to block kinase
activation, the late viral protein g1 34.5 recruits PPla to dephosphorylate elF2a, and the UL41
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protein acts as an endoribonuclease to degrade XBP1 mRNA.36 Similarly, recent studies of
Legionella pneumophila, the organism responsible for Legionnaires' disease, show that the
pathogen forestalls a prototypical ER stress response by repressing translation of a subset of
UPR-associated genes to prevent host-cell apoptosis that would otherwise be induced. 38 The
relevant bacterial effector proteins may serve as springboards for biomimetic approaches to
modulate UPR pathways.
Emerging Functions of the UPR. Beyond established roles in development and immunity, new
functions for and consequences of the UPR continue to emerge. ER recycling via ER-phagy is
critical for ER homeostasis 39 and several constituent biochemical pathways were recently
mapped.40' 41 A possible role for the IRE1-XBPls arm of the UPR in inducing such ER-phagy
may exist.4 2 By reducing organelle size and/or disposing of dysfunctional ER regions, UPR
induction of selective ER-phagy could serve as a counterpart to membrane expansion
mechanisms for resolving ER stress.
The discovery that the IRE1-XBP1s axis of the UPR is responsible for cell non-
autonomous UPR activation44 is also intriguing. Such cell-to-cell communication of stress is
likely to have important biological consequences that merit further investigation. ATF6 activation
was recently shown to increase not just expression but also secretion of ERdj3, an ER-localized
HSP40 co-chaperone.4 5 The consequent co-secretion of ERdj3 with misfolded client proteins
may be protective for the origin cell or ameliorate harmful protein aggregation in the extracellular
milieu. Stress-induced ERdj3 secretion thus provides a mechanism by which the UPR can
modify not just ER but also extracellular proteostasis.
Emerging functions of the UPR described above focus on direct modulation of protein
folding and production. In addition to these mechanisms, a role for the ER in regulating the
extent of protein post-translational modifications has emerged. For example, two groups
showed that the UPR can modulate hexosamine biosynthesis to promote ER client clearance
and prolong life in the face of chronic protein misfolding stress.46 47 These studies suggest that
UPR activation, and especially the IRE1-XBP1s arm of the UPR, may enhance the extent of
client protein N- and 0-glycosylation and/or modify oligosaccharyltransferase efficiency. While
the consequences merit further investigation, N-glycosylation promotes both ER client folding by
providing access to the lectin-based chaperone machinery and the identification of misfolded
proteins for ER-associated degradation (ERAD) via the lectin-based quality control machinery,
providing a potential rationale for IRE1-XBPls enhanced N-glycosylation. 8
Surprisingly, the UPR can also remodel the actual molecular architecture of N-glycans
added to ER client proteins by modulating their biosynthesis.49 Stress-independent activation of
XBP1s changes transcript levels of N-glycan modifying enzymes, leading to altered mature
glycan structures on model secreted N-glycoproteins. More work is required to establish the
biological relevance and consequences of this phenomenon. However, this newly established
connection between N-glycan signatures and the UPR suggests that the UPR may
unexpectedly influence processes such as cell-cell interactions, cell-matrix interactions, and
trans-cellular communication by actually modifying the molecular structure of secreted ER
clients. In the following chapters, we report the first evidence that XBP1s activation does
indeed remodel the distribution of cellular N-glycan structures (Chapter V). We also present
evidence that the N-glycan on the collagen-I C-terminal propeptide domain buffers collagen-I
folding against ER stress and destabilizing mutations (Chapter VI). These findings highlight
cross talk between UPR signaling and N-glycosylation as a new mechanism for regulating
secretory proteostasis.
Dysregulated ER Proteostasis and Disease. When proteostasis networks function properly, cells
maximize production of properly folded, functional proteins. Meanwhile, quality control
mechanisms ensure that only folded proteins are transported to their final locations, while
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production of misfolded and aggregated proteins is minimized (Figure 4.3A). The UPR regulates
this process by sensing the accumulation of misfolded proteins, whether due to genetic
mutations or adverse physiological conditions, and remodeling the ER proteostasis network to
resolve emerging problems.
Chronically dysregulated ER proteostasis, unresolved by the UPR, leads to diverse
protein misfolding and aggregation-related diseases. For many mutations that destabilize or
prevent the folding of a protein, the UPR may in principle have the potential to resolve the
proteostatic defect - if it is activated. However, just one mutant protein misfolding in a
background of thousands of well-behaved proteins may not always be a sufficient signal to
trigger a protective UPR. In other cases, the ER may be overwhelmed by high concentrations of
an aggregating mutant protein, leading to chronic ER stress and cellular apoptosis. In either
scenario, pharmacologic perturbation of the UPR could be therapeutically useful. Moreover,
many cancer cells rely on constitutive activation of pro-survival pathways (in particular the IRE-
XBP1s arm) within the UPR.5 2 This observation suggests that UPR inhibition could also prove
valuable for diseases that do not stem directly from protein misfolding.
Concept Summary. Even this cursory survey of the roles of the UPR in health and disease
reveals a striking functional spectrum. Beyond the traditional UPR, IRE1, PERK, and ATF6
participate in various normal physiological processes, upregulating UPR-associated transcripts
to facilitate differentiation and sustain the activity of professional secretory cells. Studies on
different models of pathogen infection demonstrate that UPR arms also can be selectively
suppressed or activated in order to bypass cytotoxic stress-signaling pathways and promote cell
survival. Such mechanisms are appealing starting points for efforts to better understand and
manage cases of chronic ER stress associated with disease. Finally, recent findings suggest
new roles for the UPR in regulating extracellular proteostasis and signaling, perhaps via post-
translational alterations in ER client protein molecular structures.
Targeting the UPR to Modulate ER Proteostasis
The intrinsic functions of the UPR in development and immunity, regulating cell survival
and death, and resolving proteostatic stress have motivated extensive method development
efforts to uncover small molecule UPR activators and inhibitors. Such tools are enabling
detailed dissection of innate UPR function and revealing the therapeutic potential associated
with targeting the UPR. This section reviews selected chemical genetic and small molecule
approaches to modulate the UPR, and briefly describes insights obtained using such methods in
disease model systems.
Stress-Dependent Methods to Modulate the UPR. Traditional approaches to activate the UPR
rely on small molecules that cause ER stress. Such compounds include tunicamycin, which
inhibits protein N-glycosylation; thapsigargin, which disrupts ER calcium homeostasis; and
dithiothreitol, which reduces disulfides. All these methods globally and strongly activate the UPR
by inducing extensive protein misfolding and aggregation. While such strategies have proven
valuable for mapping UPR signaling pathways, they are less suited for mechanistic work as they
induce high and physiologically irrelevant levels of stress. Moreover, these compounds are not
helpful for therapeutic proof-of-principle studies, as the cytotoxic and pleiotropic side effects of
their use obscure any potentially beneficial effects of UPR activation.
One approach to bypass these issues is to administer very low concentrations of ER
toxins to induce only moderate stress. Alternatively, a chemical genetic strategy was recently
pioneered to transiently activate the UPR without inducing apoptosis." The method involves
expressing an ER-targeted HaloTag protein that can be conditionally destabilized by
conjugation to a small molecule hydrophobic tag (HyT36). Treatment of ER-targeted HaloTag-
expressing cells with HyT36 destabilizes the protein, causing mild but acute accumulation of
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misfolded proteins in the ER and consequent UPR activation. While the mechanistic details are
not yet fully elucidated, the ERHT/HyT36 system provides a valuable tool to study aspects of
global UPR activation distinct from the stress-independent, arm-selective techniques described
below.
Stress-Independent Methods to Modulate the UPR. An important element of any strategy to
discover and validate small molecule UPR arm activators is verifying that the compounds
directly and selectively activate a particular arm of the UPR, without inducing ER protein
misfolding or other forms of stress. To address this concern, recent work has delineated
comprehensive transcriptional profiling strategies to validate stress-independent, arm-specific
UPR activators.55 While several small molecule leads have been developed that activate
endogenous IRE1 and/or ATF6,55 56 potency and selectivity, as well as mechanistic
characterization, will benefit from further work. Selective small molecule activators of
endogenous PERK have thus far proven elusive. On the other hand, salubrinal, 7 guanabenz, 8
ISRIB,59 and Sephin1 60 can modulate the PERK-induced translational block either up or down
by altering elF2a phosphorylation status (Figure 4.1). Other explanations for the biological
phenotypes induced by guanabenz and Sephin1 may also prove relevant.61 Notably, these
compounds also modulate overlapping aspects of the integrated stress response, rendering
such small molecules neither UPR- nor PERK-specific. For example, salubrinal also targets the
constitutively expressed elF2a phosphatase CReP.57 Finally, while small molecule inhibitors of
endogenous IRE1 have been well characterized,62-64 compounds that inhibit ATF6 are only now
beginning to emerge. 5
Given the paucity of small molecules to modulate arms of the UPR in a stress-
independent manner, over the past fifteen years the field has turned to chemical genetic
approaches. One strategy involves fusion of PERK's kinase domain to a tandem-modified
FK506-binding domain, Fv2E. Treatment with the small molecule AP20187 induces Fv2E-PERK
dimerization, auto-phosphorylation, and downstream PERK signaling.66 , 67 The Fv2E fusion
strategy was also applied to recapitulate the regulated RNase activity of IRE1.6 8 A
complementary strategy based on bump-hole protein engineering employs an 1624G mutation to
allow binding of a small molecule ligand in the ATP pocket of IRE1, but not other kinase active
sites, resulting in selective, stress-independent activation of IRE1's RNase domain. Addition of
the ligand 1NM-PP1 to cells expressing IRE1a1 624G results in selective IREl-dependent XBP1
mRNA splicing in the absence of ER stress.69-' These PERK and IRE1-targeted chemical
genetic strategies allow for uncoupling of UPR arm activation from stress, but require careful
engineering of cells to ensure minimal background signaling and robust inducibility. Their
application has helped to clarify the consequences of ER stress. For example, chronic PERK
activity, but not 1NM-PP1-induced IRE1 activity, is cytotoxic, suggesting a model in which the
duration of PERK signaling regulates cell survival versus apoptosis decisions.66 Intriguingly, the
advent of RNase inhibitors targeting wild-type IRE1, such as KIRA6, revealed that IRE1 can
also promote apoptosis through formation of oligomers with hyperactive RNase activity. Thus,
cell fate may not necessarily be determined by opposing signals from IRE1 and PERK, but
rather by the degree and timescale of activation (whether homeostatic or cytotoxic) experienced
by both kinases.
An alternative chemical genetic strategy is to confer small molecule-dependent activity
upon the UPR transcription factors, independent of the upstream signal transducers IRE1,
PERK, and full-length ATF6. This approach has proven most successful for XBP1s and ATF6f
(Figure 4. 1). In the simplest case, tetracycline (Tet)-regulated expression of the UPR
transcription factors ATF6f73 and XBP1s 16' 7 under control of the Tet-repressor domain has
been applied in several model systems. A challenge is the requirement for incorporation of the
Tet-repressor in target cells and tissues. Moreover, Tet control of protein expression is rarely
dose-dependent, resulting in high, non-physiologic levels of the Tet-inducible gene. 6' 75 Such
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overexpression of UPR transcription factors can cause off-target mRNA upregulation and often
induces apoptosis, limiting its applicability.
More recently, destabilized domains76' 7 were leveraged to achieve orthogonal activation
of XBP1s and/or ATF6f in a single cell. Fusing a destabilized variant of the dihydrofolate
reductase from E. coli (DHFR) to the N-terminus of ATF6f results in a constitutively expressed
DHFR.ATF6f fusion protein that is directed to rapid proteasomal degradation. Addition of the
small molecule pharmacologic chaperone trimethoprim stabilizes DHFR, preventing degradation
and allowing the DHFR-fused ATF6f transcription factor to function.' 6 A related approach was
used to control the activity of the XBP1s transcription factor, via fusion to an FKBP12
destabilized domain that can be stabilized by the small molecule Shield-1. 75 The method
requires minimal cell engineering, can be used in virtually any cell line of interest (including
primary cells), and provides for highly dose-dependent control of transcription factor activity
within the physiologically relevant regime. Moreover, fusion of destabilized domains to dominant
negative versions of the UPR transcription factors can permit small molecule-dependent
inhibition of endogenous transcription factor activity. 5 The advantages of destabilized domains
for conferring small molecule control onto UPR and other stress-responsive transcription
factors78 have led to their adoption by a number of research groups in studies of stress-
responsive signaling.
Chemical genetic strategies provide valuable temporal and ligand concentration-
dependent control of UPR arm activity. However, they must be applied with caution to ensure
that engineered domains are compatible with the natural function of the target protein. IRE11624G
for example, does not share the same mechanism of activation as wild-type IRE1, and may
exhibit altered kinase activity; similarly, the fusion of destabilized domains to UPR transcription
factors may alter their function. Expression levels of engineered proteins, whether dictated by
the leakiness of the system or by copy number per cell, must also be optimized. Thus, while
such strategies have enabled substantial progress in the UPR field (especially with regard to
potential therapeutic benefits of UPR activation in disease model systems, discussed below),
they do not ablate the need for highly selective and potent small molecule UPR modulators that
function independently of protein misfolding stress.
Activating the UPR to Address Diseases Linked to Dysregulated ER Proteostasis. Small
molecule and chemical genetic methods to modulate the UPR, including those described above,
have been extensively applied to test whether UPR-mediated remodeling of the ER proteostasis
network is a viable strategy to address ER protein misfolding- and aggregation-related diseases.
In particular, various approaches have been used to address dysregulated proteostasis
associated with the three types of defects highlighted in Figure 4.3.
In the first category of pathologic ER proteostasis defects, protein misfolding/aggregation
diseases manifest owing to a combination of underactive quality control and insufficient folding
activity (Figure 4.3B). The insufficient ER proteostasis environments that characterize such
disorders stem from the inability to sense misfolding of an individual mutant protein and/or the
permitted secretion of malformed, aggregration-prone proteins into the extracellular milieu.
One example of underactive quality control is the transthyretin (TTR) amyloidoses,
79wherein misfolded or unstable TTR escapes the ER and later aggregates in peripheral tissues.
TTR is a secreted tetrameric protein whose extracellular disassembly provides the necessary
template for oligomers to form.' 81 Numerous mutations destabilize the tetramer, accelerating
disassembly, aggregation, and disease pathology. Two treatments currently exist: (1) gene
therapy via liver transplantation, as the liver is the primary source of TTR, and (2) small
molecule pharmacologic chaperones that stabilize secreted TTR tetramers and thereby prevent
79oligomnerization.
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Figure 4.3: Proteostasis (im)balances in health and disease. (A) When proteostasis is
properly balanced, production of folded, functional client proteins and quality control
surveillance are maximized, while misfolding and aggregation are minimized. Maintaining the
balance between production of folded, functional proteins and quality control or clearance of
misfolded, non-functional proteins is essential for health. In protein misfolding/aggregation
disorders linked to defects in ER proteostasis, (B) insufficient quality control, (C) hyperactive
quality control and failed folding, and/or (D) failed clearance leading to intracellular protein
aggregation and chronic ER stress/UPR activation can all cause a pathologic loss of
proteostasis balance. Modulating proteostasis network activities holds potential to resolve
such defects.
An alternative potentially synergistic possibility is enhancing the stringency of ER quality
control, perhaps via UPR-mediated remodeling of the ER proteostasis network to reduce the
secretion and promote the degradation of destabilized TTR variants. By lowering misfolding
TTR concentrations in the sera, this strategy would likely reduce pathologic oligomer formation.
Indeed, stress-independent activation of ATF6 using the chemical genetic DHFR.ATF6f
construct preferentially directs destabilized TTR variants towards ERAD, drastically reducing
their secretion.16 82 Importantly, the approach does not influence the secretion of stable, wild-
type TTR. These results hint at the potential of stress-independent UPR activation to improve
cellular capacity to prevent the secretion of misfolded, potentially toxic species. Stress-
independent XBP1s and/or ATF6 activation is also effective in preventing the secretion of
amyloidogenic light chain.83 Such findings motivated significant efforts to identify small molecule
activators of ATF6 that appear very promising and may provide leads for clinical development.55
A second, less intuitive category of ER proteostasis defects arises when cells execute
an overly stringent survey of client protein folding status (Figure 4.3C). As in cases of healthy
proteostasis, aggregation is minimized, but a slow-folding or moderately misfolded ER client is
prematurely directed to degradation when, if given sufficient time or assistance, it could have
adopted a sufficiently folded, functional state to avert pathology. Such indiscriminate
degradation owing to excessively stringent quality control results in loss-of-function phenotypes.
Onset of disease occurs when the amount of protein present and able to function in its natural
location falls below the required threshold of essential biological activity. Relaxed quality control
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may, in these cases, allow such ER clients to adopt sufficiently folded, functional states to traffic
to their destinations and thereby ameliorate disease.
One case where hyperactive quality control appears to be associated with pathology is
the lysosomal storage diseases. An example is Gaucher's disease, which is caused by
mutations that destabilize glucocerebrosidase (GCase). GCase is a hydrolytic enzyme that folds
in the ER and is then trafficked to the lysosome, where it degrades encapsulated glycolipids.
Misfolding-prone and destabilized GCase variants can be identified by overly stringent ER
quality control machinery and targeted for degradation by the proteasome. 4 Even a slight
improvement in trafficking to the lysosome would likely provide therapeutic benefit. Mu and
coworkers discovered that global UPR activation by induction of mild ER stress significantly
enhances trafficking of the L444P GCase variant to the lysosome in an IRE1- and PERK-
dependent manner, with a corresponding decrease in degradation. 5 The resulting
enhancement in lysosomal GCase activity can be synergistically enhanced by co-administration
of GCase-stabilizing pharmacologic chaperones. More recently, both modulation of Ca 2
concentrations in the ER and knockdown of specific ER proteostasis network components like
FKBP10 and ERdj3, which direct GCase to degradation, were shown to provide similar
benefits.86 -8" Thus, reducing quality control stringency via UPR-mediated and/or more targeted
perturbations of the ER proteostasis network may hold potential for diseases associated with
hyperactive quality control.
A third category of disease-causing ER proteostasis defects emerges when protein
misfolding or aggregation in the ER causes chronically unresolved stress and consequent
cellular dysfunction. While the IRE1 and ATF6 arms of the UPR can help cells tolerate such
chronic stress, as has been observed in fly models of retinal degeneration,9 " chronic
activation of the PERK arm leads directly to apoptosis. Thus, long-term UPR activation can
severely threaten tissue homeostasis (Figure 4.3D), engendering a vicious cycle in which
protein misfolding caused by mutations, aging, and the like results in cell death, increasing the
demand on surviving cells in a given tissue to produce folded, functional protein. The increased
protein-folding load placed on the surviving cells results in additional chronic ER stress, UPR
activation, and further tissue loss. Unresolved chronic ER stress is associated with a wide
variety of disorders and diseases, including obesity and neurodegeneration.91 Strategies to
inhibit UPR-mediated apoptosis could be valuable in these situations, as could methods to
alleviate chronic stress by enhancing folding or quality control (as in Figures 4.3B and 4.3C).
UPR-mediated ER proteostasis network remodeling has shown promise for several
diseases where aggregation is observed in the ER. For example, ATF6 and PERK activation
enhance clearance of mutant, aggregating rhodopsin variants that cause retinitis pigmentosa.
Similarly, ATF6 activation assists the clearance of the aggregating Z variant of a-1-antitrypsin
that normally causes inflammation-induced hepatotoxicity (by a gain-of-function mechanism)
and/or proteolytic damage to lung tissue (by a loss-of-function mechanism). Clearance of
these protein aggregates from the ER is thus an attractive therapeutic strategy. An alternative
approach, instead of activating UPR arms, is to simply lower the net protein load on the ER and
allow endogenous mechanisms to resolve the proteostasis defect. This strategy involves
application of molecules that function downstream of PERK to translationally attenuate the
protein folding challenge faced by the ER. Related strategies have shown promise in both
diabetes- and amyotrophic lateral sclerosis-related model systems. 5
While the division of disease-causing ER proteostasis defects into the three categories
in Figures 4.3B-D provides valuable context, few diseases fit seamlessly. For example, lax
quality control that permits excessive accumulation of mutant GCase variants may cause
chronic, damaging ER stress and/or disrupt general protein trafficking mechanisms, a
mechanism that could well be biologically relevant for Gaucher's disease. Intriguingly, GCase
deficiency promotes neurodegeneration in Parkinson's disease, possibly through the loss of
stabilizing effects on a-synuclein oligomers or by inducing lysosome dysfunction, providing
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further evidence that multiple shared mechanisms may underlie and connect otherwise
disparate pathologies.94 Another pertinent example is the collagenopathies such as
osteogenesis imperfectaY which appear to encompass all three types of ER proteostasis
defects described above. Collagen is a challenging protein to fold,96 with both globular and
triple-helical regions, abundant and critical post-translational modifications, and dimensions too
large for standard COP-Il transport vesicles. Numerous mutations in collagen strands and in
components of the collagen proteostasis network cause diverse collagenopathies, depending on
the specific type of collagen involved. Mutations can lead to intracellular collagen accumulation
and chronic ER stress, can cause collagen strands to be subjected to excessive quality control
and degradation, and/or produce variants that functionally disrupt tissue architecture.97' 98
Whether ER proteostasis imbalances can be remedied in osteogenesis imperfecta and the other
collagenopathies remains to be determined, but such pathologies do highlight the complexity
associated with many protein misfolding-related diseases.
Concept Summary. Directly targeting particular arms of the UPR via both stress-dependent and
-independent approaches will require minimizing off-target effects and separating overlapping
activities, whether this entails uncoupling an apoptotic, late-stage UPR from a stress-sensing,
early-stage UPR, uncoupling IRE1 kinase from RNase activity, or uncoupling UPR activation
from ER stress. While the development of improved methods continues, the application of
existing tools to various model systems confirms the therapeutic potential of adapting secretory
proteostasis through the UPR. Although the details of the energy landscapes of misfolding and
aggregation-prone proteins are unique, we note that they often share features in terms of their
interactions with the ER proteostasis network. Focusing on commonalities may thus yield
broadly applicable rather than disease-specific therapeutic approaches.
Beyond the UPR
The preceding discussion emphasizes the substantial promise of UPR modulation to
resolve disease-causing ER proteostasis defects. However, global remodeling of the ER
proteostasis network by UPR perturbation could have deleterious effects on wild-type, well-
behaved proteins or on innate functions of the UPR. Targeted drug delivery to diseased tissues
could help sidestep off-target effects, but remains difficult. Alternatively, although the UPR is the
master regulator of the ER proteostasis network (Figure 4.2), it is still just one of many hubs
(Figure 4.4). In many cases, it may be possible to design small molecules that target
proteostasis nodes downstream of the UPR's transcription/translation response to resolve
proteostasis defects. Such approaches could have a larger therapeutic window owing to more
precise manipulation of specific mechanisms. Testing these strategies requires selective
chemical biology and genetic tools to manipulate the activities of chaperones, quality control
pathways, and the like. In addition to the example of translational attenuation discussed above,
this section briefly considers two other nodes downstream of the UPR where targeted
investigation has become increasingly possible: the ER's ATP-dependent chaperones and
ERAD-mediated quality control.
Targeting ATP-Dependent Chaperone Systems in the ER. The ATIP-dependent chaperones
Grp94 (a heat shock protein 90, or Hsp9O, isoform), BiP (a heat shock protein 70, or Hsp70,
isoform) and their corresponding Hsp40-like co-chaperones and nucleotide exchange factors
are central components of the ER proteostasis network (Figure 4.2). They play key roles both in
assisting client protein folding and in recognizing and targeting misfolded proteins for quality
control. Given the importance of dysregulated proteostasis in cancer and other diseases, Hsp90
inhibitors have been particularly sought after as therapeutics. A number of potent inhibitors have
been discovered9 1-1 2 and show promise in cancer model systems. However, the high sequence
and structural similarity of Hsp90 isoforms" poses difficulties for the design of selective small
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Figure 4.4: Targeting functional nodes in the ER proteostasis network. Representative hubs
in the ER proteostasis network; colored boxes give a qualitative measure of methods
available to modulate each node. Red: few and/or poorly characterized tools; blue: many
and/or well-characterized tools. Nodes from Figure 4.2 are aligned with the broader axes of
quality control, folding, degradation, and secretion. For many diseases, coordinated
regulation of multiple nodes in one or more of the relevant pathways may produce the most
therapeutic benefit.
molecule inhibitors. Indeed, the most widely used Hsp90 inhibitors target multiple Hsp90
isoforms. Such promiscuity remains a significant challenge, even among compounds reported to
be selective for the ER-resident isoform Grp94. 04 Particularly with respect to ER proteostasis,
development of selective Grp94 inhibitors is essential to reduce undesirable cytotoxicity and
ensure that only the intended proteostasis network node is targeted.
Fortunately, the ATP binding pocket of Grp94 is the most distinctive amongst the Hsp90
chaperone isoforms,105 and recent progress in developing chemical tools for targeting Grp94 is
encouraging. Rigorous structure-based analyses revealed that certain members of the purine-
scaffold series bind a Grp94-specific hydrophobic pocket, permitting functional characterization
of the effects of Grp94 inhibition in cancer cells.106 Other compound classes also show
substantial promise, including radamide derivatives like Bnlm, the first Grp94-selective inhibitor
discovered.107 Improvements on Bnlm have yielded even more potent Grp94 inhibitors. 10" As
such chemical tools have become available, various groups have begun to test the
consequences of Grp94 inhibition in protein misfolding-related disease model systems. For
example, Bnlm-mediated Grp94 inhibition ameliorates excessive quality control of the
Ala322Asp variant of GABAA receptors, whose insufficient trafficking is associated with specific
forms of epilepsy.' 09 Such results are reminiscent of the ability of UPR activation to reduce
excessive quality control of GCase.85 Here, however, targeting an ER proteostasis node
downstream of the UPR offers a more specific biological response.
Selective inhibition of the ER's Hsp70 analogue BiP has proven more challenging.
Eukaryotes express as many as thirteen Hsp70 isoforms,110 including BiP in the ER, mtHsp70 in
mitochondria, the constitutive cytosolic Hsc70, and the inducible cytosolic isoform Hsp72.
Moreover, BiP association with IRE1, PERK, and ATF6 regulates UPR signaling, making it
difficult to target the chaperone without also inducing the UPR.111' 112 While a few small
molecules have been introduced as BiP inhibitors, it is not clear that they act selectively.
Nonetheless, because BiP facilitates proper folding of nascent polypeptide chains, targets
misfolded proteins for ERAD, and regulates ER stress signaling, selective modulation of BiP
activities remains a promising avenue for resolving ER proteostasis defects. The identification of
JG-98 as an inhibitor of the Bag3-Hsp72 interaction suggests that targeting protein-protein
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Figure 4.5: Advances in understanding and adapting ERAD. Current methods primarily
modulate ERAD by influencing transport and/or degradation of misfolded substrates
(indicated by red and green boxes, respectively). Other promising targets for therapeutic
intervention include the E3 ligase Hrdl (blue box), which interacts with a broad range of
protein substrates via its co-chaperones, and is involved in the selection of terminally
misfolded ER clients for ERAD.
interactions of co-chaperones with BiP could be a viable alternative strategy for modulating BiP
activity in the absence of small molecules that directly and selectively bind to BiP."113 114 The
discovery that reversible AMPylation regulates BiP function may likewise yield new opportunities
to target BiP activity with selective small molecules.1 '5
Targeting ERAD. Quality control mediated by ERAD is another proteostasis node downstream
of the UPR where selective modulation offers substantial promise in disease. The process
requires coordination of many different proteins in the ER lumen, lipid bilayer, and the cytosol in
order to recognize, capture, transport, and degrade aberrant ER client proteins that pose a
threat to cell health.5 ERAD can be viewed as a three-step process, involving (1)
selection/recognition of misfolded ER clients, (2) retrotranslocation to the cytosol, and (3)
proteasomal degradation (Figure 4.5). The detailed mechanism involves intricate networks of
chaperone-chaperone and chaperone-client interactions, as well as transport machines that we
are only beginning to understand in biochemical detail. 116-1
18
The selection/recognition step of ERAD has thus far proven challenging to target
selectively, whereas substantial progress has been made in modulating retrotranslocation and
degradation. For example, diverse and potent small molecules are available for proteasome
inhibition." Targeting the proteasome has proven therapeutically valuable in multiple myeloma,
where treatment with bortezomib or other inhibitors appears to enhance proteotoxic load in the
ER, triggering stress-induced apoptosis.120 However, proteasome inhibition can also be severely
toxic for normal cells, and it disrupts protein recycling not just in the ER but also in other
subcellular compartments.
The need for more selective modulators of ERAD prompted the search for inhibitors of
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ER retrotranslocation, and specifically for inhibitors of VCP/p97. VCP/p97 is an ATPase that
assists in the extraction of misfolded proteins from the ER for proteasomal degradation, and
also participates in other biological processes via its "segregase" activity.121' 122 A number of
VCP inhibitors have been identified via high-throughput screening and optimization efforts,
ranging from the promiscuous first-generation compound Eeyarestatin 1,123 124 to more potent
second-generation inhibitors like DBeQ12 5 and the allosteric inhibitor NMS-873. 126 Rigorous
biophysical characterization of compound selectivity and mechanism of action, including the
recent determination of a cryo-EM structure of a VCP-inhibitor complex, will continue to guide
inhibitor optimization. 127 Meanwhile, application of existing inhibitors has begun to reveal the
potential of VCP inhibition to reduce excessive quality control of misfolding ER client proteins in
a manner that is considerably more selective than proteasome inhibition.128 129
The promising results obtained by perturbing ER proteostasis network nodes
downstream of the UPR motivate extensive further investigation in this area. As highlighted in
Figure 4.4, we still lack small molecule tools to modulate many of these nodes. The emergence
of such tools will open new opportunities for mechanistic studies and disease therapies. In the
meantime, Cas9-based methods for transcriptional regulation of individual proteostasis network
components in a highly selective, small molecule dose-dependent manner13 0 should assist the
prioritization of nodes for future method development. The continued advance of high-
throughput genetic screening, as recently outlined in two reports that combine CRISPR
technology with single cell RNA-seq, also provides opportunities for identifying new targets.1
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Concept Summary. Advances in targeting Hsp90 and ERAD exemplify how much fruitful ground
lies beyond IRE1, ATF6, and PERK. Proteomic and high-throughput genetic screening
approaches constitute a critical first step in identifying relevant nodes for specific diseases.
Where key downstream nodes are known, the next task is to develop tools and modulators of
sufficient potency for mechanistic work and drug development. As is the case for Hsp90 and
other abundant protein families, researchers must not only identify what isoform is important for
a particular process, but also whether and how the relevant isoform can be targeted. Due to
high sequence and structural similarities between isoforms, this second question will likely
continue to be a significant hurdle to modulating nodes downstream of the UPR. However,
recent progress in Grp94 and VCP inhibition offers hope that combined biophysical and
biochemical approaches will yield similar advances for isoform-specific targeting of other ER
proteostasis network components.
Conclusions
As the master regulator of proteostasis in the secretory pathway, the UPR plays critical
roles in both health and disease. Various groups have demonstrated UPR participation in organ
development and innate immunity; more recently, others have revealed alternate cellular
mechanisms for resolving stress, whether in the form of newly-discovered extracellular
chaperones, membrane expansion, or changes to the oxidative folding environment. The advent
of diverse chemical and chemical genetic methods now allows researchers to more precisely
control UPR arm activation and inhibition, opening new doors to study not only the fundamental
biology of the UPR and the secretory pathway, but also the potential of UPR modulation for
therapeutic intervention. When selecting from existing tools to modulate or perturb the UPR,
researchers must balance specificity with how much engineering or deviation from the natural
system is required. Moreover, new connections between N-glycosylation and XBP1s signaling
(Chapter V) or protein folding (Chapter VI) serve as a reminder that proteostasis encompasses
not only proteins, but also post-translational modifications. The development of improved
compounds to target both the UPR and downstream secretory proteostasis network nodes
remains an urgent need and, when realized, will surely yield significant new findings. As the field
94
continues to progress, we anticipate not only the elucidation of new functions of the UPR and
improved mechanistic understanding, but also the emergence of additional disease-modifying
UPR- and ER-targeted therapeutic strategies.
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CHAPTER V
XBP1s Activation Can Globally Remodel N-Glycan Structure Distribution Patterns
Summary
Classically, the unfolded protein response (UPR) safeguards secretory pathway
proteostasis. The most ancient arm of the UPR, the IRE1-activated XBP1s-mediated response,
has roles in secretory pathway maturation beyond resolving proteostatic stress. Understanding
the consequences of XBP1s activation for cellular processes is critical for elucidating
mechanistic connections between XBP1s and development, immunity, and disease. Here, we
show that a key functional output of XBP1s activation is a cell type-dependent shift in the
distribution of N-glycan structures on endogenous membrane and secreted proteomes. For
example, XBP1s activity decreased levels of sialylation and bisecting GIcNAc in the HEK293
membrane proteome and secretome, while substantially increasing the population of oligo-
mannose N-glycans only in the secretome. In HeLa cell membranes, stress-independent XBP1s
activation increased the population of high-mannose and tetra-antennary N-glycans, and also
enhanced core fucosylation. mRNA profiling experiments suggest that XBP1s-mediated
remodeling of the N-glycome is, at least in part, a consequence of coordinated transcriptional
resculpting of N-glycan maturation pathways by XBP1s. The discovery of XBP1s-induced N-
glycan structural remodeling on a glycome-wide scale suggests that XBP1s can act as a master
regulator of N-glycan maturation. Moreover, because the sugars on cell surface proteins or on
proteins secreted from an XBP1s-activated cell can be molecularly distinct from those of an
unactivated cell, these findings reveal a potential new mechanism for translating intracellular
stress signaling into altered interactions with the extracellular environment.
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Introduction
The unfolded protein response (UPR) is classically responsible for maintaining
proteostasis in the secretory pathway.' In the metazoan UPR, three transmembrane proteins
(IRE1, PERK, and ATF6) act to detect protein misfolding stress in the endoplasmic reticulum
(ER). Once stress is detected, activation of each sensor results in the production of a distinctive
transcription factor - XBP1s, ATF4, or ATF6(1-373), respectively.2 5 The targets of these
transcription factors include a suite of ER chaperones and quality control factors that can
resolve proteostatic challenges caused by physiologic and environmental changes.6 -8 The
central role of the UPR in maintaining secretory proteostasis has catalyzed extensive efforts to
delineate relevant mechanisms of induction,9-" define cellular effects of UPR activation,12 13 and
create chemical and genetic tools to modulate the IRE1-XBPls, PERK-ATF4, and ATF6
branches of the UPR in a selective, stress-independent manner.14-16
IRE1-XBP1s is the most ancient UPR arm and is the sole pathway conserved in yeast.
It is unsurprising, then, that the IRE1-XBPls arm has overarching roles in secretory pathway
maturation and maintenance beyond just the regulation of protein folding and quality control. 8' 19
Indeed, recent work continues to define essential functions for the IRE1-XBP1s pathway in
general, and the XBP1s transcription factor, in particular, that are distinctive from functions of
the other UPR arms. For example, XBP1s is critical for development, immune response,
memory formation, and cell non-autonomous ER stress signaling.2 -23 Moreover, chronic
upregulation of the XBP1s transcription factor is a pathologic hallmark of numerous
malignancies.24 25 Consistent with its diverse regulatory functions, the IRE1-XBP1s arm can be
activated independently of PERK-ATF4 and ATF6 in response to assorted stimuli.6 11, 26 This
diversity of input signals and output functions emphasizes the broad roles of the IRE1-XBP1s
axis beyond sensing and responding to protein misfolding. Attaining mechanistic understanding
of these diverse processes requires first comprehensively defining the molecular consequences
of XBP1s induction.
The majority of proteins traversing the secretory pathway are co- or post-translationally
N-glycosylated.27 A 14-residue oligosaccharide with the structure Glc3Man9GlcNAc 2 (Gic =
glucose; Man = mannose; GIcNAc = N-acetylglucosamine) is installed on Asn residues within
specific amino acid sequons. 28 XBP1s may modulate the extent N-linked glycans are produced
by the cell, 29 thereby potentially assisting N-glycoprotein trafficking and directly enhancing
proteostasis by providing improved access to the ER's lectin-based chaperone and quality
control machineries.29 31
Downstream of N-glycan installation, the immature sugar is processed in both the ER
and the Golgi to yield the vast array of high- and oligo-mannose, hybrid, and complex N-glycan
structures presented on secreted and cell-surface proteins. 2 The molecular architecture of this
N-glycome is dynamic, with consequences for both normal and pathologic processes, including
cell motility and adhesion, cell-cell interactions, and immune system function.3336 However, our
understanding of how intracellular signaling pathways coordinately define N-glycan maturation
and thereby regulate these processes remains incomplete.
We previously reported that stress-independent activation of XBP1s can significantly
modify the structural distribution of N-glycans installed at the single N-glycosylation site of a
soluble, secreted glycoprotein domain derived from the CD2 adhesion protein.37 The shift from a
high-mannose to a hybrid N-glycan observed in that work was specifically caused by XBP1s-
mediated alterations in N-glycan maturation, not by modified CD2 protein synthesis or
trafficking. Those findings hint at the possibility that the IRE1-XBP1s arm of the UPR regulates
the molecular architecture of the endogenous N-glycome in a coordinated manner.38 By this
hypothesis, rather than merely regulating occupancy at a given N-glycosylation sequon, XBP1s
also influences the ultimate structure of the mature N-glycans displayed on cell-surface or
secreted proteins. However, the CD2 protein domain used in our prior studies was an
ectopically expressed, soluble, and glycosylation-naive protein variant,37' 39 rendering the
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biological relevance of the observed XBP1s-dependent remodeling of N-glycan maturation
uncertain.
Here, we ask (1) whether induction of the transcription factor XBP1s results in altered N-
glycan structures on endogenous proteins and (2) whether such remodeling is sufficiently
significant to be observed in a glycome-wide experiment, not just on individual, purified
glycoproteins. We find that stress-independent XBP1s activation substantially alters the
composition of the N-glycome in a cell type- and proteome-dependent manner. The resulting
changes in the distribution of N-glycan structures indicate that XBPls-activated cell
membranes, and proteins secreted from XBP1s-activated cells, are often distinguishable at the
molecular level from those of cells with basal levels of UPR signaling. These observations
suggest a new mechanism to translate intracellular stress signaling to the extracellular milieu, a
phenomenon with important implications for our emerging understanding of how the UPR
shapes higher order biological activities (e.g., organismal development and immune response)
beyond just the maintenance of ER proteostasis.
Results
Experimental Platform and Workflow to Scrutinize Effects of XBP1s on the N-Glycome. In prior
work, we used enzymatic digestions, MALDI-TOF mass spectrometry (MS), and TOF/TOF
MS/MS analyses to show that the structure of the single N-glycan on the secreted CD2
adhesion domain changes upon ER stress-independent XBP1s activation.37 The biological
relevance of those studies was limited by the focus on an ectopically overexpressed, non-native
N-glycoprotein. Moreover, while a protein-specific N-glycan maturation effect is potentially
interesting, functionally relevant N-glycan remodeling would likely involve larger-scale XBP1s-
mediated N-glycome remodeling. Our objective here, therefore, was to test the hypotheses that
XBPls-mediated remodeling of N-glycan structures (1) occurs on endogenous glycoproteins
and (2) is sufficiently significant to be observed in experiments surveying the glycome.
Application of a traditional ER stress inducer such as thapsigargin (Tg) does cause
XBP1s activation, and is therefore one approach to test these hypotheses. However, the
pleiotropic consequences of ER stressors, including extensive ER protein misfolding and high
cytotoxicity, limit the reliability and interpretation of the resulting data. Selective induction of
XBP1s using chemical genetics is an alternative strategy that we and others have employed to
elucidate the specific consequences of XBP1s activity.14 4043 This strategy results in chronic
XBP1s induction in the absence of global UPR activation by ER stress. Such selective and
chronic XBP1s activation is observed in numerous relevant settings, including development, the
immune response, and cancer.20 21 25
In this work, we employed two cell lines engineered for ER stress-independent induction
of XBP1s transcriptional activity at physiologically relevant levels. In both cell lines, XBP1s
expression was placed under control of the tetracycline repressor, providing doxycycline (dox)-
regulated expression of XBP1s. The first stable, single-colony cell line we used, termed
HEKXBPls, was derived from the human embryonic kidney cell line and was reported
previously.14 The second cell line, developed for this study, was a stable, single-colony HeLa
cell line (derived from the cervical epithelial line) termed HeLaXBPls. In both HEKXBPls (Figure
5.1A) and HeLaXBPls (Figure 5.1B) cells, treatment with dox upregulated mRNA expression for
the established XBP1s target genes ERDJ4 and SEC24D to levels similar to that induced by
treatment with the classic ER stressor Tg. In both cases, XBP1s activation occurred
independently of global UPR induction, as well-known transcripts induced by the PERK-ATF4
arm of the UPR were not upregulated (e.g., CHOP and GADD34; Figures 5.1A and 5.1 B).
In previous work, we characterized the consequences of sustained XBP1s activation on
the transcriptome and the proteome in HEKXBP1S cells. 14 As the HeLaXBP1s cell line was newly
developed, we next assessed the transcript-level changes induced by chronic, selective XBP1s
activation in this cell line. We sequenced mRNA from vehicle-, dox-, or Tg-treated HeLaXBP1S
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Figure 5.1: Characterization of HEKXBPls and HeLaXBPs cell lines and experimental
workflows for glycomic analyses. Transcript levels of genes regulated by the IRE1-XBPls
arm (ERDJ4 and SEC24D) or the PERK-ATF4 arm (CHOP and GADD34) of the UPR
were measured in HEKXBPls cells (A) and HeLaXBP1s cells (B) by qRT-PCR. (C)
Experimental workflows for isolating membrane proteomes (HEKXBP1s and HeLaXBP1s) or
secretomes (HEKXBP1s) in control, XBPIs-activated, or Tg-treated cells. (D) Workflow for
glycan analysis by lectin microarrays. (E) Workflow for MS analysis of N-glycomes.
cells in biological triplicate. Hierarchical clustering of differentially expressed coding genes
showed that XBP1 s activation preferentially clustered with vehicle-treated rather than Tg-treated
samples, indicating that the transcriptional consequences of chronic XBP1s activation were
significantly muted relative to treatment with an ER stressor (Figure S1A). As expected (Figure
S1B), and in line with our previous observations for HEKXBP1 cells, 14 gene set enrichment
analysis revealed specific gene sets enriched in the XBPls-activated lines alone (e.g., the
unfolded protein binding gene set), others that were enriched in both XBPIs-activated and Tg-
treated cells (e.g., the response to ER stress gene set), and a third group of gene sets that were
enriched only in the Tg-treated cells (e.g., the intrinsic aptotic signaling in response to ER
stress gene set; see Tables S1A-D for full results). HEK * and HeLa XB1s cells thus provide
two distinct cell types in which we can induce sustained XBP1s activity over the time period
required for an intracellular signal like XBPIs-mediated transcription to propagate to the mature
N-glycoproteome, mimicking biological cases of extended XBP1 s activation.25 '
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With appropriate cell lines in hand, we devised an experimental workflow to test for
effects of XBP1s activation on N-glycan maturation. As illustrated in Figure 5.1C (left panel), we
treated HEKXBPls cells in complete media with vehicle (control), dox (to activate XBP1s), or Tg
(to induce ER stress and the global UPR), followed by isolation of the membrane fraction by
ultracentrifugation. Alternatively, we treated HEKXBP1s cells identically in a serum-free media
formulation (Freestyle TM media) such that we could harvest and concentrate the secreted
proteome for downstream glycomic analyses while minimizing contamination from serum
glycoproteins. We used FreestyleT M media instead of serum-free Dulbecco's Modified Eagle's
medium (DMEM) because we have observed that serum-free DMEM causes significant cell
stress over longer treatments such as the 24 hours used here. Grp78 was detected in the
Freestyle TM media only upon XBP1s activation (Figure S2), suggesting that the presence of any
ER proteins in the XBP1s-activated secretome is a consequence of UPR activity, as has
previously been observed by others. For HeLaXBPls cells, we carried out an identical workflow
(Figure 5.1C, right panel) but isolated only the membrane fraction, as in our observation HeLa
cells are less secretory than HEK cells.
After isolating membrane and secreted protein fractions, we next carried out two types of
glycomic experiments on the samples: 1) Lectin microarray analysis, which enables us to
directly compare relative levels of glycan motifs/substructures,6 ' and 2) Mass spectrometry,
which provides a more detailed analysis of glycan structures. We used dual-color lectin
microarrays (Figure 5.1D) on biological triplicates to gain insight into potential glycome
remodeling due to XBP1s activation and/or Tg treatment. We measured the relative binding of
fluorescently labeled glycoproteome samples and an orthogonally-labeled common reference to
immobilized lectins on our microarray. This technology, which leverages the known glycan-
binding preferences of lectins to gain insight into changes in the levels of glycan substructures
(e.g., a2,6-sialylation), provides a systems-level perspective on differences in the N- and 0-
linked glycan epitopes present in a sample.' 47 The lectin microarrays we employed were
comprised of -90 unique lectins with diverse sugar-binding specificities (a complete list of the
lectins included in the array for HEKXBPls and HeLaXBP1s samples is provided in Tables S2A and
S2B, respectively). Samples were labeled with Alexa Fluor 647 or 555, mixed with an equal
amount of an orthogonally labeled common reference sample (a mix of all replicates for all
conditions) and incubated with the microarray. The resulting data (normalized to the reference)
provides relative quantitation of the glycan epitopes/substructures recognized by a particular
lectin across sample conditions.
We used MALDI-TOF MS and TOF/TOF MS/MS (Figure 5.1E), to obtain a molecular-
level view of N-glycome composition in all our samples. We performed GC-MS analyses in
parallel, which provides further detail by allowing for identification of specific sugar linkages. All
MS analyses were performed in a minimum of biological duplicate. The MS data validates and
enhances results derived from the lectin microarrays, and adds more detailed structural
information. The standard MS techniques used herein pinpoint shifts in the overall composition
of the glycome within a sample (i.e., what % of overall glycans in a given sample have sialic
acid), but do not provide direct comparison of a specific glycan's absolute abundance between 2
samples (i.e., how much sialic acid is expressed in sample 1 vs. sample 2). Thus, % changes
from MS represent shifts in the profile whereas % changes from the lectin microarray represent
changes in the overall levels of an epitope. By combining the ability of lectin microarrays to
examine directly the relative levels of a glycan motif with the more detailed structural information
gathered from MS, we were able to more thoroughly investigate glycosylation changes, with
microarray data providing collective expression changes for glycan motifs regardless of parent
glycan backbone, and MS supplying more detailed structural analysis of the individual glycans
expressed. Together these two techniques enabled us to evaluate, at high resolution, whether
and to what extent XBP1s modulates glycan structure. Results from these complementary
glycomic analyses are presented in the sections below.
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Figure 5.2: Analysis of the HEKxBP's membrane glycoproteome. (A) Heat map of lectin
microarray data generated from isolated HEK XBPs membrane glycoproteomes under vehicle-
treated, XBP1s-activated, or Tg-treated conditions. Full lectin names, print concentration, and
sources are listed in Table S2A. Color intensity represents normalized log2 ratio data relative to
a pooled sample reference. Each column represents one biological replicate of the indicated
sample. Select lectin groups with shared binding specificities are annotated at right of heatmap.
See also Figure S3A and Table S3A in the Appendix. (B) Partial MALDI-TOF mass spectra from
the HEKXBP1s membrane proteome revealed decreased sialylation on bi- (see Figure S3C), tri-,
and tetra-antennary N-glycans upon XBPls activation. Green and red peaks correspond to tri-
and tetra-antennary N-glycans, respectively, with various levels of sialylation. Manually inserted
green and red shaded areas highlight the distribution shift of sialylation towards fewer NeuAcs
on the corresponding tri- and tetra-antennary N-glycans. Structures outside a bracket were not
unequivocally defined. "M" and "m" designations indicate major and minor abundances,
respectively. Putative structures are based on composition, tandem MS, and knowledge of
biosynthetic pathways. All molecular ions are [M+Na]*. High mass spectra are presented in
Figure S3B, with GC-MS data in Table S4 (see Appendix). Experiments were carried out on two
biological replicates. (C) Table highlighting key XBP1s-induced changes to the HEKXBPls
membrane N-glycome and the analytical methods by which these changes were observed (see
also Tables S5 and S6).
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XBP1s Remodels the HEKXBPls Cell Membrane N-Glycome. We began by assaying the N-
glycome of HEKXBP1s cell membranes upon XBP1s activation or Tg treatment, following the
workflow in Figure 5.1C. Cells were treated with dox to activate XBP1s for 72 h or Tg to induce
the UPR for 24 h. Membrane fractions were harvested and processed for glycomic analyses as
described above.
Lectin microarray analysis of selective XBP1s activation in HEKXBP1s membranes (Table
S3A) revealed a significant decrease in a2,6-sialylation (Figures 5.2A and S3A left panel). The
a2,6-sialic acid-specific lectins SNA-1, TJA-l, and PSL- showed an average 29% decrease in
binding relative to the vehicle-treated control. Our engineered recombinant lectin diCBM40,
which binds both a2,3- and a2,6-linked sialic acids with similar affinity,48 showed a 35% loss in
binding, further supporting a decrease in a2,6-sialylation. XBP1s activation also decreased
bisecting N-glycans, as indicated by decreasing PHA-E signal (Figures 5.2A and S3A left
panel).
Fully consistent with the lectin microarray analyses, MALDI-TOF MS analysis confirmed
that XBP1s activation of HEKXBP1S cells resulted in reduced sialylation of cell membrane N-
glycans and provided additional detail into the specific epitopes affected. Specifically, in XBP1s-
activated cells the relative abundance of ions at m/z 3054 and 3415 (green peaks in Figure
5.2B, top versus middle panels) - corresponding to tri-antennary N-glycans with one or two
NeuAc (N-acetylneuraminic acid) residues, respectively - decreased with respect to the relative
abundance of the ion at m/z 2693, an undecorated tri-antennary N-glycan. The ratio of ions at
m/z 3054/2693 indicated an -84% decrease in sialylation of tri-antennary glycans in XBP1s-
activated cells. Similar results were observed for tetra-antennary N-glycans in XBP1s-activated
cells (red peaks in Figure 5.2B, top versus middle panel). Specifically, the relative abundances
of ions at m/z 3503, 3864, and 4226, which correspond to singly, doubly and triply sialylated
structures, decreased substantially upon XBP1s activation compared with the relative
abundance of the undecorated tetra-antennary N-glycan with m/z 3142. The ratio of ions at m/z
3503/3142 indicated an -85% decrease in sialylation of tetra-antennary glycans in XBP1s-
activated cells. Similar but less intense reductions in sialylation were also observed for higher
mass N-glycans (Figure S3B). For example, in XBP1s-activated cells (Figure S3B, top versus
middle panel) the ions at m/z 5124 and 5485 - corresponding mainly to tetra-antennary N-
glycans with two additional LacNAc (N-acetyllactosamine) repeats and three or four NeuAc
residues - decreased by -22 and -44%, respectively, compared to the relative abundance of
the ion at m/z 4763, which only has two NeuAc residues (Figure S3B, top versus middle panel).
Lower mass bi-antennary glycans also displayed an -80% decrease in sialylation (Figure S3C,
left versus middle panel).
We also performed GC-MS linkage analysis (Table S4) to add linkage details to our
findings from the MALDI-TOF MS and TOF/TOF MS/MS, and to further verify our findings from
the lectin microarrays. The detection of 6-linked galactose showed that a portion of NeuAc
residues were a2,6-linked. The abundance of these a2,6-linked NeuAc residues substantially
decreased in XBPls-activated HEKXBP1s cells (23.6% in vehicle samples versus 4.0% in XBP1s-
activated samples), in concordance with the MALDI-TOF MS data and with the lectin microarray
data that specifically indicated reduced a2,6-sialylation (Figure 5.2A). In addition to the results
regarding sialylation, we identified 3,4,6-linked mannose by GC-MS, verifying the presence of
minor amounts of bisecting N-glycans in the sample. The abundance of these epitopes also
decreased upon XBP1s activation HEKXBP1s cells (Table S4), again in full agreement with our
observation of decreased bisecting N-glycans by lectin microarrays (Figure 5.2A).
Collectively, these data reveal that XBP1s activation in HEKXBP1s cells substantially
remodeled the composition of the membrane N-glycome, as summarized in Figure 5.2C and
Table S5. Moreover, XBP1 s-induced changes in the N-glycome were consistently detected both
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via lectin microarrays and MS. In particular, we observed a strong reduction in sialylation,
specifically a2,6-sialylation, as well as a reduction in bisecting N-glycans.
Next, to ask whether global induction of ER protein misfolding, and therefore all UPR
pathways, has related effects on N-glycome composition, we performed the same lectin
microarray and MALDI-TOF MS analyses on membrane N-glycans from Tg-treated HEKXBP1s
cells. We found that the overall glycomic profile closely mirrored that of selective XBP1s
activation in that we observed reduced sialylation and a reduction in bisecting GIcNAc (Table
S3A). However, the magnitude of the changes was less substantial. For example, statistically
significant lectins SNA-1 showed a 19% decrease in binding and diCBM40 showed a 40%
decrease in binding (Figures 5.2A and S3A right panel). However, while other a2,6-sialic acid
lectins (e.g., PSL and TJA-I) also displayed reduced overall binding, they did not meet the
statistical cutoff. A reduction in sialylation was also observed in the MALDI-TOF MS data,
evident both in the relative abundance of sialylated to undecorated tri-antennary N-glycans
(green peaks in Figure 5.2B, top versus bottom panel) and the relative abundance of sialylated
to undecorated tetra-antennary N-glycans (red peaks in Figure 5.2B, top versus bottom panel).
The ratios of ions at m/z 3054/2693 and m/z 3503/3142 revealed, in both cases, an -85%
decrease in sialylation on tri- and tetra-antennary N-glycans upon Tg treatment. Sialylation of bi-
antennary N-glycans also decreased substantially upon Tg treatment (Figure S3C, left versus
right panel). GC-MS linkage analysis (Table S4) confirmed a decrease in a2,6-linked NeuAcs,
evidenced by a shift in the relative abundance of 6-linked galactose from 23.6% on vehicle-
treated HEK XBP1s cells to 4.1% on Tg-treated cells. Like XBP1s, activation of global ER stress by
Tg also caused a loss of bisecting GlcNAc, observed by reduced PHA-E binding in lectin
microarrays (Figures 5.2A and S3A right panel) and a decrease in 3,4,6-mannose by GC-MS
analysis (Table S4). Notably, a gain in Core 1/3 O-glycans was also observed upon Tg
treatment, evidenced by increased binding to the lectins AIA, MPA, and MNA-G (Figures 5.2A
and S3A right panel). Detailed O-glycan analysis was not performed using MALDI-TOF MS
here, but this last result suggests that further investigation may reveal interesting ER stress-
mediated changes to 0-linked glycoforms, in addition to N-linked glycoforms. The Tg-mediated
alterations in the HEKXBP1s membrane glycome are summarized in Table S6.
XBP1s Remodels HeLaXBPls Membrane N-Glycoproteomes in a Cell Type-Dependent Manner.
We next asked whether activation of the XBP1s transcription factor has broader consequences
for N-glycome composition across cell types. In particular, because cells derived from different
tissues often have very different baseline N-glycome profiles, we were interested in the
consequences of XBP1s activation in distinctive cellular contexts. To address this question, we
employed our HeLaXBPls cells following the workflow in Figure 5.1C. We first confirmed that the
baseline glycome profiles of HEKXBP1s versus HeLaXBP1s cells were different. By lectin microarray
analysis, HEKXBP1s and HeLaXBPls cells displayed strikingly different levels of oligo-mannose N-
glycans (Man 7-Man 5) and sialylation epitopes (Figure S4). Additionally, we found using MALDI-
TOF/TOF MS/MS that, whereas high mass poly-LacNAc N-glycans in HEKXBP1S membranes
consisted of linear LacNAc repeats (Figure S3D), in HeLaXBP1s cell membranes the high mass
N-glycans consisted of I-branched poly-LacNAc repeats (Figures S5A and S5B). GC-MS
linkage analysis confirmed the presence of 3,6-linked galactose in HeLaXBP1S cells, in
concordance with the presence of I-branched LacNAcs (Table S4).
Coincident with these quite distinctive baseline N-glycome profiles, lectin microarray
analysis revealed a unique shift in the membrane glycomic profile upon XBP1s activation in
HeLaXBP1s cells (Figures 5.3A and S5C, with complete data presented in Table S3B) relative to
that observed in HEKXBPls cells. XBP1s-activated HeLaXBP1s membranes exhibited increased
levels of less processed N-linked glycans relative to vehicle-treated controls, based on
increased signal from several high- (Man 9-Man 7) and oligo-mannose binding lectins (rGRFT,
HHL, NPA, GNL, and Calsepa). Additionally, XBP1s activation resulted in increased core
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Figure 5.3
XBP1Is-Induced Changes to N-Glycans in HeLaxO"* Membranes
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Figure 5.3: Analysis of the HeLaXBPis membrane glycoproteome. (A) Heat map of lectin
microarray data generated from isolated HeLa ^ BP1S membrane glycoproteomes under vehicle-
treated, XBP1s-activated, or Tg-treated conditions. Full lectin names, print concentration, and
sources are listed in Table S2B. Color intensity represents normalized log2 ratio data relative to
a pooled sample reference. Each column represents one biological replicate of the indicated
sample. Select lectin groups with shared binding specificities are annotated at right of heatmap.
See also Figure S5C and Table S3B in the Appendix. (B) Partial MALDI-TOF mass spectra from
the HeLa XBP1s membrane proteome revealed increased abundance of tetra-antennary N-glycans
upon XBP1s activation. Green and red peaks correspond to tri- and tetra-antennary N-glycans,
respectively, with various levels of sialylation. Manually inserted green and red shaded areas
highlight the increased abundance of tetra-antennary N-glycans. Structures outside a bracket
were not unequivocally defined, and "M," "m," and "vm," designations indicate major, minor, and
very minor abundances, respectively. Putative structures are based on composition, tandem
MS, and knowledge of biosynthetic pathways. All molecular ions are [M+Na]*. High mass
spectra and selected MS/MS fragmentations are presented in Figures S5A and S5B, with GC-
MS data in Table S4 (see Appendix). Experiments were carried out on two biological replicates.
(C) Table highlighting key XBP1s-induced changes to the HeLaXBP1s membrane N-glycome and
the analytical methods by which these changes were observed (see also Tables S5 and S6).
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fucosylation (PSA and LcH) and s1,6-GlcNAc branching (PHA-L, which binds tri- and tetra-
antennary glycans). In contrast to HEKxBPls cells, no shift in sialylation was observed.
MALDI-TOF MS analysis was fully consistent with these findings from the lectin
microarray analyses. Similar to the microarray data, no significant changes in sialylation were
observed. For example, the ratio of ions at m/z 3054, 3415 and 3776 (corresponding to tri-
antennary N-glycans with one to three NeuAc residues, respectively) over the ion at m/z 2693
(corresponding to non-sialylated tri-antennary N-glycan) did not shift between vehicle-treated
controls and XBPIs-activated HeLaXBP1s cells (comparing the intensity of the green peaks within
the green shaded areas in Figure 5.3B, top versus middle panels). Similarly, no change was
observed in sialylation of the tetra-antennary N-glycans (comparing the intensity of the red
peaks within the red shaded areas in Figure 5.3B, top versus middle panels). Instead,
consistent with the lectin microarrays, the most striking consequence of XBP1 s activation for the
HeLaXBP1s membrane glycome was a 97% increase in the relative abundance of tetra- versus tri-
antennary N-glycans (intensity of all the red versus all the green peaks in Figure 5.3B, top
versus middle panels). GC-MS linkage analysis further confirmed the MALDI-TOF MS and
microarray data, demonstrating (i) an increase in tetra-antennary N-glycans revealed by
increased 2,4- and 2,6-linked mannose in the partially permethylated alditol acetates (Table S4)
and (ii) an increase in core fucosylation revealed by increased levels of 4,6-linked GIcNAc
(Table S4).
As performed in our experiments here, MALDI-TOF MS does not permit quantitation of
relative high- and oligo-mannose levels between two samples, and so we were unable to further
validate that particular finding from the lectin microarray using the MS data. Moreover, the
experimental strategy of cell membrane isolation by ultracentrifugation can be problematic when
assessing changes in levels of less processed N-glycans on membrane proteins, as all cell
membranes are isolated in the ultracentrifugation step. That is, the method cannot distinguish
N-glycans displayed on intracellular, immature membrane glycoproteins from N-glycans on
membrane glycoproteins that have trafficked through the Golgi to the cell surface. To further
evaluate the increase in high-mannose levels observed via lectin microarrays upon XBP1s
activation (Figure 5.3A) we turned to a lectin-based flow cytometry approach. We treated
HeLaXBP1s cells with dox to induce XBP1s or vehicle for 72 h, as above, and then incubated live
cells with biotinylated HHL, a lectin that preferentially binds high-mannose N-glycans We then
stained cells with Cy5-streptavidin to enable quantitative fluorescent detection of high-mannose
N-glycans. XBP1s-activated HeLaXBP1s cells displayed a modest but significant increase in HHL
signal when compared to vehicle-treated control cells (Figure S6A, left and middle panels).
Control experiments inhibiting lectin binding with methyl a-D-mannopyranoside confirmed that
HHL was binding high-mannose N-glycans, as expected (Figure S6A, right panel). Treatment of
cells with the mannosidase I inhibitor 1-deoxymannojirimycin55 , 56 also led to an increase in HHL
binding without causing a loss of cell viability (Figures S6B-D), further confirming that HHL
detected high-mannose structures.
Collectively, these data reveal that XBP1s activation in HeLa XBP1S cells substantially
remodels the composition of the HeLa membrane N-glycome in well-defined ways observed via
multiple analytical methods, as summarized in Figure 5.3C and Table S5. In particular, we
observed strong increases in both core fucosylation and the abundance of tetra-antennary N-
glycans via both lectin microarray and MALDI-TOF MS analyses. In addition, the combination of
lectin microarrays and lectin flow cytometry experiments revealed that XBP1s activation
increased levels of high- and oligo-mannose N-glycans on the HeLaXBP1s cell surface.
Stress-induced, global UPR activation via Tg treatment of HeLaXBP1s cells also caused
increases in high-mannose levels (Figures 5.3A and S5C right panel; see also Table S3B),
demonstrated by significantly increased binding of the al,2-mannose-specific antiviral lectins
rSVN and rCVN, in addition to rGRFT. However, Tg treatment also induced a loss of P1,6
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branched N-glycans based on decreased signal from PHA-L, revealing a distinct difference from
the XBP1s-induced signal (Figures 5.3A and S5C right panel). Again, no changes in sialylation
were observed. These observations were fully confirmed by our MALDI-TOF MS analysis, in
which Tg-treated cells did not display increased tetra-antennary N-glycans relative to vehicle-
treated cells (red versus green shading in Figure 5.3B, top versus bottom panels). Instead, as
anticipated from the lectin microarray work (Figure 5.3A), a decrease in 2,4- and 2,6-linked
mannose was observed by GC-MS after Tg treatment, the latter being consistent with a loss of
P1,6 branched N-glycans (Table S4). The Tg-mediated alterations in the HeLaXBP1s membrane
glycome are summarized in Table S6.
In summary, the ability of XBP1s (or even stress-induced UPR activation) to globally
remodel the N-glycome extends beyond just a single cell type. The molecular nature of the
resulting changes in N-glycan distribution patterns is cell type-dependent, likely owing at least in
part to differences in baseline N-glycome composition, and the size of the effects can be quite
substantial.
XBP1s Remodels the N-Glycan Composition of the HEKXBPl" Secretome. The observation that
XBP1s activation alters the structure distribution pattern of N-glycans on cell surfaces in a cell
type-dependent manner suggests that cell-cell interactions, cell adhesion, and receptor
signaling could all be modified by XBP1s. Beyond cell membranes, a large portion of the N-
glycoproteome is comprised of soluble, secreted proteins. Alterations in the N-glycans on
secreted proteins could provide a mechanism for long-distance transmission of cell stress
signals, or engender other important phenotypes. Therefore, we next asked whether XBP1s-
mediated remodeling extends to the secreted N-glycome.
The secretome from XBPls-activated HEKXBPls cells displayed substantial N-glycome
remodeling when analyzed by lectin microarrays (Figures 5.4A and S7 left panel, with complete
data presented in Table S3C). A decrease in both P1,6 N-glycan branching (PHA-L) and
bisecting GIcNAc (PHA-E) was observed, as was also observed in the HEKXBP1s membrane N-
glycome. A modest (27%) but not statistically significant decrease in binding to a2,6-sialylation
epitopes based on the lectins SNA-l and diCMB40 was also observed. These results were
confirmed by our MALDI-TOF MS and GC/MS analyses (see below). We also observed a
significant increase in binding to oligo-mannose-targeting lectins (HHL, UDA, NPA, Calsepa,
and GNA), a consequence of XBP1s activation that was notably absent from the HEKXBP1S
membrane samples (Figure 5.2A).
MALDI-TOF MS analysis (Figure 5.4B) revealed that N-glycans isolated from the
secretome of HEKXBP1S cells featured abundant core fucosylated bi- (purple peaks; m/z 2244,
2605, and 2966), tetra- (red peaks; m/z 3142, 3503, 3864, 4226 and 4587), and to a lesser
extent tri-antennary (green peaks; m/z 2693, 3054, 3415, and 3776) N-glycans. Upon XBP1s
activation, the tri- and tetra-antennary, but not the bi-antennary, N-glycans exhibited reduced
sialylation (Figure 5.4B, upper versus middle panel). For example, the relative abundance of
molecular ions at m/z 3503, 3864, 4226, and 4587 compared to m/z 3142 was reduced from
vehicle-treated levels in the XBPls-activated secretome (red peaks in Figure 5.4B, upper
versus middle panel). GC-MS analysis confirmed a small reduction in ca2,6-sialylation overall
(Table S4: 6-linked Gal: Veh - 98.9% versus XBP1s - 63.8%), consistent with our lectin
microarray analysis. The decreases in bisected N-glycans and 11,6-branching observed by
microarray were also confirmed by our GC-MS data (Table S4: 3,4,6-linked Man: Veh - 4.7%
versus XBP1s - 2.3%; 2,6-linked Man: Veh - 105.8% versus XBP1s - 71.1%).
Collectively, these data reveal that XBP1s activation in HEKXBP1 cells substantially
remodels the composition of the secreted N-glycome, as summarized in Figure 5.4C and Table
S5. Lectin microarray analyses revealed an increase in oligo-mannose levels. Both lectin
microarray and MALDI-TOF MS analyses demonstrated a decrease in bisecting N-glycans.
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Figure 5.4: Glycomic analysis of the HEKXBPls secretome. (A) Heat map of lectin microarray
data generated from isolated HEKXBPis secreted glycoproteomes under vehicle-treated, XBP1s-
activated, or Tg-treated conditions. Full lectin names, print concentration, and sources are listed
in Table S2A. Color intensity represents normalized log2 ratio data relative to a pooled sample
reference. Each column represents one biological replicate of the indicated sample. Select lectin
groups with shared binding specificities are annotated at right of heatmap. See also Figure S7
and Table S3C. (B) MALDI-TOF mass spectra of the HEKXBPIs secretome revealed modestly
decreased sialylation of tri-antennary and tetra-antennary N-glycans upon XBP1s activation.
Purple, green and red peaks correspond to bi-, tri- and tetra-antennary N-glycans with various
levels of sialylation, respectively. Manually inserted purple, green and red shaded areas
highlight the distribution shift of sialylation on the corresponding bi-, tri- and tetra-antennary N-
glycans. Non-core fucosylated structures corresponded to residual fetal bovine serum-derived
N-glycans that we also characterized previously (brown peaks; m/z 2792, 3602, and 3964) 57.
These fetal bovine serum-derived N-glycans were observed consistently in all samples and
were excluded from the analyses as previously described 58 . Structures outside a bracket
have not been unequivocally defined. Putative structures are based on composition, tandem
MS, and knowledge of biosynthetic pathways. All molecular ions are [M+Na]+. Experiments were
carried out on two biological replicates. GC-MS data are presented in Table S4 (see Appendix).
(C) Table highlighting key XBP1s-induced changes to the HEKXBP1S secreted N-glycome and the
analytical methods by which these changes were observed (see also Tables S5 and S6).
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MALDI-TOF MS showed a loss of sialylation on specific N-glycan epitopes (for tri- and tetra-
antennary but not bi-antennary N-glycans), suggesting possible protein-specific effects
influencing loss of sialylation. While the reduction in bisecting N-glycans and a loss of sialylation
are both consistent with our observations for the HEKXBP1S membrane N-glycomes (Figure
5.2C), the increase in oligo-mannose levels is limited to the secretome. This observation
highlights the importance of separately evaluating membrane and secreted N-glycans in
glycomic experiments, as we have also noted in prior work.
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We also analyzed the consequences of stress-induced, global UPR activation via Tg
treatment on the composition of the secreted N-glycome in HEKXBP1s cells. The secreted N-
glycome of Tg-treated HEKXBP1s cells was similar to that of XBP1 s-activated cells in that reduced
levels of s1,6 N-glycan branching (decreased binding to PHA-L) and bisecting GIcNAc
(decreased binding to PHA-E) were observed (Figures 5.4A and S7 right panel; see also Table
S3C). MALDI-TOF MS and GC-MS analyses (Figure 5.4B, top versus bottom panel, and Table
S4) confirmed the decreases in levels of tri- and tetra-antennary N-glycans (s1,6 N-glycan
branching shown by changes in 2,4-linked mannose and 2,6-linked mannose levels). There was
no impact on overall a2,6-sialylation, although a decrease in a2,3-sialylation was observed via
reduced binding to MAL-l, MAL-Il, and diCBM40 (Figure 5.4A). In contrast to the secretome of
XBPls-activated cells, Tg treatment did not induce an increase in oligo-mannose levels. The
Tg-mediated alterations in the HEKXBP1S secreted glycoproteome are summarized in Table S6.
XBPIs Does Not Significantly Alter the Proteomic Composition of the HEKxBPlS Secretome. We
questioned whether XBP1s-driven changes in the N-glycan architecture of the HEKXBP1s
secretome could be attributed to changes in the composition of the proteome caused by XBP1s
activation. To assess this hypothesis, we induced XBP1s by dox treatment for 24 hours and
then collected conditioned, serum-free DMEM after a 6 hour incubation on vehicle-treated or
dox-treated cells in biological triplicate. We used serum-free DMEM, not FreestyleTM media
optimized for HEK cell growth, because FreestyleTM media contains various proprietary peptides
that interfere with MS analysis. The use of serum-free DMEM limited us to a 6 hour incubation
instead of the longer incubation used in our glycomic experiments, to avoid extensive autophagy
induction and cell toxicity. We precipitated total protein from the collected media, followed by
denaturing, reducing, alkylating, and trypsinizing to peptides. The digested samples were then
labeled with isobaric mass tags to permit quantitative assessment of proteome composition and
identify any XBPIs-mediated changes. Using this approach, we were able to quantify 700
secreted proteins across all samples (Table S7). Using significance thresholds of unadjusted p-
value 5 0.05 and fold-change 1.5, we found that levels of only 16 of these 700 proteins were
changed by XBP1s activation (we further note that no proteins qualified using a false discovery
rate (FDR) threshold of 10% by Benjamini-Hochberg analysis). Of those 16 proteins, only 9 are
annotated in UniProtKB as being N-glycosylated. These data lead us to conclude that the
observed changes in the secreted glycome are unlikely to be driven by changes in the
composition of the secreted proteome. Rather, we hypothesize that altered biosynthesis of N-
glycans is the controlling factor.
Selective XBPIs Induction Remodels the Glycogene Transcriptome. Control mechanisms of N-
glycan biosynthesis are not well understood. One possible way in which induction of XBP1s
could lead to an altered glycome is through enhanced flux through the secretory pathway that
overwhelms the N-glycan maturation machinery and causes uncoordinated changes in structure
distribution patterns. However, global changes in protein secretion that might suggest the Golgi
N-glycan maturation pathway is overwhelmed upon XBP1s activation have not been detected
(see Table S7 and work by Wiseman and colleagues14 ). Moreover, while the changes in oligo-
mannose levels in HeLaXBP1s membranes and HEKXBP1s secretomes could possibly be linked to
increased flux overwhelming the N-glycan maturation pathway, it seems unlikely that many of
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the other changes observed (e.g., increases in core fucosylation, alterations in N-glycan
branching, and changes in specific types of sialylation) could be explained by this hypothesis.
Furthermore, changes in oligo-mannose levels were not observed in the HEKXBP1s membrane
glycome. Thus, although we cannot completely exclude the possibility, we believe the
'overwhelming flux' hypothesis is unlikely to be correct.
A second possible explanation is that XBP1s activation either directly (as it is a
transcription factor), or indirectly (as it can alter the expression of other transcription factors 1
64) modifies the expression of enzymes involved in N-glycan maturation and biosynthesis
(known as glycogenes), leading to transcriptionally encoded changes in N-glycome architecture.
This explanation would be consistent with prior work showing that alterations in the expression
of glycogene transcripts can induce changes in the N-glycome.51, 65 To evaluate this possibility,
we used both previously published data for HEKXBP1s cells 14 and our new RNA-Seq data for
HeLaXBP1s cells to characterize the glycogene transcript-level changes induced by chronic,
selective XBP1s activation in vehicle- versus dox-treated cells. In both HEKXBP1S cells and
HeLaXBP1s cells, gene set enrichment analyses highlighted N-linked glycosylation as a highly
enriched pathway under conditions of chronic, selective XBP1s activation (see Table S1C and
Ref. 14). Indeed, GO groups related to protein glycosylation are the most enriched gene sets in
XBP1s-activated cells, after XBP1s- and IREl-regulated aspects of the classical unfolded
protein response. Furthermore, standard GSEA indicated strong enrichment of genes involved
in biosynthesis of the lipid-linked oligosaccharide in both HEK iPs and HeLaXBPls cells (Figure
S8 and Table S1E). However, our data suggest that XBP1s activation does not globally alter
transcripts involved in N-glycan maturation, as examination of the comprehensive gene set
involved in N-glycan trimming and elaboration showed no global enrichment in XBP1s-activated
cells (Figure S8 and Table S1E). This observation suggests that XBP1s regulates specific
subsets of these glycogenes, consistent with the changes in levels of only specific epitopes
observed in our glycomic analyses.
We next manually curated a list of 1310 genes related to protein N-glycosylation from
gene ontology data sets (the gene sets used and full list of N-glycosylation-related genes
analyzed are shown in Tables S8A and S8B, respectively). These N-glycosylation-related genes
included not just enzymes involved in N-glycan biosynthesis, trimming, and modification, but
also sugar transporters, monosaccharide synthases, and catabolic enzymes. We plotted the
changes in expression levels of these individual glycogenes upon XBP1s activation for HEKXBP1s
and HeLaXBP1s cells in the volcano plots in Figures 5.5A and 5.5C, respectively. As some
glycogenes are expressed at low levels,66 we also employed a commercially available Qiagen
RT2 Profiler Human Glycosylation PCR Array to analyze transcript levels of selected
glycogenes. For transcripts that were detected by multiple methods, we used the qPCR array
results, rationalizing that the latter is more sensitive. 7
For HEKXBP1s cells, 39 of 950 expressed glycogene transcripts were altered (shown in
teal in Figure 5.5A) by chronic XBP1s activation using a significance cutoff of false discovery
rate (FDR; for microarray data) or p-value (for qPCR array data) 0.05, in addition to a fold-
change threshold 1.5 (see Table S8C for a complete list of results). This analysis (1) confirms
the remodeling of the glycogene transcriptome induced by XBP1s activation in HEKXBPlS cells,
especially for a number of glycogenes directly involved in N-glycan maturation, and (2) is in
concordance with key features of the N-glycome remodeling caused by XBP1s activation in both
the membrane and secretome of HEKXBP1s cells (Figures 5.2C and 5.4C, respectively).
Specifically (Figure 5.5B), reduced levels of MGAT3 (shown in pink in Figure 5.5A), which is the
enzyme responsible for introduction of bisecting GIcNAc residues, 8 correlate with the reduction
in bisected N-glycans observed most significantly in the HEKXBPls membrane N-glycome (Figure
5.2C), but also in the secreted N-glycome (Figure 5.4C). Although below the threshold for
significance, there was also a decrease in the transcripts of the x2,6-sialyltransferase ST6GALI
(0.69-fold for XBP1 s-activated HEKXBP1s/control, p = 0.23) and an increase in transcript levels
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Figure 5.5: Glycogene analysis in HEKXBPls and HeLaXBPs cells. Transcript levels for
numerous enzymes involved in key steps of N-glycan biosynthesis and maturation pathways
were modulated upon XBP1s activation. (A) Volcano plot showing XBP1s activation-induced
changes in glycosylation-related transcripts in HEKXBP1s cells. Glycogenes analyzed are
listed in Table S8B. Data shown were obtained either from the Qiagen Human Glycosylation
qPCR Array or, if a transcript of interest was not included in the qPCR array, extracted from
previously published HEKXBP1s microarray data. 14 Transcripts shown in teal meet significance
and fold-change thresholds of FDR or p-value : 0.05 and fold-change 2 1.5 upon XBPIs
activation. Gene symbols are shown for outliers and transcripts of particular interest. (B)
XBPls-mediated changes in the HEKXBPIs transcriptome directly correlate with some of the
observed changes to the HEKXBP1s N-glycome. Decreased expression of MGAT3 (shown in
pink in (A)), a GIcNAc transferase,68 could account for the loss in bisecting GIcNAc observed
on HEKX PI secreted and membrane glycoproteins upon XBP1s activation. Decreased
expression of ST6GAL1 and increased expression of NEU could account for the reduced
sialylation observed for HEKXBP1S secreted and membrane glycoproteins upon XBP1s
activation. (C) Volcano plot showing XBP1s activation-induced changes in glycosylation-
related transcripts in HeLaXBP1s cells, generated from Qiagen Human Glycosylation qPCR
Array or, if a transcript of interest was not included in the qPCR array, RNA-Seq data as
described for (A). Transcripts shown in blue meet significance and fold-change thresholds of
FDR or p-value s 0.05 and fold-change 1.5 upon XBPls activation. (D) XBPIs-mediated
changes in the HeLaXBP1s transcriptome directly correlate with at least some of the observed
changes to the HeLaXBP1s N-glycome. Increased expression of GFPT1, PGM3, SLC35A3, or
UAPI, which are enzymes involved in regulating UDP-GIcNAc availability (shown in orange
in (C)), could contribute to increased tetra-antennary N-glycans observed on HeLaXB is
membranes upon XBP1 s activation (see also Figure S9).
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for the sialidase NEUI (1.4-fold for XBPls-activated HEKXBP1s/control, p = 0.25) that together
may explain the loss of a2,6 sialylation, especially on more branched structures, that we
observed (Figure 5.5B). Interestingly, the transcript levels for ST6GALI go up in HeLaXBPls cells
upon XBP1s activation (Table S8D, 2.3-fold for XBPls-activated HeLaXBP1s/control, p = 0.060),
which may balance the increase in NEUI (3.0-fold for XBP1s-activated HeLaXBP1s/control, p
0.003) and account for the lack of change in a2,6 sialic acid in that cell line (see Figure 5.3A).
For HeLaXBPls cells, 155 of 1075 expressed glycogene transcripts were altered (shown in
blue in Figure 5.5C) by chronic XBP1s activation using a significance cutoff of FDR (for RNA-
Seq data) or p-value (for qPCR array data) 0.05, in addition to a fold-change threshold 1.5
(see Table S8D for a complete list of results). As was also the case in the HEKXBP1S
transcriptome data, this analysis again (1) confirms the remodeling of the glycogene
transcriptome induced by XBP1s activation in HeLaXBP1s cells, especially for genes directly
involved in N-glycan maturation, and (2) is again in concordance with at least one key feature of
the N-glycome remodeling caused by XBP1s activation in HeLaXBP1s cell membranes (Figure
5.3C). Specifically (Figure 5.5D), XBP1 s-activated HeLaXBP1s cells exhibited increased
expression of genes affecting nucleotide sugar availability (see Figure S9 and Table S8D).
Among the genes significantly overexpressed, we observed the plasma membrane glucose
transporters, such as GLUT1 and GLUT3 (encoded by SLC2AI and SLC2A3, respectively),
which could potentially increase glucose availability in the cytosol. We also identified enzymes
in the hexosamine biosynthetic pathway required for the biosynthesis of the UDP-GIcNAc sugar
donor,69' 70 including PGM3 (4.35-fold increase), UAPI (2.12-fold increase), and the rate-limiting
GFPTI (3.15-fold increase).7 ' The increased expression of these enzymes, which collectively
regulate cytosolic levels of UDP-GIcNAc (Figure S9), was accompanied by an increase in the
Golgi UDP-GIcNAc transporter SLC35A3, thus increasing potential UDP-GIcNAc availability for
Golgi glycosyltransferases. 72 Levels of UDP-GIcNAc have been shown to affect the levels of tri-
and tetra-antennary N-glycans. 0 It is therefore likely that, even in the absence of altered
MGAT5 expression, the abundance of tetra-antennary N-glycans observed in HeLaXBP1 cells
might increase with XBP1s activation owing to increased UDP-GIcNAc concentrations in the
Golgi.73 The connection between changes in UDP-GIcNAc levels and MGAT5-dependent P1,6
branching, in the absence of protein expression changes, is well-established. 4 In further
support of this hypothesis, changes in the level of functional PGM3 have been correlated with
altered N-glycomic profiles in human neutrophils75 and increased expression of UAPI in human
prostate cancer cells has been correlated with increased abundance of UDP-GIcNAc.
Collectively, these transcript-level results provide insights into the detailed mechanism of
some of the XBP1s-induced changes in cellular N-glycome architectures. XBP1s activation
results in a coordinated remodeling of the glycogene transcriptome at multiple levels,
particularly for specific subsets of genes involved in N-glycan maturation and the availability of
nucleotide sugar donors. In several cases, the alterations in glycogene transcript levels are in
concordance with N-glycome-level changes induced by XBP1s activation. It should be noted,
however, that N-glycosylation is regulated at many levels - not just transcriptionally, but also at
the levels of translation (via miRNA), enzyme localization, and sugar metabolism/transport.2 9 , 30
51, 66, 77-79 Thus, it is expected that XBPls-induced changes in the glycogene transcriptome
would be unlikely to explain all the N-glycome changes we observed. Altogether, these data are
consistent with XBP1s-mediated changes in the N-glycome reflecting a coordinated response
driven in part by glycogene transcriptome remodeling.
Discussion
Previous work has revealed the paradigmatic role of XBP1s in resolving protein
misfolding stress and in expanding the secretory pathway.80 The impact of XBP1 s activation on
N-glycan maturation for specific ectopically overexpressed secreted proteins and possibly on N-
glycan site occupancy has also been demonstrated.2 9 37 However, prior to this work no evidence
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that selective XBP1s activation could alter N-glycan maturation on endogenous proteins existed.
Strikingly, our data show that chronic XBP1s activation can generate changes of sufficient
magnitude to be detected in glycome-wide assays that assess global carbohydrate composition
in cell membranes and in the secretome.
XBPls-mediated changes in N-glycome composition occur across multiple cell types.
The nature of these changes displays some cell type specificity, likely owing to the very different
baseline N-glycome compositions of different cells. As summarized in Table S5, upon stress-
independent XBP1s activation in three different sets of samples, we observed increases in
oligo-mannose levels in two sample sets (HEKXBPIs secretomes and HeLaXBP1S membranes),
reductions in sialylation in two sample sets (HEKXBP1s membranes and HEKXBP1s secretomes),
decreases in bisecting GIcNAc in two sample sets (HEKxBPls membranes and HEKXBP1S
secretomes), and increases in core fucosylation and tetra-antennary N-glycans in one sample
set (HeLaX PiS membranes). These results were consistently observed by multiple analytical
methods, including lectin microarrays, MALDI-TOF MS, GC-MS, and lectin flow cytometry. We
note that, in many cases, related changes were also induced by global, stress-mediated UPR
activation using Tg treatment (Table S6). However, the capacity of XBP1s activation alone to
remodel the N-glycome indicates the key role of this transcription factor in driving N-glycome
remodeling and highlights that ER stress is not required.
XBP1s-induced alterations in N-glycome architectures appear to reflect, at least in part,
a coordinated response owing to remodeling of the glycogene transcriptome. In particular,
changes in the expression of specific transcripts encoding enzymes directly involved in N-glycan
maturation were induced by XBP1s activation. N-Glycome remodeling driven by changes in
glycogene transcript levels is consistent with observations that differential expression of
5167 81glycosylation-related transcripts,' or even individual glycogenes, can give rise to cell type-
and disease-specific glycosylation profiles. However, full prediction of how glycogene
transcriptome changes will be reflected in secreted and cell membrane N-glycome architectures
remains very challenging, likely owing to the fact that multiple variables, and not just glycogene
transcript levels, play a role in N-glycan biosynthesis.2 9 30, 51, 66, 77-79 Thus, unsurprisingly,
although some features of the XBPls-remodeled N-glycome correlate with transcript-level
changes in glycogene expression (Figures 5.5B and 5.5D), a direct correlation with all features
does not exist. Further studies to fully detail the intermediate steps that propagate XBP1s
activation to an altered N-glycome are an important subject for future work.
Another interesting aspect of our data is the differential impact of XBP1s activation on
membrane versus secreted glycoproteins, particularly with respect to an increase in oligo-
mannose levels in the secretome. Secreted glycoproteins on exosomes have been shown to
have a glycosylation phenotype distinct from that of the originating cell surfaces. 0 Moreover
high- and oligo-mannose is one of the enriched epitopes observed in exosomes, and there are
data indicating that glycosylation can act as a trafficking marker for these secreted vesicles.8 2 In
the body, secreted glycoproteins can impact biology at sites distant to the cell, and there are
many glycan-binding proteins involved in innate immunity. Non-cell autonomous UPR signaling
has been observed in metabolic regulation, immune system activation, and tumorigenesis, 3 all
processes that are also responsive to target- and/or epitope-specific glycosylation.8
Cumulatively, these observations raise the intriguing possibility that cells may use XBP1s-
enacted changes in glycosylation in the secretome to signal for immune system functions or for
cell non-autonomous stress signaling. 23 , 86-88
Selective activation of the IRE1-XBP1s arm of the UPR, even in the absence of ER
protein misfolding stress, is a widely observed biological phenomenon. For example, selective
XBP1s activation is involved in both memory formation and circadian clock regulation.22 89
Similarly, selective induction of the XBP1s arm of the UPR plays a critical role in aspects of the
immune response and in development.2 0 21 The molecular mechanisms by which XBP1 s activity
influences these processes continue to be investigated, but our results indicate that a functional
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role for XBP1s-altered glycosylation must be considered. Beyond these phenomena, selective,
chronic XBP1s activation is also commonly observed in malignancies. 2 One common view
suggests that the IRE1-XBPls pathway is constitutively activated in these cancer cells to
resolve ER protein misfolding stress. However, it is noteworthy that another common feature of
cancer cells is modified N-glycosylation . Our findings open the possibility of a mechanistic
connection between chronic XBP1s activity in cancer and metastasis-promoting, neoplastic N-
glycosylation patterns.
In conclusion, our results suggest a new function of the XBP1s arm of the UPR that
merits more detailed mechanistic and functional investigation to fully elucidate the roles of the
UPR in cellular homeostasis. In ongoing work focused on this objective, we are now using
glycoproteomic strategies to identify the specific endogenous proteins whose N-glycans are
altered by XBP1s, and characterizing the functional consequences of such N-glycome
remodeling. This phenomenon provides a potential new pathway for intracellular stress
signaling to be propagated to the extracellular milieu. XBP1s-induced changes to the N-glycome
also may hold implications for pathologic processes, such as development of neoplastic
glycosylation patterns that support cancer metastasis.
Materials and Methods
Cells and Reagents. HEKXBP1S cells were cultured as previously described. 37 HeLa-TREx cells
were obtained from Invitrogen and cultured in complete DMEM supplemented with 10% fetal
bovine serum (FBS), as well as geneticin sulfate (G418, 500 tg/mL) to maintain the tetracycline
repressor. A pLenti4.XBP1 s construct, along with a linear marker for puromycin resistance, was
transfected into HeLa.TREx cells using Xfect (Clontech). Stable HeLaXBP1S cell lines were
selected by culturing in puromycin (0.5 ig/mL). An optimized single colony was selected and
characterized by Western blot and qPCR before use in these experiments.
RNA Extraction, Real-Time qPCR, RNA-Seq and Membrane/Secretome Preparation for
Glycomic Analyses. Detailed protocols are provided in the Appendix.
Lectin Microarray Glycomic Analyses. Lectin microarrays were generated as previously
described.94 Briefly, they were manufactured in-house with a Nano-plotter v2.0 piezoelectric
non-contact array printer (GeSiM) using a nano A-J tip. Arrays were printed on Nexterion Slide
H (Schott Nexterion) under 50% relative humidity at a surface temperature of 12 C.
Commercial lectins and antibodies were purchased from Vector Labs, R&D Systems, Santa
Cruz, TCI, AbCam, E.Y. Labs, or Sigma-Aldrich. The recombinant lectins rGRFT, rCVN, and
rSVN were generous gifts from Dr. B. O'Keefe (NCI Frederick). For a list of all printed lectins
see Table S2. We note that while the diversity of printed lectins allows for a wide range in the
detection of glycan epitopes, we are unable to observe some epitopes (e.g. ca2,8-linked sialic
acids) on our current array.
Prior to sample hybridization, lectin microarray slides were blocked for 1 h with 50 mM
ethanolamine in 50 mM sodium borate buffer (pH 8.8) followed by three washes with 0.005%
PBS-T (pH 7.4). Sample protein concentration and the degree of fluorescent label incorporation
was determined by measuring absorbances at 280, 555, and 650 nm per the manufacturer's
instructions on a NanoDrop ND-2000c spectrophotometer (Thermo Scientific). Equal protein
amounts (5 [tg) of sample and contrasting labeled reference were mixed in 0.005% PBS-T (pH
7.4) for a final concentration of 67 ng/ tL of protein. Slides were then loaded into a hybridization
cassette (Arrayit) to isolate individual arrays (24 per slide). Samples were loaded onto individual
arrays along with one array for the reference vs reference sample per slide. Samples were
hybridized for 2 h at 25 0C with gentle agitation. After hybridization, samples were removed and
arrays were washed 4x with 0.005% PBS-T (pH 7.4) for 10 min each. Slides were removed,
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submerged in ddH 20, and spun dry. Arrays were scanned using a GenePix 4300A array
scanner (PMT 550 laser power 100% for both fluorescent channels).
Background-subtracted median fluorescence intensities were extracted using GenePix
Pro v7.2. Non-active lectins were defined as having an average of both channel SNRs <3 in
>90% of the data and removed prior to further analysis. Data were median-normalized in each
fluorescent channel and the log2 of the sample/reference ratio was calculated for each technical
replicate for each lectin. Technical replicates were then averaged for each lectin within each
array. The ratios across individual biological triplicates per lectin were compared across
treatments using a two-tailed Student's t-test.
MALDI-TOF MS and TOF/TOF MS/MS Glycomic Analyses. All samples were treated as
described previously.95 Briefly, each sample was subjected to sonication in the presence of
detergent (CHAPS), reduction in 4 M guanidine-HCI (Pierce, Cramlington, Northumberland,
UK), carboxymethylation, and trypsin digestion. The digested glycoproteins were then purified
by HLB plus C 1 -Sep-Pak (Waters Corp, Hertfordshire, UK; 186000132). N-Glycans were
released by peptide N-glycosidase F (E.C. 3.5.1.52; Roche Applied Science, Burgess Hill, UK)
digestion. Released N-glycans were permethylated using the sodium hydroxide procedure and
purified by classic C 1 -Sep-Pak (Waters, WAT051910). Permethylated N-glycans were eluted at
the 50% acetonitrile fraction. We note that polysialylated structures deriving from the activity of
a2,8-sialyltransferase (ST8SIA2) enzyme were not analyzed from the above released N-
glycans.9 6
MS and MS/MS data were acquired using a 4800 MALDI-TOF/TOF (Applied
Biosystems, Darmstadt, Germany) mass spectrometer. Permethylated samples were dissolved
in 10 tL of methanol and 1 kL of dissolved sample was premixed with 1 tL of matrix (10 mg/mL
3,4-diaminobenzophenone in 75% (v/v) aqueous acetonitrile), spotted onto a target plate and
dried under vacuum. For the MS/MS studies the collision energy was set to 1 kV, and Ar was
used as the collision gas. The 4700 Calibration standard kit, calmix (Applied Biosystems), was
used as the external calibrant for the MS mode and [Glul] fibrinopeptide B human (Sigma-
Aldrich) was used as an external calibrant for the MS/MS mode.
MS and MS/MS data were processed using Data Explorer 4.9 Software (Applied
Biosystems). The processed spectra were subjected to manual assignment and annotation with
the aid of a glycobioinformatics tool, GlycoWorkBench. 7 The proposed assignments for the
selected peaks were based on 12C isotopic composition together with knowledge of the
biosynthetic pathways. The proposed structures were then confirmed by data obtained from
MS/MS and linkage analysis experiments.
For MALDI-TOF analysis of secretome samples, we note that even in commercial
"serum-free" media, MS detects serum-derived glycoproteins.57 In prior work we have shown
that the FBS-derived glycans can be identified and removed from the analysis without impacting
analysis of other glycan structures, just as we have done here.5 ' 59 Thus, the presence of these
peaks does not significantly impact detection of other glycan structures in the secretome.
GC-MS Glycan Linkage Analyses. Partially methylated alditol acetates (PMAAs) were prepared
as previously described.95 Linkage analyses of PMAAs were performed on a Scion 456-GC SQ
instrument (Bruker) fitted with a BR-5ms fused silica capillary column (15 m x 0.25 mm i.d.;
Bruker). The sample was dissolved in -20 tL of hexanes and injected manually (4-5 [L) at a
split ratio of 1/10. Injector temperature was set at 250 *C. Helium was used a carrier gas at
constant flow of 1 mL/min. PMAAs were eluted with the following linear gradient oven: initially
the oven temperature was set at 60 *C for 1 min, heated to 300 0C at a rate of 8 *C per min,
then held at 300 *C for 1 min.
Lectin Flow Cytometry and Metabolic Assays. Detailed protocols are provided in the Appendix.
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Proteomics Analysis. Detailed protocols are provided in the Appendix.
Data Deposition
The RNA-Seq data reported in this paper have been deposited in the Gene Expression
Omnibus (GEO) Database, http://www.ncbi.nlm.nih.gov/geo, with accession no. GSE1 12589.
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CHAPTER VI
Identification of a Functional Role for the Conserved N-Glycan
on the Collagen-I C-Terminal Propeptide
Summary
In the human body, collagen-I constitutes the primary component of bone, skin, and
other organs. Collagen-I is synthesized in the endoplasmic reticulum (ER) with globular N- and
C-terminal propeptides flanking the triple-helical domain; folding begins with the C-terminal
propeptide (C-Pro), which initiates assembly and determines the stoichiometry of the trimeric
procollagen molecule. A key feature of the C-Pro domain is a single conserved N-glycosylation
sequon. What is the purpose of the collagen-I N-glycan? C-Pro domains are cleaved before
collagen is incorporated into the extracellular matrix (ECM), making an extracellular role
unlikely. N-glycans facilitate protein folding in the ER by providing access to specialized
chaperone and quality control systems, but attempts to establish an intracellular role have so far
been unsuccessful. However, we hypothesized that the collagen-I N-glycan is critical for
instances in which collagen-I folding is challenged by ER stress or by destabilizing mutations.
One such example is C-Pro mutations that delay collagen-I folding, resulting in retention of
collagen molecules and diseases such as osteogenesis imperfecta (01). We tested our
hypothesis using the 01 variant Colal (I) C1299W and found that the N-glycan is essential for
folding and secretion. Furthermore, we show that even wild type Colal (1) requires the N-glycan
under conditions of ER stress. Our results identify, for the first time, a functional role for the
highly conserved N-glycan on the collagen-I C-Pro domain and demonstrate that a single N-
glycan can effectively buffer protein folding against stress incurred during development,
disease, or tissue repair.
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Introduction
The collagen protein family plays critical structural and dynamic roles in numerous
organisms. In the human body, collagens provide mechanical strength to tissues and mediate
processes such as development, wound healing, and cell-cell interactions.' Among the fibrillar
collagens, collagen-I constitutes the primary component of bone, skin, and other organs. While
the unique structural properties of the collagen-1 triple helix facilitate its biological functions, they
also present constraints for its folding and secretion. Production of collagen-I molecules involves
a dedicated cohort of chaperones and enzymes that shepherd the protein through folding, post-
translational modification, and triple helix assembly. 2 A crucial step in collagen- biosynthesis is
the folding of the globular C-terminal propeptide (C-Pro) domain, which is responsible for
initiating collagen-I folding, determining chain register within the triple helix, and maintaining the
appropriate 2:1 Colc1 (1):Cola2() stoichiometry."
The C-Pro domain contains a highly conserved N-glycan on each chain of the collagen-
triple helix. Previous work has shown that other conserved features of the C-Pro domain, such
as the network of cysteine residues that forms stabilizing inter- and intra-chain disulfides, are
critical for C-Pro function and collagen-I stability.6 These findings suggest that the single N-
glycan in the C-Pro domain is also required for folding and/or function. Yet the raison d'stre of
the N-glycan has remained elusive: the extracellular protease bone morphogenic protein-1
(BMP-1) cleaves the C-terminal propeptide prior to matrix incorporation of collagen-1 fibers,
suggesting that the N-glycan cannot have a biological function in the ECM.7 And while Colal (I)
8chains with destabilizing C-Pro mutations can be targeted for ER-associated degradation, an
intracellular role for the N-glycan in this process, or in collagen-I folding in general,' has not
been found.
Glycobiology, however, argues that the C-Pro N-glycan must exist for a reason. Besides
functioning as extracellular signals, N-glycans influence folding and quality control in the
endoplasmic reticulum (ER). Nascent N-glycoproteins with unfolded or misfolded regions bind to
chaperones calnexin and calreticulin upon exposure of the Glc1Man9GlcNAc 2 sugar (where Gic
= Glucose, Man = Mannose, and GlcNAc = N-Acetylglucosamine).' 0 Removal and re-addition of
the glucose residue by glucosidase 11 and UDP-Glc:glycoprotein glucosyltransferase,
respectively, facilitate additional cycles of engagement with calnexin and calreticulin, whereas
folding-competent glycoproteins are released for transport to the Golgi. Terminally misfolded
proteins have not only the glucose residue, but also additional mannose units, removed; the
action of ER a-mannosidase I triggers extraction of glycoproteins to the cytosol and subsequent
degradation by the proteasome.
We hypothesized that the C-Pro N-glycan might be required for collagen- folding in the
context of ER stress or destabilizing mutations. The function of the N-glycan would thus only be
detectable when collagen folding was challenged. To test this hypothesis, we generated a non-
glycosylated C-Pro variant by genetic substitution of the native acceptor asparagine with
glutamine. We then expressed glycosylated or non-glycosylated versions of a disease-
associated Colal(l) C-Pro domain in mammalian cells and assayed the secretion of these
constructs. We find that the Cola1 (1) C1299W mutant is highly dependent on the N-glycan, while
the N-glycan is dispensable for wild type Colal(l). ER stress, however, reveals an essential
function for the N-glycan on wild type Colal (1) as well. Our results provide the first evidence of a
function for the N-glycan in collagen-I proteostasis, and motivate continued efforts to examine
the consequences of this highly conserved post-translational modification.
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Results
The Collagen-I N-Glycan is Highly Conserved Across Species. The N-glycosylation motif on
Colal(l) is located in the C-terminal propeptide (C-Pro) domain at residue 1365 (Figure 6.1A).
Studies of the human collagen-Ill homotrimer revealed that the C-Pro domain adopts a flower-
like structure, with a-helical coiled coils forming the stalk, inter- and intra-chain disulfide-bonds
that form the Ca 2 -binding base, and antiparallel P-sheets that form the inner and outer faces of
the petals." Mapping the location of this asparagine onto the crystal structure of a Cola1 (1) C-
Pro homotrimer shows that the N-glycan is positioned on the outer face of each petal, directed
into the solvent (Figure 6.1C). Sequence alignments of the C-Pro domain show that the N-
A. Colal (I) Structure B. Species Conservation of the Colal (I) N-Glycan
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TFLRLMSTEASQNITYHCKNSVAYMDQQTGNLKKAL
AFMRLLANYASQNITYHCKNSIAYMDEETGNLKKAV
TFLRLLSTEGSQNITYHCKNSIAYLDEAAGNLKKAL
AFLRLLSSRASQNITYHCKNSIAYMDQASGNVKKAL
TFLRLLSASAHQNVTYHCYQSVAWQDAATGSYDKAL
TFLRLLSKEASQNITYICKNSVGYMDDQAKNLKKAV
NFLKLLSATARQNFTYSCQNAAAWLDEATGDYSHSA
TFLKLLTASARQNFTYHCHQSAAWYDVSSGSYDKAL
TFLRLLSVSAHQDVSYPCSGAA---------RDGPL
NFLHLLSSEATHIITIHCLNTPRWTSTQTS-GPGLP
NFLHLLSSEVTQHXITIHCLNMTVWQEGTGQTPAKQA
QGCNLDAIKVFCNMET-GETCVYPTQPSVAQKNWYI
QGCARDAFRVFCNFTAGGETCVTPRDDVT-------
LGCPSDAIEVFCNFSAGGQTCLPPVSVTKLEF----
LGCSSDTIEVSCNFTHGGQTCLKPITASKVEF----
Figure 6.1: The collagen-I N-glycan is highly conserved across species. (A) Schematic of the
Cola (I) sequence. The N-glycosylation motif is located in the C-terminal propeptide (C-Pro)
domain. A representative glycan structure is shown, using standard symbols from the
Consortium for Functional Glycomics (CFG) nomenclature. (B) The Cola1(I) N-glycosylation
motif, highlighted in yellow, is highly conserved across species. Sequences of Cola1(I) or
relevant analogues were aligned using Constraint-based Multiple Alignment Tool (COBALT;
https://www.ncbi.nlm.nih.gov/tools/cobalt/). (C) Crystal structure of the collagen-I C-Pro
domain (PDB: 5K31), showing the location of the N-glycan in magenta. The asparagine was
changed to a glutamine for crystallization. (D) The Cola (I) N-glycosylation motif, highlighted
in yellow, is highly conserved across human fibrillar collagens. Collagen chains Cola2(XI),
Cola1(XXIV), and Cola1(XXVII) have an N-glycosylation sequon in a different location from
that of Colal (1).
137
1-22 162
1388
1290
1411
1390
1764
1423
1669
1732
1664
1630
1786
1314
1620
1597
1742
N-Glycosylation of Non-Fibrillar Human Collagens
Gene N-Glycosylated? Number of Sites
COL4AI I
COL4A2 1
COL6AI 5
COL6A2 6
COL6A3 10
COL6A5 4
COL6A6 9
COL7AI 3
COL8AI 0
COL8A2 0
COL9A1 1
COL9A2 0
COL9A3 I
COL12A1 5
COLI4AI 0 
COL14AI 5
COL15A1 V AMW
COL16A1 2
COL17A1 I U
COL18AI 4
COLI9A1 0 A
COL2OA1 1
COL21A1 1
COL22AI 1
COL23A1 0
COL25A1 0
COL28AI (4)
Table 6.1: N-Glycosylation patterns are not conserved among non-fibrillar, human collagens.
Table of non-fibrillar human collagen genes, showing number of annotated N-glycosylation
sites (UniProtKB). Sequences that contained N-glycosylation sequons but were not
annotated as being N-glycosylated have the number of sites shown in parentheses.
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glycosylation motif of Colal (1) is highly conserved across species (Figure 6.1B). Remarkably,
the N-glycan is also present in all human fibrillar collagens, although the N-glycosylation sequon
is shifted earlier in Cola2(XI), Cola1 (XXIV), and Colal (XXVII) (Figure 6.1D). Non-fibrillar human
collagens have varying numbers of N-glycosylation sites distributed across the protein, with
many chains containing multiple sequons (Table 6.1).
The N-Glycan is Required for Secretion of Misfolding Collagen-I Variants. The preservation of
the N-glycosylation motif across species and collagens suggests that the N-glycan is important
for collagen folding and/or function. N-glycans have been shown to stabilize protein structure
and promote folding on isolated domains, 12 and the collagen- C-Pro domain must fold first
before triple helix assembly can occur.2 One approach to determine biological roles of N-glycans
involves mutating asparagine residues in N-glycosylation sequons to glutamines. Previous
studies on Colal (1) using this method surprisingly found that removal of the N-glycan caused no
change in collagen-I secretion or matrix deposition by mouse fibroblasts.g However, those
studies only examined wild type Colal (1), and so we wondered if the function of the N-glycan
might be revealed by performing similar experiments with misfolding Colal (1) variants.
We selected the disease-associated Colal(l) C1299W variant for our studies. The
mutation removes a cysteine residue from the disulfide bonding network," and might be
expected to impact chain selection.6 In addition, Colal(I) C1299W results in a relatively mild
osteogenesis imperfecta phenotype, and so we reasoned that protective functions of the N-
glycan would be revealed by exacerbated misfolding of Colal (I) C1299W upon genetic glycan
removal.13 We elected to perform initial studies on the isolated C-Pro domain, which we have
shown can be expressed in various cell types in native, trimeric form.14 We therefore generated
N-terminal HA-tagged constructs of Colal(1) wild type, Colal(1) N1365Q, Colal(1) C1299W, and
Colal (I) C1299W/N1365Q C-Pro domains, and expressed the constructs in HEK293 cells.
Immunoblotting analysis of conditioned media showed that removal of the N-glycan does
not prevent secretion of Colal (1) wild type C-Pro, consistent with previous reports;9 trimerization
of Colal(l) N1365Q also did not appear to be affected (Figure 6.2A). In contrast, Colal(l)
A. B.
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Figure 6.2: The N-glycan is required for secretion of misfolding collagen-I variants. (A)
Western blot of Colal (1) C-Pro domains expressed in and secreted from HEK293 cells. Cells
were plated and allowed to adhere overnight before transfection with the indicated Colal(I)
C-Pro constructs and Lipofectamine3000. Secretion of Colal (I) C1299W C-Pro is prevented
by removal of the N-glycan. (B) Western blot of soluble and insoluble intracellular fractions
following expression of Colal (1) C-Pro domains in HEK293 cells.
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C1299W C-Pro was no longer secreted upon removal of the N-glycan. Immunoblotting analysis
of the intracellular fraction revealed that the loss of Cola1 (1) C1 299W/N1 365Q secretion was not
due to retention of the double mutant (Figure 6.2B). While Cola1(l) N1365Q appeared more
prone to aggregate than the Cola1(l) wild type construct, Cola1(l) C1299W/N1365Q,
surprisingly, did not show an increased tendency to aggregate relative to Cola1(l) C1299W
(Figure 6.2B).
Chemically Phenocopying Genetic Removal of the N-Glycan Sequon. In the absence of
increased aggregation or intracellular retention, our results suggested that removal of the N-
glycan might direct the Cola1(l) C1299W C-Pro towards proteasomal or autophagasomal
degradation. Cellular quality control of N-glycoproteins in the ER predominantly involves two
chaperones, calnexin and calreticulin.10 These glycoprotein-binding lectins capture and release
partially folded or misfolded N-glycoproteins displaying a Glc1Man9GlcNAc 2 sugar; substrates
that fail to fold are subsequently targeted for extraction from the ER and degradation by the
proteasome.
We examined the effects of preventing Colal(l) C1299W entry into the
calnexin/calreticulin cycle by treating cells with the a-glucosidase inhibitor castanospermine. -17
Treating cells with castanospermine did not alter secretion of Colal(l) wild type or Colal(I)
N1365Q (Figure 6.3A). Similar to the wild type, the secretion of Colal (I) C1299W/N1365Q was
also not affected by treatment with castanospermine; however, all tested concentrations of
inhibitor markedly reduced the secretion of Cola1(l) C1299W (Figure 6.3B), showing that
chemically preventing access to the calnexin/calreticulin cycle mimics genetic removal of the N-
glycan on a misfolding Colal (1) variant.
A. B.Western Blot - Media Western Blot Quantification
Castanospermine: NT _ + Wild type + C1299W
-- WldtypeNtoQ + C1299WNtoQ
Colal (1) 1.5
Colal(I) N1365Q 
_ 1.0
Castanospermine: NT - -
C1299W 1 -0 W 4 o 4
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C1299WN1365Q 0.0
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Figure 6.3: Chemically phenocopying genetic removal of the N-glycan sequon. (A)
Representative Western blot of Cola1 (1) C-Pro domains expressed in and secreted from
HEK293 cells treated with increasing concentrations of castanospermine. HEK293 cells
were plated and allowed to adhere overnight. The next day, cells were transfected with the
indicated Colal (1) C-Pro constructs using Lipofectamine3000. The following day, cells
received fresh media and either DMSO or increasing concentrations of castanospermine:
125, 250, 500, or 1000 IAM. Media was collected for 6 h before harvesting for
immunoblotting. NT = no transfection. (B) Quantification of Western blots shown in (A),
normalized to the amount of Colal (1) C-Pro secreted from DMSO-treated cells.
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The N-Glycan Protects Colal(I) Against Stress-Induced Aggregation. These data showed that
the N-glycan is essential when destabilizing amino acid substitutions induce collagen-I
misfolding. Wild type collagen, however, folds well. Given that the N-glycan is highly conserved,
we wondered if there might be cases where the N-glycan is required for wild type Colal (1) to
fold. Collagen-producing tissues are known to experience physiological ER stress induced by
the high secretory output of ECM proteins that accompanies development and remodeling
processes.'18 20 We therefore hypothesized that the N-glycan might protect wild type Cola1(l)
from misfolding under challenging conditions of physiological ER stress.
To test our hypothesis, we transduced primary fibroblasts with full length Colal (1) wild
type or Colal(l) N1365Q adenoviruses, induced endogenous collagen-I secretion with
ascorbate, and assayed Colal(l) wild type or Colal(l) N1365Q behavior in the absence
(DMSO) or presence of ER stress (induced by treatment with the Ca2 ' homeostasis disruptor
Thapsigargin; Tg). While full length Colal(I) N1365Q was secreted robustly by vehicle-treated
cells, inducing ER stress with Tg strongly reduced mutant secretion (Figure 6.4A); secretion of
wild type Cola1 (1), by contrast, was not significantly affected by Tg. In the absence of ascorbate,
which is required to facilitate proper hydroxylation of the collagen-I triple helix by prolyl-4-
hydroxylase, 2 Colal(I) N1365Q was also secreted much less efficiently than under
ascorbate-supplemented conditions (Figures 6.4A and 6.4B).
We next examined whether the reduced secretion of Colal (1) N1365Q might be due to
intracellular retention of misfolding chains. Consistent with the results obtained using the
isolated C-Pro domain, Colal(l) N1365Q did not accumulate intracellularly relative to Colal(l)
wild type (Figure 6.4C), under either basal or ER stress conditions. Notably, we observed
increased Grp94 signal upon expression of Colal (1) N1365Q under basal levels (Figure 6.4C a-
KDEL, top band), suggesting that simply removing the N-glycan from Colal(l) triggers
misfolding that then activates the Unfolded Protein Response. We did not observe differences in
aggregation propensity for Colal(l) wild type or Colal(l) N1365Q (Figure 6.4D); the Colal(l)
N1365Q protein is thus likely targeted for degradation by the proteasome or autophagy.
Together, our results reveal that the function of the Colal(l) N-glycan is to protect collagen
chains from stress-induced aggregation, likely by providing access to the calnexin/calreticulin
chaperone cycle.
Discussion
A specific N-glycan site on the transmembrane glycoprotein CD147 was found to
facilitate access to calnexin-mediated folding; genetic removal of the acceptor asparagine
caused BiP and Hrdl-dependent routing of CD147 N152Q to ER-associated degradation
(ERAD). 23 We have shown here that the single N-glycan on the Colal(l) C-Pro domain is
similarly needed to allow access to the calnexin/calreticulin chaperone cycle. Remarkably, the
importance of the N-glycan for wild type Colal (1) is not apparent under basal conditions, but
becomes detectable when folding is challenged, whether by hydroxylation deficient conditions,
chemically-induced ER stress, or by the presence of a disease-associated mutation. We do not
observe significant increases in Colal (1) aggregation, suggesting that when access to
calnexin/calreticulin is prevented, the protein is directed to cellular quality control pathways.
Patient cell lines expressing mutants in the Cola1 (1) C-Pro domain that prevent trimer formation
and interchain disulfide formation show elevated BiP and Grp94 levels; BiP was also found to
stably associate with Colal (1) in that same study. Whether BiP, Grp94, or other chaperones
are involved in quality control of misfolding, non-glycosylated Colal (I) is the subject of ongoing
work.
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Colal(I) against stress-induced aggregation. (A)
from primary fibroblasts expressing full length
Cells were plated and allowed to adhere overnight
before being transduced with HA.Cola1(l) wild type or cMyc.Cola1(l) N1365Q
adenoviruses. The next day, cells were split 1:4 into 12-well plates. The following day,
cells received fresh media, endogenous collagen-I expression was induced with
ascorbate, and cells received DMSO or 750 nM Tg. Conditioned media was collected for
24 h before harvesting for immunoblotting. (B) Quantification of secreted adenoviral
Colal(I) constructs, normalized to levels of Colal(I) collected from DMSO and
ascorbate-treated cells. Note that removal of the N-glycan reduces secretion of wild type
Cola (1) under both hydroxylation-deficient (no ascorbate) and ER stress (Tg treatment)
conditions. (C) Western blot of soluble lysate from cells treated as described in (A). (D)
Western blot of the insoluble intracellular fraction from cells treated as described in (A).
Insoluble pellets were washed with PBS and then incubated in SDS solubilization buffer
to dissolve proteins prior to immunoblotting analysis.
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We previously found that stress-independent activation of the XBP1s branch of the UPR
shifts the distribution of mature N-glycoforms on the Cola (I) C-Pro domain in osteosarcoma
cells. 14 Furthermore, we have shown that XBP1s activation also alters the structures of mature
N-glycans on endogenous membrane-associated and secreted glycoproteins (e.g., Chapter V).
As XBP1s activation has been linked to cartilage development, it will be interesting to determine
if the structures of the Cola (1) and Cola2(1) N-glycans similarly shift in a differentiation and/or
tissue-dependent manner. These findings also raise the possibility that the N-glycan might have
functions beyond promoting folding of the C-Pro domain. A number of collagen types (IV, VIII,
XV, XVIII, and XIX) contain domains that can be cleaved by extracellular proteases to release
bioactive signaling molecules, or matricryptins.7 While an analogous process has not been
identified for collagen-1, the C-Pro domain is known to persist in serum,25 where it could
ostensibly interact with glycan-binding components of the innate immune system such as
galectins.26 Moreover, 0-linked glycosylation of collagen-IV has been shown to mediate
27endocytic uptake of collagen by the uPARAP/Endo180 mannose receptor, and so perhaps the
N-glycan on the C-Pro domain mediates similar interactions with other cell surface proteins.
In summary, we demonstrate that the Colal(l) N-glycan is necessary to rescue
misfolding chains by allowing the protein to access the calnexin/calreticulin chaperone cycle.
This work expands the mechanisms that govern collagen-I secretion (e.g., Chapters 11 and 111),
and points to possible connections between stress-associated changes in N-glycan maturation
and Colal(l) C-Pro signaling (e.g., Chapter V). The agreement between our results with full
length Colal(l) and the isolated Cola1(l) C-Pro domain validates our transient expression
system as a means to examine N-glycan function in the context of diverse collagen-I variants. In
addition to testing other disease-associated Cola1(l) C-Pro substitutions, engineered changes
to the N-glycan itself may also prove informative for identifying glycan- versus sequence (or
conformation)-specific determinants of chaperone-client binding-through installation of
additional N-glycan sequons, relocation of the N-glycan to another solvent-exposed region of
the C-Pro domain, or addition of chemically-induced constraints on N-glycan maturation. 8 30 We
anticipate that future studies will provide further insight into collagen-I proteostasis, as well as
general principles of N-glycan dependent quality control in the ER that may well extend to other
proteins in the secretory pathway.
Materials and Methods
Cell Lines and Reagents. HEK293 cells were grown in complete DMEM (Corning)
supplemented with 10% fetal bovine serum (FBS), 100 IU penicillin, 100 tg/mL streptomycin,
and 2 mM L-glutamine (Corning). Healthy dermal fibroblasts (GM05294; Coriell Cell
Repositories) were cultured in complete MEM supplemented with 15% FBS, 100 IU
penicillin/100 tg/mL streptomycin, and 2 mM L-glutamine (Corning). Secretion of endogenous
collagen-I was induced in primary fibroblasts using 200 VM sodium ascorbate (Amresco).
Immunoblots were probed with the following primary antibodies, as indicated: HA
(ThermoFisher 26183), Cola2(1) (Abcam ab96723), Colal(l) (NIH LF-68), Cola1(l) (Sigma
HPA008405), P-actin (Sigma A1978), FLAG (Agilent 131 200473), c-Myc (Sigma M4439).
Vector Construction. Site-directed mutagenesis was performed on a previously described
PPT.HA.Cola1().pENTR1A plasmid, using the QuikChange 11 XL Site-Directed Mutagenesis Kit
(Agilent).3 Collagen pENTR1A vectors were then recombined into pAd.CMV.V5.DEST Gateway
destination vectors34 using LR clonase (Life Technologies). The following primers were used to
generate the C1299W [Forward primer: 5'-CTGGTGAGACCTGGGTGTACCCCACTC-3';
Reverse primer: 5'- GAGTGGGGTACACCCAGGTCTCACCAG-3'] or the N1365Q [Forward
Primer: 5'-CCGAGGCCTCCCAGCAGATCACCTACCA-3'; Reverse Primer: 5'-
CAGTGGTAGGTGATCTGCTGGGAGGCCT-3'] variants.
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Adenoviral Production. Adenoviral vectors encoding HA.Colal(), HA.Colal(I)C1299W,
Myc.Cola1()N1365Q, or Myc.Cola1()C1299W/N1365Q were used to produce adenovirus
according to the manufacturer's instructions (LifeTechnologies ViraPower Adenoviral
Expression System). Viruses were subsequently amplified in 293A cells and titrated with
GM05294 cells to select an appropriate volume to use for experiments.
Adenoviral Transduction. GM05294 fibroblasts were plated at a density of 3.5 x 105 cells/plate
in 60-mm dishes the day before transduction. After being allowed to adhere overnight, cells
received fresh media and were transduced with adenoviruses encoding HA.Colal(l) and c-
Myc.Cola1(l)N1365Q, as indicated. The next day, cells received fresh media. Two days post-
transduction, cells were split 1:4 into 12-well plates. Collagen-I expression was induced with
ascorbate the following day as described for Western blotting, and cells were treated with
DMSO or 750 nM thapsigargin (Tg). After 24 h, the media was collected, separated on 4/8%
Tris-Gly SDS-PAGE gels, and probed for HA or c-Myc.
Western Blotting Analysis and SDS Solubilization. Samples of medium were denatured by being
boiled in Laemmli buffer (supplemented with 167 mM 1,4-dithiothreitol; DTT), separated on
homemade 4/8% Tris-Gly SDS-PAGE gels, and transferred to nitrocellulose membranes. Non-
reduced samples were boiled in Laemmli buffer without DTT prior to SDS-PAGE. Because of
cross-reactivity between antibodies, samples of medium for collagen-I blots were run on
duplicate gels, transferred, and then probed separately for either mouse anti-HA or mouse anti-
c-Myc.
For Western blots of cell lysates, cells were trypsinized, washed with phosphate-buffered
saline (PBS), and lysed in Triton-X lysis buffer with 1.5 mM phenylmethylsulfonyl fluoride
(PMSF) and a protease inhibitor tablet (Pierce). Lysates were then cleared by centrifugation at
21.1 x 10 3 g and 4 'C for 15 min. Total protein in the supernatant was quantified using the
bicinchoninic acid assay, and equal amounts of total protein were analyzed for each sample.
Each experiment was performed in biological triplicate. Blots were imaged after incubation with
appropriate primary and 800CW or 680LT secondary antibodies (LI-COR) by scanning on an
Odyssey infrared imager (LI-COR), followed by quantification using ImageJ.
For SDS solubilization, insoluble pellets obtained after the centrifugation step of cell lysis
(above) were washed in 1 mL of PBS with vortexing, and then spun at 21.1 x 103 g for 15 min.
Pellets were then incubated with 4 volumes of SDS solubilization buffer (1% SDS, 50 mM Tris,
150 mM NaCl, 10 mM MgC 2 , pH 7.5), vortexing, at room temperature for 3 h. Pellets were
removed from the vortexer and incubated at room temperature overnight. The next day,
samples were heated with Laemmli buffer (supplemented with 167 mM DTT), separated on
homemade 4/8% Tris-Gly SDS-PAGE gels, and transferred to nitrocellulose membranes.
Castanospermine Treatment. HEK293T cells were plated at a density of 7.5 x 105 cells/well in
six-well plates and allowed to adhere overnight. The next day, cells were transfected with the
indicated Cola1(I) C-Pro constructs using 1 jg of DNA/well and Lipofectamine3000. The next
day, cells were split 1:4 and allowed to adhere overnight. The following day, cells received fresh
media and either DMSO or increasing concentrations of castanospermine: 125, 250, 500, or
1000 pM. Media was collected for 6 h before harvesting for immunoblotting.
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CHAPTER Vil
Perspectives on the Field
In the course of research on protein folding, it can be easy to think that proteostasis is
chiefly concerned with how much of a protein exists in folded form. The challenge of maintaining
proteostasis in the cell thus becomes equivalent to recruiting chaperones, tuning translation and
degradation rates, and ensuring that a given protein has sufficient time, space, and assistance
to assume its native fold, while avoiding off-pathway oligomer and aggregate formation. This
perspective is useful for thinking about protein folding in cells, and lends itself well to interpreting
data from biochemical techniques that reveal how much of a protein is made, degraded, or
stable. What it often fails to capture, however, is the importance of location. Where a protein
ends up, and the extent to which this location is in line with where it is intended to be, arguably
has as much significance for function as how much folded protein exists at all.
Because proteins rarely exist in isolation outside the test tube, the location of a protein
plays a large part in deciding what neighbors it has, and what processes it can or cannot
access. Subcellular compartments have distinct stress responses, designated isoforms of key
chaperones, and different metal and redox conditions.'-4 It is not surprising, then, that cells have
innate safeguards against misplaced proteins, from localization sequences and cargo sorting
proteins to pH-dependent recycling systems that determine protein trafficking pathways and
organellar protein composition.
This thesis has considered two examples of methods cells can use to direct the
localization of specific proteins. In the first case (Chapters 11 and 111), cells regulate the export of
collagen-I by controlling its membrane carriers. ER-resident (Tangol, Hsp47, cTAGE57-') and
cytosolic (Hsp90p, and possibly NudCL; this work, as well as KLHL12, CUL3, ALG2, and
PEFl 12, 13) proteins are recruited to collagen-I at ER exit sites (ERES) and assist in transporting
it from the ER. The inability of collagen-I to fit into conventional packaging vesicles, and the
inclusion of chaperones like Hsp47 in the secretion machinery, allows cells to monitor collagen-I
folding and (mostly) release it only when appropriate. The second case involves modification of
the proteins themselves. Glycosylation of specific residues on proteins can influence their
recruitment to microvesicles or provide epitopes for recognition by lectins and receptors,14 15
perhaps in response to cell-wide transcriptional changes (Chapter V). Alternatively, the
presence of a single conserved N-glycan might enable proteins to engage lectin chaperones
that facilitate their folding and/or secretion, as we observed in Chapter VI.
Moving forward, there is much work left to do. One area of particular interest is the
proposed post-translational modification used to initiate membrane and/or COP-Il protein
recruitment.12 The monoubiquitin moiety installed on Sec3la by a KLHL12-CUL3 complex bears
similarities to a polyubiquitin motif required for post-Golgi anterograde, but not retrograde,
trafficking. In this instance, a KLHL20-CUL3 complex ubiquitinates the protein coronin 7 and
targets it to the trans-Golgi network. Time-lapse confocal microscopy revealed that KLHL20-
CUL3 activity enables formation and elongation of cargo carriers from the TGN, likely by
stabilizing F-actin during carrier coat assembly. 16 The export of representative secretory cargo
was impaired in KLHL20-depleted cells, pointing to non-degradative ubiquitylation as a means
of regulating secretion from both the ER and the TGN.17 18
The existence of a common, ubiquitin-based signal for carrier growth and protein export
might also indicate a more integrated picture of membrane utilization. It is possible, for instance,
to envision cellular membrane distribution determining the balance between protein production
(by expanding the ER and contributing to carrier growth) and degradation (via autophagosome
formation or reducing ER volume). While speculative, this framework finds support in recent
studies that directly link membrane availability to collagen secretion. An RNAi screen for
Drosophila genes involved in collagen IV production identified dynamin, a GTPase required for
endocytosis, as a screening hit.19 The dynamin-deficient phenotype of autonomous, pericellular
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collagen IV deposits could be rescued by depleting lipids from growth medium and thereby
reducing excess plasma membrane. Such deposits are distinct from those observed upon
Tangol knockdown, which are solely intracellular. And although the basement membrane
components nidogen (-139 kDa, 24 nm in radius) and perlecan (-470 kDa, 170 20 nm in
length) accumulated with collagen IV in dynamin-deficient adipocytes, laminin (140-400 kDa,
depending on the chain; 130 nm in length) was not detected in the collagen-IV deposits; the
results therefore suggest that protein identity, rather than size, determines susceptibility to
pericellular trapping by collagen IV in the presence of excess plasma membrane.
The collagen and coat protein adapter Tangol has been proposed to recruit ERGIC-
derived membranes to ERES, driving expansion of collagen-containing COP-Il vesicles.9 20
Consistent with this hypothesis, knockdown of Tangol in Drosophila causes intracellular
retention of the large protein Dumpy and the collagen gene Viking, blocking smaller cargoes
from exiting the ER. However, Tangol depletion also disrupted ER-Golgi morphology even in
the absence of Dumpy, suggesting that the protein may have roles in organelle organization
outside of vesicle expansion.2 ' Thus, while specific signaling mechanisms (whether through
post-translational modification or through designated cargo-receptor interactions) are needed to
initiate secretion of large cargo, the dynamin and Tangol deficiency phenotypes suggest that
controlling membrane abundance constitutes another key mode of regulating secretion.
Knockdown of syntaxins 5 and 18, membrane-associated proteins that drive vesicle fusion,
impacted collagen VII secretion ;20 it therefore seems likely that other transmembrane proteins
beyond these may prove to be involved as well.
We must note, however, that the signaling mechanisms for initiating collagen secretion
are not yet defined. While biochemical, high-resolution imaging, and in vitro reconstitution
assays support the hypothesis that collagen is exported from the ER in discrete vesicles that
contain monoubiquitylated Sec3l a, 12 , 322 imaging and genetic knockdown experiments by other
groups have suggested the possibility of a continuous, membrane-bound carrier that remains
associated with the ER.2  At the time of writing, preliminary work by another group has argued
against transport of collagen-I in COP-Il coated vesicles, presenting data that appears to be
more consistent with contiguous carriers that extend from the ER to eventually fuse directly with
the Golgi.2 Resolution of the debate thus awaits additional evidence, perhaps through
application of other methods such as proximity labeling, which can address these alternate
theories.
Yet even in the absence of a complete mechanism, the assays and small molecule
modulators originating from studies of collagen-I secretion provide tools for asking a new set of
questions. Collagen types Ill and V, for instance, are fibrillar collagens that co-assemble with
collagen-I to regulate fibrillogenesis and fibril diameter, respectively, in the extracellular
matrix.26 27 What secretion pathways these collagens use, and to what extent the process is
jointly regulated with secretion of collagen-, could provide insight into EDS disease phenotypes
associated with mutations in these collagens 28 , 29 while identifying shared (or type-specific)
features of collagen secretion mechanisms. A natural starting point for these studies might be
examining collagen-Ill and -V secretion by cells treated with small molecule modulators of
collagen-I secretion (Chapter II), or transduced with shRNA constructs against genes identified
as collagen-I interactors.30 Annexin A2 and Golim4, in particular, are strong candidates for initial
shRNA studies, as both proteins localize to the secretory pathway and were required for
endogenous collagen-I secretion by Saos-2 cells. While in vitro studies of collagen secretion
have predominantly focused on either type VII or type I, Tangol KO mice showed defective
secretion of types I - IV, VII, and IX.31 Such findings might suggest that types I and Ill (and II
and IX, which co-assemble in cartilage32 ) share the same secretion pathway, but that their
respective binding partners collagen-V and collagen-XI are exported through a different
mechanism.
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Another area for future work involves transcriptional regulation of collagen secretion.
Besides the classical UPR stress sensors IRE1, PERK, and ATF6, five additional ATF6-like
transcription factors have been identified. These transcription factors show low (-30%) overall
sequence identity with ATF6, but contain key features of ATF6 protein structure, including a
transcriptional activation domain, a bZIP domain, transmembrane region, and a motif for
cleavage by site 1 protease (S1P). 33 , Among these new proteins, the osteoblast-specific
OASIS and the chondrocyte-specific BBF2H7 target genes such as COLIA1 and SEC23A,
respectively, and are required for bone (OASIS) or cartilage (BBF2H7) development.35 36 Dual
regulation of secretion-related genes appears possible, as ATF6 and BBF2H7 knockouts both
showed reduced expression of Sec23a and Sec13. ATF6 activity, however, is not sufficient for
secretion of extended collagen-Il fibrils.3 1
OASIS-'- mice accumulate collagen-I in the rough ER of osteoblasts, and chondrocytes
from BBF2H7-'- mice contain aggregated collagen-Il in the rough ER, indicating that these
transcription factors likely regulate collagen secretion.35' 36 Surprisingly, overexpression of the
active N-terminal portion of BBF2H7 causes embryonic lethality in the medaka fish, and studies
of BBF2H7 function in this system required transient expression at an early stage of
development, well before formation of the notochord and secretion of type 11 collagen.37
However, doxycycline-responsive versions of OASIS and BBF2H7 have been stably integrated
into MEFs and used to show that both transcription factors are regulated in a mechanism
distinct from that of ATF6.38 It would therefore be interesting to introduce an orthogonal, small
molecule-regulated version of ATF6 39 to explore effects of controlled joint activation of these
transcription factors, and perhaps obtain insight into the distinct transcriptional requirements for
the secretion of large proteins such as collagen-I and II.
Finally, we have found that the transcription factor XBP1s is capable of globally altering
the structures of N-glycans on cell surface and secreted proteins (Chapter V). Such work builds
on previous reports that XBP1s activity can increase glycosylation by controlling biosynthesis of
precursors.40 We also show that, at least for misfolding variants of the collagen-I C-terminal
propeptide domain, that a conserved N-glycan facilitates secretion of the protein, possibly by
allowing it to access the calnexin/calreticulin lectin chaperones (e.g., Chapter VI). The presence
of N-glycans has been found to both enhance protein stability and promote folding,'" suggesting
that a similar mechanism may motivate conservation of the N-glycan on the collagen-I
propeptide.
Increasing evidence suggests that 0-glycosylation, however, also acts to regulate
protein secretion. O-GlcNAcylation stabilizes nucleoporins against proteasomal degradation,
and has begun to gain acceptance as an intracellular signal akin to phosphorylation .
Removal of O-GlcNac was first found to promote phosphorylation of the Sec24 protein family,
impairing membrane recruitment and initiating a temporary trafficking block during mitosis.44 A
subsequent study of heterozygous and homozygous mice deficient for the glycosyltransferase
Galnt1 showed that loss of 0-glycosylation impaired secretion of collagen IV in the developing
submandibular gland and activated both XBP1s and ATF6. 45 Notably, ablation of N-
glycosylation by treatment with tunicamycin not only caused global ER stress, but also caused
mistargeting of the non-basement membrane component E-cadherin, indicating distinct roles for
N- and 0-linked sugar modifications.
Since then, 0-GlcNAcylation has been identified on several components of the COP-Il
machinery. Modification of Sec3la on the residue Ser964 decreases its affinity for ALG2 and
increases membrane association of Sec3la, supporting ERES formation and protein
secretion. 6 O-GlcNAcylation by the glycosyltransferase PGANT4 protects Tangol from furin
proteolysis in Drosophila, allowing for protein secretion and maintenance of Golgi structure; 0-
glycosylation sites have also been identified on mammalian Tangol, and so proteolysis of non-
glycosylated Tangol may prove to be a conserved mode of regulating protein activity.47
Meanwhile, a recent proteomics-based approach found O-GlcNAcylation sites on Sec23a,
151
Sec24b, Sec24c, Sec3la, and TFG, which were shown to media protein-protein interactions in
mammalian cells.48 Expression of the Ser 84Ala mutant of Sec23a caused collagen retention in
the ER of chondrosarcoma cells, and a nonglycosylatable mutant of Sec23a was only partially
able to rescue collagen secretion in the Sec23a-depleted crusher zebrafish model. 0-
GlcNAcylation levels have been found to correlate with both chondrocyte49 and osteoblast
differentiation, 50 which could link the observed O-GIcNAc modification of COP-Il proteins with
BBF2H7 and OASIS signaling. Furthermore, the substrate specificity of the O-GIcNAc
transferase seems to depend on UDP-GIcNAc concentration, which points to possible cross-talk
between N-glycosylation and O-GlcNAcylation via XBPls-mediated changes to UDP-GIcNAc
availability.5 That N-glycosylation sites have also been assigned to Tangol further suggests
that N- and 0-glycosylation may coordinately regulate protein secretion, the details of which
may prove relevant for our understanding of both development and disease.52
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Appendix: Supporting Information for Chapter V
Supporting Experimental Procedures
RNA Extraction and Real-Time qPCR. HEKXBP1s and HeLaXBP1s cells were plated and treated as
for lectin microarray analysis (below). After 72 h of XBP1s activation with 1 pg/mL dox (or 24 h
of treatment with 0.1% DMSO or 750 nM Tg), cells were washed with PBS and RNA was
extracted using the Omega E.Z.N.A. Total RNA extraction kit. cDNA was prepared from 500 ng
RNA, normalized for all samples in each run, using an Applied Biosystems Reverse
Transcriptase cDNA Kit in a BioRad Thermocycler. Samples were run on a Light Cycler 480 11
Real Time PCR Instrument in the MIT BioMicro Center using previously described primers and
data were analyzed as described previously. 1,2 For qPCR arrays, HEKXBP1s and HeLaXBP1S cells
were treated for 48 h with 1 pg/mL dox or 0.1% DMSO prior to harvesting. RNA was then
extracted using the Qiagen RNeasy kit, cDNA was prepared from equal amounts of RNA using
the Qiagen RT2 First Strand Kit in a BioRad Thermocycler, and samples were loaded on an RT 2
Profiler PCR Array for Human Glycosylation (Qiagen PAHS-046Z). Analyses were performed in
a Light Cycler 480 11 Real Time PCR Instrument in the MIT BioMicro Center. Data from three
biological replicates were analyzed using the AACt method. A list of glycogenes was manually
curated from the HEKXBP1S microarray 2 and HeLaXBP1s RNA-Seq data, and then combined with
detected glycogenes from the PCR array (Table S8). Significance cut-offs used were FDR or p-
value 0.05 and fold-change 2 1.5.
RNA-Seq. HeLaXBPls cells were plated in biological triplicate at a density of 6 x 105 cells per well
in 6-well plates and allowed to adhere overnight. Cells were then treated for 48 h with vehicle or
1 tg/mL dox, or for 24 h with 750 nM Tg. Cells were harvested and RNA was extracted using
the RNeasy Plus Mini Kit (Qiagen). RNA quality was confirmed using a Fragment Analyzer
(Advanced Analytical). RNA samples were then loaded on a HiSeq cartridge as a 50 base
single-end run with 6 + 6 nucleotide indexes. H. sapiens RNA-Seq reads were aligned to hg19
with bowtie version 1.0.1 3 and expression was summarized using rsem version 1.2.264 using
the ensemble gencode annotation release 75. Differential expression analysis was done with
deseq2 version 1.10.0 5 running under R version 3.2.3. Default options were selected for deseq2
runs, except Cooks Cutoff and Independent Filtering were both set to false during results
preparation. Gene Set Enrichment Analysis6 Java command-line version 2.3.0 beta was run in
both pre-ranked and standard mode using the stat output from deseq2 to order genes. Custom
gene sets and a selected subset from MSigDB version 5.2 were analyzed; these gene sets are
provided in Table SlE. Hierarchical clustering was performed with Spotfire 7.6.1, using counts
of transcripts with highest expression for each gene.
Membrane Proteome Preparation. HeLaXBP1s or HEK293XBP1s cells were plated in 10 cm dishes
at a density of 1 x 106 cells per plate and allowed to adhere overnight. The next day, XBP1s
expression was induced by treatment with 1 pg/mL dox. Vehicle and Tg-treated plates received
fresh media and either DMSO or 750 nM Tg for 24 h before harvesting. After 72 h of induction,
cells were harvested by scraping in 1 x PBS + 1 mM EDTA, sonicated to disrupt cells, and then
centrifuged at 35k RPM at 4 *C for 1 h to pellet the membrane fraction. Pellets were
resuspended in 100 pL PBS, homogenized with 21G and 27G needles, and protein
concentrations were measured via A280 on a NanoDrop ND-1000 spectrophotometer.
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Secretome Preparation from HEKXBPls Cells. Prior to plating cells, 15 cm dishes were coated
with 0.05 mg/mL of poly-D-lysine hydrobromide (Sigma P6407) for 10 min at room temperature.
Each dish was washed three times with PBS before seeding with 10 x 106 HEKXBP1s cells in
complete medium. After 24 h, media were changed to add the appropriate compounds: 1 pg/mL
dox for XBP1s activation or 0.1% DMSO for control. After another 24 h, media were removed
and cells were washed with PBS (containing Ca 2 ' and Mg 2+) three times. Cells were then
incubated in FreestyleTM medium (Gibco) with either 1 tg/mL dox, 0.1% DMSO, or 750 nM of
Tg. Conditioned media were harvested from cells after a total of 48 h with dox or DMSO, or 28 h
with Tg. Medium samples were filtered through 0.2 pm PES membranes (VWR) and
concentrated in 3 kDa MWCO centrifugal units (Millipore Amicon Ultra). For immunoblotting
analysis of the secretome, 6 x 105 HEK BP1s cells were plated per well on poly-D-lysine coated
6-well plates and treated with dox or vehicle as described above. After 24 h, cells were washed
with PBS (containing Ca2+ and Mg 2+) three times and then incubated in DMEM (+10% FBS, L-
glutamine) or FreestyleT M media, with or without 1 Vg/mL dox. Conditioned media were collected
after 48 h, spun at 1.5k RPM at 4 *C for 5 min to pellet cell debris, and then run on 4/8% SDS-
PAGE gels. Proteins were transferred to nitrocellulose membranes and incubated with an a-
KDEL (recognizes both Grp78 and Grp94, Enzo ADI-SPA-827) antibody. Blots were developed
with the appropriate 800CW secondary antibody (LI-COR) prior to scanning on an Odyssey
infrared imager (LI-COR).
Lectin Flow Cytometry. HeLaXBP1s cells were treated with or without dox for 72 h, then very
briefly trypsinized. Cells were washed twice with 2% FBS in PBS, and 1 x 106 cells/sample were
incubated for 30 min at 4 0C with HHL-biotin (Vector Labs) at 5 tg/mL. Competitive sugars (200
mM a-methylmannoside, Sigma-Aldrich) were pre-incubated 30 min with lectins at room
temperature for inhibitory controls. Cells were washed and resuspended in 20 ptg/mL of Cy5-
streptavidin (Thermo Fisher Scientific) for 20 min at 4 *C in the dark. Cells were resuspended in
1 mL of 2% FBS/PBS, passed through cell strainers (Falcon), and analyzed on a BD Accuri C6
flow cytometer.
CelTiter-Go Assay. HeLaXBP1s cells were cultured with or without doxycycline (1 tg/mL, 72 h) or
1-DMM (80 pg/mL, 24 h). Cells were counted and plated at 1 x 104 cells/well 24 h prior to
carrying out the assay according to the manufacturer's instructions (Promega). In brief, cells
were cultured in 100 [L of culture media and an equal volume of reagent was added to lyse
cells for 2 min. After incubation at room temperature for 10 min, luminescence measurements
were taken.
Resazurin Assay. HeLaXBP1s cells were cultured with or without doxycycline (1 Vg/mL, 72 h) or 1-
DMM (80 Vg/mL, 24 h). Cells were counted and plated at 1 x 104 cells/well 24 h prior to
measurements. Resazurin was added to cells at a final concentration of 0.03 mg/mL for 60 min
at 37 'C. Fluorescence readings were taken at 560 nm excitation, 590 nm emission.
Secretome Proteomics Analysis. HEKXBP1s cells were treated with either vehicle or doxycycline
for 16 h, washed well, and incubated in DMEM without serum for 6 h. Proteins were then
precipitated from conditioned media with 10% TCA for 1.5 h at 4 *C and resolublized using 1%
aqueous Rapigest (Waters) in 100 mM HEPES pH 8.0. Proteins were reduced with 5 mM TCEP
(Sigma) for 30 min at 37 *C, alkylated with 10 mM iodoacetamide (Sigma) for 30 min in the dark
at room temperature, digested with 0.5 jg trypsin overnight at 37 *C and 600 rpm, labeled with
appropriate isotopic TMT reagent in 40% CHC 3N for 1 h, quenched with 0.4% ammonium
bicarbonate for 1 h, pooled, evaporated, resuspended in buffer A (5% CHC 3N, 0.1% formic
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acid), brought to pH < 2 with formic acid, heated at 37 0C to precipitate Rapigest, and stored at -
80 *C prior to LC/LC-MS/MS analysis.
Nanopure water and mass spectrometry grade solvents were used for all preparations.
MudPIT loading columns were prepared by briefly dipping 250 tm inner diameter (ID)
undeactivated fused silica capillaries (Agilent) in 3:1 Kasil 1624 (PQ Corp) : formamide, curing
overnight at 100 OC, and trimming the frit to 1 mm. The columns were then rinsed with MeOH,
loaded under pressure with 2.5 cm strong cation exchange resin (SCX Luna, 5 Vm diameter,
125 A pore size, Partisphere), and loaded with another 2.5 cm reversed phase resin (C18 Aqua,
5 prm diameter, 125 A pore size, Phenomenex). The columns were rinsed well with methanol
and buffer A prior to loading the peptide digest, and further washed with buffer A. Analytical
columns were prepared by pulling 100 Vrm ID-fused capillaries to a 5 pXm ID on a P-2000 tip
puller (Sutter Instrument Co.) and loaded with 15 cm of reversed phase resin, followed by
methanol rinsing and equilibration in buffer A. For LC-MS/MS, each loading column was
connected to the analytical column by a zero-dead-volume union, and connected to the HPLC
through a tee junction that allowed connection to the 2.5 kV ESI voltage. A flow rate of 300
nL/min was maintained through a 1:1000 split flow line from an Agilent 1200 pump. MuDPIT
experiments were performed where each step corresponds to 0, 10, 20, 30, 40, 50, 60, 70, 80,
90, and 100% buffer C being run for 4 min at the beginning of each gradient of buffer B.
Electrospray was performed directly from the analytical column by applying the ESI voltage at a
tee (150 mm ID, Upchurch Scientific) directly downstream of a 1:1000 split flow used to reduce
the flow rate to 300 nL/min through the columns. Electrospray directly from the LC column was
done at 2.5 kV with an inlet capillary temperature of 275 *C.
Data-dependent acquisition of MS/MS spectra were performed with the following
settings: eluted peptides were scanned from 300 to 1600 m/z with resolution 30000 and the
mass spectrometer in a data dependent acquisition mode. The top ten peaks for each full scan
were fragmented by HCD using a normalized collision energy of 45%, a 100 ms activation time,
and a resolution of 7500. Dynamic exclusion parameters were 1 repeat count, 30 ms repeat
duration, 500 exclusion list size, 120 s exclusion duration, and exclusion width between 0.51
and 1.51. Protein and peptide identification and protein quantitation were done with the
Integrated Proteomics Pipeline - IP2 (Integrated Proteomics Applications, Inc., San Diego, CA.
http://www.integratedproteomics.com/). Tandem mass spectra were extracted from raw files
using Raw Xtractor 1.9.13 and were searched against a database containing 20245 human
sequences (longest entry for the IPI database for each protein) with reversed sequences using
ProLuCID. Carbamidomethylation (+57.02146 Da) of cysteine and TMT tagging of N-termini and
of lysine residues (+229.1629 Da) were considered as static modifications. Peptide candidates
were filtered using DTASelect2 (version 2.0.27) for a false positive (decoy) peptide ratio of -1%.
Quantitation was performed using Census7, followed by deconvolution of isotopic impurity as
reported in the lot analysis supplied by Thermo Fisher, and finally normalization of ratio values
based on the mode. Redundant peptides were generally assigned to all proteins. The heavy to
light ratio was quantified by Census.
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Supporting Tables
Table SI: GSEA results and gene sets (see xIs file in Supporting Reference [9]).
Table SIA (Sheet 1). GSEA results for Tg treatment using c5bp (MSigDB), shown in Figure
S1B.
Table S1 B (Sheet 2). GSEA results for Tg treatment using c5mf (MSigDB), shown in Fig. S1 B.
Table S1C (Sheet 3). GSEA results for XBP1 s activation using c5bp (MSigDB), shown in Figure
S1B.
Table S1 D (Sheet 4). GSEA results for XBP1 s activation using c5mf (MSigDB), shown in Figure
S1B.
Table S1 E (Sheet 5). Full list of glycogenes in custom "lipid-linked oligosaccharide biosynthesis"
and "trimming and elaboration" gene sets used for generating enrichment plots shown in
Figure S8A and B.
Table S2. List of lectins used on the microarrays (see xIs file in Supporting Reference [9]).
Table S2A (Sheet 1). List of lectins used for HEK293XBPIs microarray experiments. Lectin print
concentration, print sugar, and glycan epitope are indicated. Duplicate lectins obtained from
different sources are noted in the last column.
Table S2B (Sheet 2). List of lectins used for HeLaXBPIS microarray experiments. Lectin print
concentration, print sugar, and glycan epitope are indicated. Duplicate lectins obtained from
different sources are noted in the last column.
Table S3. Processed lectin microarray data (see xIs file in Supporting Reference [9]). Data
represent median normalized log2 values of sample to pooled-sample reference ratios.
Table S3A (Sheet 1). HEKXBP1s membrane data
Table S3B (Sheet 2). HeLaXBP1s membrane data.
Table S3C (Sheet 3). HEKXBPls media data.
Table S4: GC-MS linkage analysis of partially methylated alditol acetates (PMAA) from vehicle,
XBPls-activated, and thapsigargin-treated membrane (HEKXBP1s and HeLaXBP1s) and secreted
(HEKXBP1s) glycoproteins. N-Linked glycans were permethylated, hydrolyzed, reduced,
acetylated and analyzed by GC-MS (see Experimental Procedures).
Quantlcatona Identlflcatlonb Residue Rt HEK membrane C HeLa membrane C HEK secretomec(min) Vehicle XBP1s Tg Vehicle XBP1s Tg Vehicle XBP1s Tg
101, 102,115,118, 131,162,175 142,187 t-Fuc 13.88 30.1 9.6 9.2 20.6 25.9 36.5 84.8 95.5 121.5
1 129,145,161,162,205 71,87,113,174 tan 15.32 163.9 189.7 205.4 134.4 151.8 369.8 20.2 25.3 29.4
1 02 .18f-129,145,161,162,205 71,87,113, 174 t-Gal 15.59 48.6 25.3 23.4 58.7 92.5 49.1 133.1 154.9 76.9
, 129,30, 161,8190 71, 87,88 2-Man 16.44 276.9 297.5 335.4 321.0 300.9 460.4 190.1 222.0 308.9
130,190,205 87,88 100, 129, 145,161,174,205 2-Gal 16.71 1.2 0.3 0.7 0.0 0.7 0.0 2.9 2.3 1.0
8,143 87,101, 29, 174, 202,217, 234 3-Gal 16.77 29.3 6.7 4.0 26.5 25.3 11.9 56.2 36,1 61.4
2 118,29,59 182 71, 99,143,173,189,233 6-Gal 17.24 23.6 4.0 4.1 0.0 4.1 0.0 98.9 63.8 100.1
190,233 87,88,172,173 2,4-Man 17.58 13.7 6.5 7.3 8.2 16.6 5.3 36.1 25.8 25.6
100,129,130,189,190 87,88,99,143,159,173,174 2,6-Man 17.91 30.5 11.0 9.6 16.2 26.5 9.4 105.8 71.1 36.0
118,.129,.189,234 74,87 1, 160, 1 .74,202 245 3,6-Man 18.15 98.6 99.6 99.2 100.0 100.0 100.0 95.3 97.7 96.3
18,129,189,234 747, 101,160,174,202 3,6-Gal 18.32 n.d n.d. n.d. 11.9 16.4 6.7 n.d. n.d. n.d.
11,39 87,97, 129,160,202 3,4,6-Man 18.56 1.4 0.4 0.8 n.d. n.d. n.d. 4.7 2.3 3.7
117,129,143,145, 159,203,205 75,187,217 t-GIcNAc 18.98 2.4 1.8 4.2 1.9 2.1 0.0 4.8 2.7 1.3
117,159,233 75,99, 143,171,203 4-GIcNAc 19.83 163.1 56.0 70.1 66.0 206.7 35.3 415.7 108.7 89.1
117142,59 75,99,171,231,244 3,4-GIcNAc 20.62 1.5 0.9 0.8 1.2 2.8 1 5.2 2.2
117, 159 75.99,124,127, 142, 143,201,245 4,6-GIcNAc 21.05 6.6 1.8 3.7 5.4 10.6 3.1 30.3 11.9 10.9
'Electron impact fragment ions used for quantification of the PMAA residues. For relative abundance, in order to minimize
interference from the baseline and/or contamination, all fragment ions greater than 100 (>100) were used for the extracted
ion current (XIC) chromatogram, as indicated above.
b Electron impact fragment ions used for identification of the PMAA residues, in addition to the ions used for quantification.
c Relative abundances were obtained by normalizing the integrated area peak of the extracted ion current (XIC)
chromatogram of a specific residue to the summed integrated areas of the XICs of 3,6-linked mannose and 3,4,6-linked
mannose.
d n.d. = not detected.
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Table S5: Summary of observed changes to the HEKXBP1s and HeLaXBPs N-glycome with
XBP1s activation.
Observed Change with XBP1s HEKXBPS HEKXBPIS HeLaXBPsMembrane Secretome Membrane
Increased high-rannosee I
Decreased sialylation V I
Decreased bisecting GIcNAc V V
Increased core fucosylation -
Increased tetra-antennary glycans I I I
Table S6: Summary of observed changes to the HEKXBP1s and HeLaXBP1s N-glycome
UPR activation by treatment with Tg.
Observed Change with Tg HEKXBPIS HEKXBPs HeLaXBP1sMembrane Secretome Membrane
Increased high-mannose I
Decreased sialylation V- --
Decreased bisecting GIcNAc I -
Increased core fucosylation
Decreased branching I I
Increased core 1/3 O-glycans I V I _ I
with global
Table S7. MS analysis of the HEKXBP1s secretome with XBP1s activation (see .xs file in
Supporting Reference [9]). Spectral counts, m/z ratios, and normalized intensities for all proteins
detected by TMT-MS with or without XBP1s activation in Replicates 1-3 (Sheets 7A-7C,
respectively). Processed data are presented in Sheet 7D.
Table S7A (Sheet 1). Full TMT-MS data for the 6 h secretome of HEKXBP1s cells (Replicate 1).
Table S7B (Sheet 2). Full TMT-MS data for the 6 h secretome of HEKXBP1s cells (Replicate 2).
Table S7C (Sheet 3). Full TMT-MS data for the 6 h secretome of HEKXBP1s cells (Replicate 3).
Table S7D (Sheet 4). Fold-change and significance values for all proteins in the XBP1s
secretome. Proteins that met fold-change and significance cut-offs are highlighted; significance
and fold-change cut-offs were as follows: p-value 0.05, fold-change 1.5-fold. Proteins
annotated as N-glycosylated (UniProtKB) are indicated along with the reported number of N-
glycan sequons.
Table S8: HEKXBPls and HeLaXBP1s glycogene data (see .Xs file in Supporting Reference [9]).
Table S8A (Sheet 1). Gene sets related to N-glycosylation (including glycosyltransferases,
glucosidases, and sugar transporters) were selected from MSigDB and used to generate Figure
5.5.
Table S8B (Sheet 2). Full list of unique genes contained in the selected gene sets listed in Table
S8A.
Table S8C (Sheet 3). Fold-change and significance values for glycogenes in HEKXBP1s cells with
XBP1s activation used to generate Figure 5.5A. Glycosylation-related genes listed in Table S8B
were extracted from the HEKXBP1s microarray data and were integrated with glycosylation PCR
array data; bold-faced genes have fold-change and significance values obtained from the qPCR
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arrays. Significance and fold-change cut-offs were as follows: FDR or p-value 5 0.05, fold-
changes 1.5-fold (XBP1s versus vehicle). Genes from the list in Table S8B that were not
detected in either data set are not shown.
Table S8D (Sheet 4). Fold-change and significance values for glycogenes in HeLaXBP1s cells with
XBP1s activation used to generate Figure 5.5C. Glycosylation-related genes listed in Table S8B
were extracted from the HeLaXBP1s RNA-Seq data and integrated with glycosylation PCR array
data; bold-faced genes have fold-change and significance values obtained from the qPCR
arrays. Significance and fold-change cut-offs were as follows: FDR or p-value 5 0.05, fold-
changes 1.5-fold (XBP1s versus vehicle). Genes from the list in Table S8B that were not
detected in either data set are not shown.
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B Enrichment Plots: XBP1s vs Vehicle
HeLaXBPi RNA-Sea Results
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Figure SI: RNA-Seq highlights distinctive effects of stress-mediated global UPR activation versus
stress-independent XBPIs activation. (A) Hierarchical clustering of differentially expressed protein-
coding genes. HeLaXBP1S cells were plated at a density of 6 x 105 cells per well in 6-well plates and
allowed to adhere overnight. Cells were then treated with dox (1 pg/mL, 48 h), DMSO (0.1%, 24 h),
or thapsigargin (Tg; 750 nM, 24 h), total RNA was extracted with the Qiagen RNeasy Plus Mini Kit,
and samples were loaded on a HiSeq cartridge. Supervised hierarchical clustering was performed
using Ward's method implemented in Spotfire 7.6.1 with row-centered log2 FPKM data for genes
differentially expressed in at least one of the following comparisons: Tg versus vehicle, XBP1s vs
vehicle, or XBP1s vs Tg. For the hierarchical clusting, differentially expressed genes were defined
as those having absolute log(2) fold-change > 1 and FDR adjusted p-values < 0.05. (B) Selected
GSEA enrichment plots for XBP1s versus vehicle and Tg versus vehicle showing distinct effects of
XBPls-activation versus global UPR activation with the ER stressor Tg.
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Figure S2: Freestyle Tm and complete DMEM media Western blot. Western blot of
conditioned media from HEKXBPls cells cultured in complete DMEM or FreestyleTM media,
shown at both low and high exposure. HEKXBPIs cells were plated at a density of 6 x 105 cells
per well on poly-D-lysine coated 6-well plates and allowed to adhere overnight. Cells were
then treated with or without dox (1 tg/mL, 24 h), after which plates were washed three times
with PBS (containing Ca2+ and Mg 2+) prior to treatment with either full DMEM (+10% FBS, L-
glutamine) or FreestyleTM media, with or without 1 pg/mL dox. Conditioned media was
collected for 48 h, spun at 1.5k RPM at 4 *C for 5 min to pellet cell debris, and then run on
4/8% SDS-PAGE polyacrylamide gels. Grp78 signal was detectable in Freestylerm media
samples, but only upon XBPls activation.
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Lectin Microarray Analysis of HEKxP'Is Membranes
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Figure S3: Analysis of the HEKXBPIs membrane glycoproteome. (A) Lectin microarray analysis
of membrane proteomes isolated from HEKXBPlS cells showed decreased sialylation and a loss
of bisecting GlcNAc upon XBP1s activation (left panel). Tg treatment (right panel) also showed
decreases in sialylation and bisecting GlcNAc, along with an increase in core 1/3 O-glycans.
Spot colors correspond to lectin sugar specificity, as indicated; the dotted line represents a
significance cutoff of p-value 5 0.05 across three biological replicates. (B) MALDI-TOF MS
spectra of high mass N-glycans. Red, yellow and green peaks correspond to tetra-antennary N-
glycans with 2, 3 and 4 additional LacNAc repeats, respectively, with various levels of
sialylation. Yellow and green shaded areas, manually inserted, highlight the shift towards fewer
NeuAc residues. Structures outside a bracket have not been unequivocally defined, and "M,"
"Im," and "vm," designations indicate major, minor and very minor abundances, respectively.
Putative structures were assigned based on glycan composition, tandem mass spectrometry
data, and knowledge of biosynthetic pathways. (C) Zoomed-in MALDI-TOF MS spectra
indicating bi-antennary N-glycans (red peaks) with varying levels of sialylation. Putative
structures were assigned based on glycan composition, tandem mass spectrometry data, and
knowledge of biosynthetic pathways. (D) MALDI-TOF/TOF MS/MS spectra (selected from
corresponding panels in Fig. S3B) for vehicle, XBP1s-activated, and Tg-treated HEKXBP1s
membrane proteomes. Spectra depict fragments of the [M+Na]f molecular ion found at m/z
5124. Structures above each horizontal dashed arrow indicate loss of the designated N-glycan
sequence from the molecular ion; vertical dashed lines indicate the corresponding fragment ion
peak. All molecular and fragment ions are [M+Na]*. Cartoon structures were drawn according to
the Consortium for Functional Glycomics (http://www.functionalglycomics.org) guidelines. For
the molecular ion at m/z 5124, note the fragment ions at m/z 4300, 3850, 3401 and 2952 that
correspond to loss of sialylated-LacNAc, sialylated-LacNAc 2, sialylated-LacNAc 3 and sialylated-
LacNAc 4 respectively. The presence of such fragment ions suggests the existence of structural
isomers corresponding mainly to tetra-antennary (and to a lesser extent tri-antennary) N-
glycans. The relative abundance of these fragment ions did not shift between vehicle-treated,
XBPls-activated and Tg-treated HEKXBP1s cells, further suggesting that the ratio of structural
isomers remained relatively constant. Similar results were obtained for other ions (data not
shown).
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Figure S4: Differences in baseline HEKXBPls and HeLaXBPs membrane glycoproteomes. Heat
map of lectin microarray data generated from isolated HEKXBPls and HeLaXBP1s membrane
glycoproteomes under vehicle-treated conditions. Samples were run on the same lectin
microarray slide. Color intensity represents normalized log2 ratio data relative to a pooled (in
this case, multi-cell line) sample reference. Each column represents one biological replicate of
the indicated sample.
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Figure S: Analysis of the HeLaXBPs membrane N-glycoproteome. (A) MALDI-TOF MS spectra
of high mass N-glycans and (B) MALDI-TOF/TOF MS/MS spectra (selected from corresponding
panels in Fig. S5A) for vehicle, XBP1s-activated, and Tg-treated HeLaXBP1s membrane
proteomes. MALDI-TOF/TOF MS/MS spectra depict fragments of the [M+Na]' molecular ion
found at m/z 5300. (C) Lectin microarray analysis of membrane proteomes isolated from
HeLaXBP1s cells showed an increase in high-mannose N-glycans upon XBP1s activation (left
panel), as well as increases in core fucosylation and tetra-antennary N-glycans (P1,6-GlcNAc).
Tg activation (right panel) showed a similar gain of high-mannose N-glycans, but not increased
s1,6-GlcNAc branching. Spot colors correspond to lectin sugar specificity; the dotted line
represents a significance cutoff of p-value 0.05 across three biological replicates.
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Lectin Flow Cytometry Confirms Increase in
High-Mannose N-Glycans with XBP1s on HeLaXBPs Cells
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Figure S6: Lectin flow cytometry confirms that XBP1s activation increases high-mannose N-
glycans on HeLax""BP cells. (A) Lectin flow cytometry on live HeLaXBP1s cells confirmed the
increase in levels of high-mannose N-glycans on the cell surface (left panel, histogram;
middle panel, quantification). Inhibitory sugar controls (right panel) were performed with
methyl-mannose. Cell viability analyzed by CellTiter-Glo (B) or resazurin assay (C) was not
significantly affected by treatment with dox (1 pg/mL, 72 h) or 1-deoxymannojirimycin (1-
DMM, Sigma-Aldrich; 80 pg/mL, 24 h). 1 x 104 HeLaXBP1s cells were seeded for each well 24
h prior to measurements. Error bars represent SEM from four replicates. (D) To verify that
HHL recognized high-mannose glycans, HeLaXBP1s cells were treated with 80 tg/mL of 1-
DMM for 12 h to inhibit mannosidase-I and thus increase high-mannose N-glycan levels prior
to analysis.
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Lectin Microarray Analysis of the HEKBPs Secretome
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Figure S7: Analysis of the HEKXBPIs secreted glycoproteome. Lectin microarray analysis of the
HEKXBP1s secretome showed a decrease in bisecting GlcNAc and an increase in early processed N-glycans upon XBP1s activation (left panel). Tg treatment (right panel) showed a decrease in multi-
antennary N-glycans with no gain in high-mannose structures. Spot colors correspond to lectin
sugar specificity; the dotted line represents a significance cutoff of p-value s 0.05 across threebiological replicates.
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Figure S8: XBP1s impacts expression of genes involved in lipid-linked oligosaccharide
biosynthesis. (A) GSEA enrichment plots for HEKXBPIs microarray data upon XBP1s
activation using the custom gene sets listed in Table SIE. Standard GSEA was run using
signal-to-noise ratio as a ranking metric. (B) Enrichment plots for HeLaXBPls RNA-Seq data
upon XBP1s activation using the custom gene sets listed in Table S1E. Standard GSEA was
run using signal-to-noise ratio as a ranking metric.
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Figure S9: XBPIs impacts expression of genes involved in nucleotide sugar donor
biosynthesis. Simplified biosynthetic pathway of nucleotide sugars depicting the
enzymes/transporters that are significantly upregulated upon XBP1s activation in HeLaXBP1s
cells. Transcripts shown in green (all with significant expression changes based on FDR or p-
value 5 0.05) encode enzymes or transporters with a fold-change 1.5, while genes in black
encode enzymes with fold-change between 1.0-1.5-fold. Note that GNPDAI, which together
with GNPDA2 catalyzes the reverse reaction of GFPTI, was significantly decreased (0.79-
fold) in HeLaXBP1s cells (Table S8D). Biosynthetic pathway adapted from Ref. [8] and the
KEGG database (Homo sapiens nucleotide sugar metabolism, http://www.kegg.jp).
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